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ABSTRACT 
 
KEDUO QIAN: Design, Synthesis, and Biological Evaluation of Betulinic 
Acid Derivatives as Potent Anti-HIV-1 Agents 
(Under the Direction of Kenan Professor Kuo-Hsiung Lee) 
 
The overall goals of this research were to design and synthesize novel 
betulinic acid (BA) derivatives and to evaluate their biological activities, establish 
structure-activity relationships (SAR), and investigate mechanism(s) of action. Three 
specific goals were identified in this study: 1) establish the detailed SAR of C-3 
modified BA analogs for HIV-1 maturation inhibitors and further improve antiviral 
activity profiles; 2) investigate the impacts of C-19 isopropenyl moiety to the antiviral 
activity and develop 28,30-disubstituted BA analogs as novel HIV-1 entry inhibitors; 
3) develop 3,28-disubstituted BA analogs as bifunctional HIV-1 inhibitors. 
More than 50 BA derivatives were synthesized and evaluated in HIV-1 
replication inhibition assay in this research. Compound 82 with enlarged C-3’ 
substitution of C-3 side chain showed an extremely potent anti-HIV-1 activity with an 
EC50 value of 0.0006 µM, which was better than the current clinical trial candidates 
bevirimat (DSB) in HIV-1IIIB infected MT-2 cell line. In contrast, C-30 substitutions 
through ether bond do not influence the antiviral potency of the derivatives 
significantly. Incorporation of water-solubilizing moieties into C-30 position can 
 iii
improve the hydropholicity and solubility of the C-28 modified BA derived HIV-1 
entry inhibitors significantly, which led to the discovery of 112 with a significant 
anti-HIV-1 activity (EC50: 0.09 µM) similar to the previous best hints. The C-28 side 
chain was further modified to increase the metabolic stability, resulting in the 
identification of novel 3,28-disubstituted BA analogs 131 and 132, with better 
stability and extremely potent antiviral activities (EC50 ~0.006 µM) which are slightly 
better than that of bevirimat.  
In a different project, we discovered that C-3 modification and C-30 
modification can increase the anti-proteasome activity of BA dramatically. 
3,30-disubstituted BA analogs may be developed into potent proteasome inhibitors 
and potential anti-cancer agents, which represents another promising direction for the 
development of BA derivatives. 
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Chapter 1. Human Immunodeficiency Virus (HIV)，
Acquired Immunodeficiency Syndrome (AIDS) and Current 
Anti-HIV Drugs in Clinical Use 
 
1. Introduction 
Since the first person was recognized with acquired immunodeficiency 
syndrome (AIDS) in 1981, this pandemic has rapidly grown into the fourth leading 
cause of mortality globally. As the world enters the third decade of the AIDS epidemic, 
AIDS remains an exceptional crisis due to both its emergent and long-term 
development. It is estimated that human immunodeficiency virus (HIV), the etiologic 
cause of AIDS, has infected over 60 million people worldwide. Currently, there are 
approximately 33.2 million people living with HIV (Figure 1-1). In 2007, 2.5 million 
people were newly infected and 2.1 million people died of AIDS-related illnesses.1 
The four major routes of HIV transmission are unprotected sexual intercourse2, 
contaminated needles 3, breast milk, and transmission from an infected mother to her 
baby at birth 4. HIV primarily infects vital cells in the human immune system, such as 
helper T cells (specifically CD4+ T cells), macrophages and dendritic cells, resulting 
in the destruction and functional impairment of the immune system. HIV infection 
leads to low levels of CD4+ T cells through three main mechanisms: firstly, direct 
viral killing of infected cells; secondly, increased rates of apoptosis in infected cells; 
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and thirdly, killing of infected CD4+ T cells by CD8 cytotoxic lymphocytes that 
recognize infected cells. A healthy, uninfected person usually has 800 to 1,200 CD4+ 
T cells/mm3 blood. During HIV infection, the number of CD4+ T-helper cells 
progressively declines. When it falls below 200/mm3, the patients become particularly 
susceptible to many life-threatening opportunistic infections caused by microbes that 
usually do not infect healthy people, as well as suffer diarrhea, debilitating weight 
loss, neurologic conditions, and cancers, such as Kaposi’s sarcoma and certain types 
of lymphomas.5 
 
Figure 1-1. Global summary of the HIV/AIDS epidemic, December 2007 
 
2. HIV Classification 
HIV is a member of the genus Lentivirus, part of the family of Retroviridae. 
Lentiviruses have many common morphologies and biological properties. Many 
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species are infected by lentiviruses, which are characteristically responsible for 
long-duration illnesses with a long incubation period.6 Humans can be infected by two 
species of HIV: HIV-1 and HIV-2. Together with the related non-human virus, simian 
immunodeficiency virus (SIV), HIV-1 and HIV-2 comprise the subgenus “primate 
lentiviruses”. The genomic organization of these viruses is similar, but a high degree 
of genetic diversity exists.7 HIV-1 is thought to have originated in southern Cameroon 
after jumping from wild chimpanzees (Pan troglodytes troglodytes) to humans during 
the twentieth century.8 It is highly virulent and relatively easily transmitted, and is the 
cause of the vast majority of HIV infections globally. HIV-2 may have originated 
from the sooty mangabey (Cercocebus atys), and is largely confined to West Africa.8 
Compared to HIV-1, HIV-2 is less transmittable, less pathogenic, shows lower virus 
loads in the asymptomatic stage, and results in slower disease progression.9  
 
3. Structure of HIV-1 Virion 
The mature HIV-1 virion is about 120 nm in diameter and roughly spherical.10 
The viral genome contains two copies of single-stranded RNA, which code for the 
virus's nine genes, enclosed by a conical capsid (CA) composed of the viral protein 
p24. This electron dense conical core is a distinctive structural feature of HIV and can 
be observed by electron microscopy. The p24 protein can be detected by an antigen 
capture enzyme-linked immunosorbent assay (ELISA), which is one diagnostic 
method for primary HIV-1 infection. The single-stranded RNA is tightly bound to 
nucleocapsid proteins (p7, NC) and enzymes needed for the infection process of the 
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virion, such as reverse transcriptase (p64 and p51, RT), protease (p10, PR), and 
integrase (p32, IN). A matrix protein (p17, MA) surrounds the capsid, ensuring the 
integrity of the virion particle. In turn, the matrix is surrounded by the viral envelope, 
which is comprised of double-layered phospholipids taken from the cellular 
membrane when a newly formed virus particle buds from the human host cell. 
Embedded in the viral envelope are 72 copies of HIV-1 envelope glycoprotein (Env). 
Env is composed of surface glycoprotein (gp120, SU), which assembles into a trimer 
that is able to bind to cellular receptors, and transmembrane glycoprotein (gp41, TM), 
which also assembles into a trimer that anchors Env into the viral membrane.11,12 This 
envelope glycoprotein complex enables the virus to attach to and fuse into target cells, 
thereby initiating the infectious cycle (Figure 1-2). 
 
 
Figure 1-2. Schematic diagram of HIV virion structure 
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Table 1-1. HIV genes and gene products  
Gene Protein Product Function of encoded proteins 
gag 53kDa precursor Gag polyprotein precursor 
 p17 Matrix, forms outer core layer, important for virion stability 
 p24 Capsid, forms inner conical core layer, important for virion maturation 
 p7 Nucleocapsid, is tightly bound to ssRNA, important for RNA packaging 
 p6 Related to virion assembly and release 
env 160kDa precursor Envelope glycoproteins 
 gp120 Surface protein, a cap mediates receptor binding, important determinant of cell tropism 
 gp41 Transmembrane protein, a stem anchors the Env into membrane, mediates fusion 
pol Precursor Enzymes 
 p66/p51 Reverse transcriptase, with DNA polymerase and RNase activities 
 p10 Protease, mediates gag and gag/pol polyprotein cleavage 
 p32 Integrase, catalyzes proviral integration 
tat p14 Transcriptional and posttranscriptional regulator, strongly activates transcription of proviral DNA 
rev p19 Posttranscriptional regulator, facilitates nuclear export, stability, and translation 
nef p27 Early regulatory proteins, increases viral replication; down-regulates host-cell CD4 
vif p23 Virus infectivity factor, promotes infectivity and efficient transmission of viral particle 
vpu* p16 Facilitates viral maturation and release 
vpx* p14 Facilitates viral replication and nuclear entry of the pre-integration complex in macrophages 
vpr p15 Weakly activates transcription of proviral DNA 
* vpu is found only in HIV-1; vpx is found only in HIV-2 and SIV  
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The RNA genome of HIV contains 9,747 nucleotides and is the most complex 
among all retroviruses studied so far (Figure 1-3).13,14 Of the nine genes that are 
encoded within the RNA genome, three provide genetic information for HIV’s 
structural components. Each of these three genes encodes a large polyprotein 
precursor, which will be cleaved during the infection process to provide the final 
functional proteins. They are gag, which encodes a 55kDa polyprotein (Pr55Gag) that 
will be cleaved into viral core proteins including MA, CA, NC and p6 (function is 
currently unclear); pol, which encodes the three vital enzymes (RT, PR, and IN) 
required for viral replication; and env, which encodes the 160kDa envelope 
glycoprotein (gp160) that will be broken down by a host-cell protease to form gp120 
and gp41. The six remaining genes [tat, rev, nef, vif, vpr, and vpu (or vpx in the case 
of HIV-2 and SIV)] are regulatory genes that modulate the ability of HIV to infect 
cells, produce new copies of virus (replicate), or cause disease.15-17 Tat and rev are 
splitted genes, and are essential for viral replication. Their exons are spliced together 
during RNA processing. The other four genes are dispensable under certain 
circumstances and, consequently, have been named accessory genes. However, the 
existence of these gene encoded proteins is still important for the life cycle of HIV. 
For example, nef is necessary for the virus to replicate efficiently17, and vpu 
influences the release of new HIV-1 particles from infected cells18. Table 1-1 
summarizes the functions of these HIV proteins. Both ends of the viral RNA strand 
contain an RNA sequence called the long terminal repeat (LTR). LTRs act as switches 
to control production of new viruses. The LTRs are not genes, but rather are direct 
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host cell enzymes that transcribe the biological information in proviral DNA into 
RNA during viral replication.19 They can be triggered by proteins from either HIV or 
the host cell. 
 
 
Figure 1-3. Genome of HIV-1 
 
4. Life Cycle of HIV and Possible Anti-HIV Drug Targets 
The life cycle of HIV has been and continues to be well studied in order to 
identify potential antiretroviral targets. The infection proceeds as described below. 
HIV entry into host cells is a complicated process mediated by the envelope 
glycoprotein (Env). The process involves at least three steps: (1) an initial attachment 
step in which cellular CD4 receptors bind with viral gp120 and cause a 
conformational change that allows the next step of co-receptor binding; (2) CCR5 
and/or CXCR4 co-receptor binding with gp120, which results in a further 
conformational rearrangement and exposes the hydrophobic fusion domain of gp41; 
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and (3) a fusion process mediated by gp41.20 Reportedly, some HIV strains can bypass 
CD4 binding and enter target cells via direct interactions with a co-receptor molecule 
in vitro.21,22 This CD4-independent infection route was possibly developed as an 
escape mechanism from inhibitors targeting CD4-binding.23 However, 
CD4-independent infection is usually less efficient and more susceptible to 
neutralization.22,24 Numerous entry inhibitors targeting each of these three steps are in 
clinical and preclinical trials and will be reviewed in Chapter 2. 
Once gp41 causes virus and cell membranes to fuse together, the viral capsid 
is released into the target cell. Within the cytoplasm, the capsid undergoes uncoating; 
a process that is largely unknown. During uncoating, the HIV RNA genome and 
various enzymes, including RT, IN, and PR, are injected into the cytoplasm.  
Reverse transcription of the viral genomic RNA into the viral cDNA then 
occurs. This process is catalyzed by reverse transcriptase (RT). RT first mediates a 
RNA-dependent DNA polymerization reaction to transcribe the viral RNA into 
RNA-DNA hybrid molecules. The ribonuclease H (RNase H) domain of RT then 
degrades the RNA portion of the RNA-DNA hybrids. A subsequent RT-catalyzed 
DNA-dependent DNA polymerization reaction yields the viral double-stand DNA 
copy that is ready to be integrated into the target cell genome.25 The first 
FDA-licensed anti-HIV drugs, such as AZT, inhibit RT and are still a critical part of 
AIDS treatment. 
The viral double-strand cDNA produced by the reverse transcription step is 
translocated to the host cell nucleus where integration of the viral cDNA into the host 
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DNA genome takes place. The critical cutting and joining events leading to provirus 
formation are carried out by the viral integrase (IN).26 IN catalyzes two distinct 
processes known as 3'-end processing and strand transfer. In detail, IN cleaves the 
3'-end of the viral DNA to leave “sticky ends”. It also makes a cut in the host cell's 
DNA. At this cut, the HIV and cellular DNA can be stuck together as part of the cell's 
genome.26 Because IN has no known homologues in human cells, it represents a 
valuable drug target for AIDS therapy. After the viral DNA is integrated into the 
genetic material of the host, HIV may persist in a latent state for many years, which is 
the major barrier to eradication or cure of HIV. Therefore, based on our current 
knowledge, patients must remain on antiviral therapy for life.  
Following HIV integration, provirus gene expression is tightly controlled via 
the interplay of viral and multiple cellular factors. Viral proteins tat and rev are two 
regulatory proteins essential for HIV replication and have been widely investigated as 
potential targets.25 However, inhibition of HIV gene expression may lead to 
significant host cell toxicity and may force the virus into a latent state.  
After viral DNA is transcribed into viral messenger RNA (mRNA), mRNA is 
transported to the cytoplasm, where it is further translated into viral proteins by the 
cell’s machinery. Once the Gag polyprotein precursors (Pr55Gag) and Gag-Pol 
polyprotein precursors (Pr160Gag-Pol) are translated, they recruit two copies of viral 
RNA and assemble with accessory proteins (vif, vpr, nef) to form the core virion near 
the inner face of the cell membrane.27 The modified cell membrane containing 
envelope glycoproteins (Env) then surrounds the core particle and buds from the host 
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cell. This process leads to the production of immature non-infectious particles.  
During or right after budding, the Gag and Gag-Pol polyproteins are cleaved. 
This cleavage is catalyzed by the third product of the pol gene – protease (PR). PR 
recognizes and cleaves Gag and Gag-Pol polyproteins at several specific sites to 
produce viral structural proteins [matrix (MA), capsid (CA), nucleocapsid (NC) and 
p6 proteins, as well as three pol products RT, IN and PR itself], which leads to the 
formation of a mature infectious HIV virion that can infect another target cell.25 PR is 
one of the most exploited targets for the rational design of anti-HIV drugs. A novel 
recently discovered class of maturation inhibitors also focuses on blocking this step. 
 
5. Approved Antiretroviral Therapy (ART) 
Since the development of a safe and effective HIV vaccine has not yet been 
successful,28 research on antiretroviral therapy (ART) continues to focus on chemical 
anti-HIV agents. Although all of the steps in the HIV life cycle can potentially serve 
as drug targets, current AIDS drugs fall mainly into three general categories: 
nucleoside/nucleotide RT inhibitors (NRTIs), non-nucleoside RT inhibitors (NNRTIs), 
and protease inhibitors (PIs). Current available HIV entry inhibitors include Fuzeon 
(enfuvirtide), which is a fusion inhibitor (FI) approved by the FDA in March 2003,29 
and Selzentry (maraviroc), which is a CCR5 co-receptor antagonist just approved in 
August 2007.30 Lastly, the integrase strand transfer inhibitor Isentress (raltegravir) 
was approved in October 2007.31 (Table 1-2) 
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Table 1-2. US FDA approved anti-HIV drugs (brand names, generic names and abbreviation) * 
NRTIs NNRTIs PIs Entry Inhibitors Integrase Inhibitors 
Emtriva (emtricitabine, FTC) Rescriptor (delavirdine, 
DLV) 
Agenerase (amprenavir, 
APV) 
Fuzeon (enfuvirtide, 
ENF, T20) 
Isentress (raltegravir) 
Epivir (lamivudine, 3TC) Sustiva (efavirenz, EFV) Aptivus (tipranavir, TPV) Selzentry (maraviroc)  
Hivid (zalcitabine, ddC) Viramune (nevirapine, 
NVP) 
Crixivan (indinavir, IDV)   
Videx (didanosine, ddI) Intelence (etravirine) Invirase (saquinavir 
mesylate, SQV) 
  
Viread (tenofovir, TDF)  Lexiva (fosamprenavir, FPV)   
Zerit (stavudine, d4T)  Norvir (ritonavir, RTV)   
Ziagen (abacavir, ABC)  Prezista (darunavir)   
Retrovir (zidovudine, AZT +  
azidothymidine, ZDV) 
 Kaletra (lopinavir, LPV + 
ritonavir, RTV) 
  
Combivir (AZT+3TC)  Reyataz (atazanavir, ATV)   
Epzicom (ABC+ 3TC)  Viracept (nelfinavir, NFV)   
Trizivir (ABC+AZT+3TC)     
Truvada (TDF+FTC)     
* Until January 2008 
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5-1. NRTIs 
NRTIs (Figure 1-4) mimic the structures of the base substrates for DNA 
synthesis. They interact at the substrate-binding site of RT and act as chain 
terminators.32 For example, AZT, a deoxythymidine analog, was the first successful 
NRTI for the treatment of HIV infection. It is phosphorylated by cellular enzymes to 
AZT-triphosphate (AZT-TP), which is recognized by RT in place of the normal 
deoxyribonucleoside triphosphates, dNTPs, and competitively incorporated into the 
DNA strand. Because the 3'-hydroxy is replaced by an azide moiety, AZT-TP cannot 
form the normal 3' to 5' phosphodiester bond. Therefore, elongation of the growing 
DNA chain is interrupted and viral replication is inhibited.  
Viread (tenofovir disoproxil fumarate, TDF) represents the first nucleotide 
analog approved for HIV-1 treatment.33 TDF is hydrolyzed to tenofovir in vivo, and 
then phosphorylated by cellular kinases to its active metabolite tenofovir diphosphate. 
It then competes for incorporation into viral DNA and acts as a chain elongation 
terminator because it lacks a ribose ring.33 
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Figure 1-4. US-FDA approved NRTIs (date of approval) 
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5-2. NNRTIs 
NNRTIs (Figure 1-5) inactivate RT by non-competitive interaction with an 
allosteric site of the enzyme. This highly hydrophobic binding pocket of NNRTIs is 
near to, but distinct from, the polymerase active site in the p66 subunit of RT.25 The 
binding of NNRTIs does not interfere with RT binding of dNTPs, but does rearrange 
the enzyme into an inactive conformation that slows down the rate of incorporation of 
dNTPs into the DNA product.34 NNRTIs preferentially inhibit RNA-dependent DNA 
polymerization. An obvious disadvantage of NNRTIs is that drug resistance can 
emerge quickly due to rapid mutation of the RT amino acid residues surrounding the 
NNRTI-binding site.35  
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Figure 1-5. US-FDA approved NNRTIs (date of approval) 
 
5-3. PIs 
HIV-1 and HIV-2 proteases display similar structural features and belong to 
the aspartic protease group of enzymes. The HIV-1 protease is a homodimer stabilized 
by non-covalent interactions; each monomer has a 99-amino acid residue subunit. 
Each subunit contributes a conserved triad (Asp-Thr-Gly), which contains the 
catalytically active Asp25.25 These active aspartates are located at the dimer interface. 
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PIs (Figure 1-6) bind tightly to the protease surface by mimicking the structures of the 
proteolysis sites of Gag and Gag-Pol polyproteins. By binding to the active sites, PIs 
prevent protease from cleaving the viral polyprotein precursors into mature viral 
structural proteins and functional enzymes, resulting in the suppression of viral 
replication and production of immature noninfectious virions.36  
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5-4. Entry Inhibitors 
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As previously described, viral entry is a complicated multi-step process. 
Inhibitors that target one or more of these steps can potently affect viral replication. 
Currently, there are two FDA approved HIV entry inhibitors. Fuzeon (enfuvirtide, 
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ENF, T20) is a synthetic peptide with 36 amino acid residues. It functions as a fusion 
inhibitor (FI).29 Selzentry (maraviroc, MVC, UK-427,857) is an orally bioavailable 
CCR5 co-receptor antagonist.30 Their detailed mechanisms will be reviewed in 
Chapter 2.  
 
5-5. Integrase Inhibitors 
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Raltegravir (Oct 07)  
Isentress (Raltegravir, MK-0518, Merck. Inc) is the first in a new class of 
orally administered HIV-1 integrase (IN) inhibitors. This compound selectively 
inhibits the strand transfer activity of IN and consequently inhibits viral cDNA 
integration into human DNA.31 It was approved by the US FDA in October 2007 for 
treatment of antiretroviral–resistant HIV-1 infected individuals with 400 mg twice 
daily dosing via oral administration.31  
 
6. HAART and Associated Problems  
Significant progress has been made in the development of antiretroviral 
therapy (ART). ART can successfully delay destruction of the immune system, reduce 
severity and frequency of opportunistic infections, and consequently delay AIDS 
progression. Introduction of highly active antiretroviral therapy (HAART), which 
employs a combinational use of drugs with different mechanisms, can reduce viral 
load to below detectable levels in patient plasma, resulting in improved patient health 
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and life span.37-39 However, the virus is suppressed rather than eradicated by 
HAART.40-42 On HAART regimens, multiple drug therapies can lead to increased 
adverse effects and toxicities due to long-term use and drug-drug interactions.43,44 
Moreover, inadequate clinical viral suppression of HIV-1, due to various reasons, and 
the high error rate of the reverse transcriptase can lead to the emergence of 
drug-resistant and multi-drug-resistant viral strains.45 Drug-resistant virus is then 
involved in HIV transmission, and more than 25% of newly infected individuals 
harbor HIV-1 isolates that are resistant to at least one ART.46,47 Therefore, novel 
potent antiretroviral agents, which have simplified treatment regimens (fewer pills 
and less-frequent administration) and target different steps of viral life cycle, may 
hold particular promise in addressing issues of current therapies.  
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Chapter 2. HIV Entry Inhibitors and Triterpene Derivatives 
as Anti-HIV Agents – A Review 
 
1. Introduction 
HIV entry into host cells is a complicated multi-step process. Virions can first 
attach to target cells in a relatively nonspecific manner, followed by specific binding 
of HIV gp120 to the CD4 receptor on the cellular membrane. This binding induces a 
conformational change in gp120 that opens up a high-affinity binding site located 
within the third variable loop (V3) and surrounding surfaces for the chemokine 
co-receptors (primarily CCR5 and CXCR4).48 Co-receptor binding results in further 
conformational rearrangements of gp120 that expose the fusion-peptide domain of 
gp41. Insertion of this hydrophobic domain into the cell membrane leads to the 
formation of a hairpin-like fold in the gp41 subunits.20 The heptad repeat (HR) 
regions, HR1 and HR2 of the three subunits of gp41, fold and pack into a six-helix 
bundle, which brings the viral and cell membranes into juxtaposition and creates 
pores in the target cell membrane, enabling the release of viral capsid into the 
cytoplasm.49-51 Different entry inhibitors that target one or more of these steps are 
now in preclinical and clinical trials. Entry inhibitors, especially potent, orally 
bioavailable small molecules are very promising for development as therapeutic 
antiviral drugs. Herein, we review their development, mechanisms of action, and 
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possible role in anti-HIV therapy. 
 
2. Attachment Inhibitors 
2-1. Nonspecific Attachment Inhibitors 
Before gp120 and CD4 receptor binding firmly attaches HIV onto the target 
cells, less specific adsorption and attachment occur between the virions and cell 
membrane due to the interaction of the positively charged regions of Env with 
oppositely charged proteoglycans of the cell surface.52,53 Studies have reported that 
soluble polyanions, such as dextran sulfate, cyclodextrin sulfate and heparin, can 
block this nonspecific attachment of HIV virions.54  
Cyanovirin-N (Cellegy Pharmaceuticals), an 11kDa protein isolated from the 
cyanobacterium (blue-green algae) Nostoc ellipsosporum, specifically binds to a 
conserved high-mannose carbohydrate region on gp120, which prevents the 
attachment of virus to target cells at low nanomolar concentrations.55-57 Another 
example is PRO 2000 (Indevus Pharmaceuticals), a naphthalene sulfonate polymer (1) 
(Figure 2-1), which binds nonspecifically to CD4 receptor. Vaginal PRO 2000 gel has 
been effective and well tolerated in Phase I/II clinical trials.58,59 However, because of 
their mechanism of action and polymer properties, these two compounds are mainly 
being developed as topical microbicides.  
Glycyrrhizin (2) (Figure 2-1), a triterpenoid saponin isolated from licorice root 
inhibits HIV-1 replication by partially blocking viral adsorption to CD4+ cells.60 
Sulfation of glycyrrhizin (3), amphotericin B, and lentinan, as well as polysulfonates 
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[e.g., suramin (4)] and polyhydroxycarboxylates [e.g., aurintricarboxylic acid (5)] also 
interfere with the nonspecific viral attachment process (Figure 2-1).  
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Figure 2-1. Structures of some selected sulfated compounds as HIV nonspecific 
attachment inhibitors 
 
2-2. CD4-gp120 Binding Inhibitors 
Many molecules can inhibit CD4 and gp120 binding via different modes of 
action, including inhibition of attachment by targeting Env gp120 or CD4 receptor, 
prevention of necessary conformational rearrangement, and down-regulation of CD4 
expression. 
PRO 542 (Progenics Pharmaceuticals) is a recombinant tetrameric CD4-IgG2 
antibody-like fusion protein. It targets the CD4 binding site on gp120 by mimicking 
the CD4 receptor. In Phase I clinical trials, PRO 542 reduced viral load after a single 
intravenous dose and was well tolerated in infected adults and children.61,62  
TNX 355 (Tanox Inc.) is a humanized IgG4 monoclonal antibody against CD4, 
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which binds to the D2 domain of CD4 and inhibits CD4-induced post-binding 
conformational changes.63 Phase I clinical studies concluded that TNX 355 reduced 
plasma HIV-1 RNA loads and increased CD4+ T-cells.64 However, the need for 
infusion limits its clinical use. 
BMS-378806 (6) and BMS-488043 (7) (Bristol-Myers Squibb) (Figure 2-2) 
are novel, small-molecule CD4-attachment inhibitors that specifically block HIV-1 
entry by targeting Env gp120 with an EC50 value of around 5 nM.65,66 Mechanism of 
action study revealed that both compounds selectively bind to gp120 and lead to 
conformational changes in gp120 at both the CD4 and CCR5 binding regions, which 
blocks CD4-gp120 interactions. Prior addition of soluble CD4 to the assay system 
before BMS-488043 treatment negates the inhibition activity of the compound, 
indicating that inhibition of CD4-gp120 binding is the primary mode of action.67 An 
earlier report by Si et al. suggested that BMS analogs function by blocking 
conformational changes of gp120 after CD4 binding rather than by directly inhibiting 
CD4 binding;68 however, a significantly altered Env structure and high concentrations 
of soluble CD4 may have led to this conclusion.67 Drug development of BMS-378806 
was discontinued after Phase I clinical study, because target exposure was not 
achieved. BMS-488043 is currently in Phase II clinical trials.69 It is orally 
bioavailable with superior pharmacokinetic properties and good safety profiles. The 
New York Blood Center identified similar structures, NBD-556 (8) and NBD-557 (9) 
(Figure 2-2), which also contain an oxalamide moiety. These two compounds showed 
micromolar potency against HIV-1.70 Compounds 10 and 11 (Figure 2-2) disclosed by 
 21
Pfizer Inc. in patents (WO-2005016344 and WO-2005121094) also share similar 
structures with BMS analogs and have nanomolar anti-HIV activity.69  
CADA analogs (cyclotriazadisulfonamide) (12) (Figure 2-2) reportedly inhibit 
HIV replication by down-regulating CD4 expression at a post-translational step.71-73 
This category of compounds showed anti-HIV entry activity at micromolar 
concentrations.74 
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Figure 2-2. Selected structures of CD4-gp120 binding inhibitors 
 
3. Co-receptor Binding Inhibitors 
Chemokine receptors belong to the seven transmembrane G protein coupled 
receptor family. They are involved in the progression of many diseases, including 
rheumatoid arthritis, transplant rejection, asthma, cancer, HIV, and others. CCR5 and 
CXCR4 are the main chemokine receptors involved in the HIV entry process.75 Based 
on their chemokine receptor usage, HIV isolates may be divided into R5, X4, and 
R5/X4 strains.76 R5 isolates are the predominant virus strains, which are preferentially 
transmitted between HIV-infected patients.77 However, R5 variants will eventually 
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develop into R5/X4 isolates in approximately 50% of HIV-1 positive individuals, 
resulting in increased viral replication rate, faster disease progression, and the onset of 
AIDS.78  
During the HIV entry process, the CD4-gp120 complex must further bind to 
chemokine co-receptors through the gp120 V3 region in order to enter the target 
cells.79 V3 amino-acid sequences determine the usage of CCR5 or CXCR4.80 
Epidemiology data shows that individuals homozygous for δ32 CCR5 allele (no 
expression of CCR5 on cell surface) are highly resistant to HIV infection81,82 and 
apparently healthy. This fact highlights the merits of targeting co-receptor binding to 
inhibit HIV entry. 
 
3-1. CCR5 Inhibitors 
The CCR5 co-receptor binding site on HIV gp120 is concealed by V1, V2, and 
V3. The conformational change caused by the binding of gp120 with CD4 exposes 
this CCR5 binding site. When a CCR5 inhibitor is present, binding of the CCR5 
N-terminus and ECL2 (second extracellular loop) with the V3 stem of gp120 is 
blocked, resulting in inhibition of viral entry56 The strategies to block CCR5 
co-receptor binding include modified non-agonistic CCR5 chemokine natural ligands, 
CCR5 small molecule antagonists, and CCR5 antibodies.  
RANTES (13) was discovered as the natural β-chemokines ligand, which can 
compete with gp120 to bind the CCR5 co-receptor,83 and thus, inhibit HIV infection. 
However, it also triggers CCR5-mediated down-stream signaling pathways, which 
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may lead to undesired side effects. Modification of 13 led to the discovery of 
PSC-RANTES (14), which is developed as a potential microbicide 84 (Figure 2-3). 
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Figure 2-3. Structures of modified chemokine derivatives as HIV inhibitors 
 
PRO 140 (Progenics Pharmaceuticals) is another promising large molecule 
CCR5 co-receptor binding inhibitor. It is a murine anti-CCR5 monoclonal antibody 
that binds a complex epitope spanning multiple extracellular domains on CCR5.85 
PRO 140 demonstrates a potent and genetic-subtype-independent anti-HIV-1 activity 
and is currently in Phase II clinical trials.  
Because large molecules are often difficult to administer, their clinical 
application may be limited. Therefore, the search for orally bioavailable small 
molecule inhibitors remains of great interest. This search has led to the discovery of 
many small molecule CCR5 antagonists, which are very promising for development 
as therapeutic antiviral drugs. 
TAK-799 (Takeda Chemical Industries) (15) (Figure 2-4) is the first reported 
nonpeptide small molecule that antagonizes the binding of RANTES to 
CCR5-expressing Chinese hamster ovary cells at nanomolar concentrations 
(1.6-3.7nM).86 TAK-799 selectively inhibits CCR5 within the chemokine receptor 
family by binding inside a cavity formed by the transmembrane helices 1, 2, 3, and 7 
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of the CCR5 receptor.87 Although it showed no cytotoxicity to the host cells, lack of 
oral bioavailability limits its further development. Clinical trials of an injectable 
quaternary ammonium salt TAK-799 were discontinued due to local reactions at 
injection sites. Modification of TAK-799 by replacing the quaternary ammonium 
moiety with a polar sulfoxide moiety led to the discovery of TAK-652 (16)88 (Figure 
2-4). TAK-652 showed increased anti-HIV-1 activity against different clinical HIV 
subtypes with a mean EC50 value of 0.25 nM. More importantly, it has oral 
bioavailability and is well absorbed after oral administration in different preclinical 
animal studies. TAK-652 is currently in Phase I/II clinical trials. Additional high 
throughput screening against CCR5 in the same company led to the discovery of a 
different compound skeleton exemplified by 17 (Figure 2-4), which exhibits 
nanomolar anti-HIV-1 activity. However, 17 was rapidly degraded in metabolic 
stability studies. Continuing modification resulted in the identification of TAK-220 
(18)89 (Figure 2-4), an orally bioavailable, metabolically stable 
piperidine-4-carboxamide derivative, which is also in clinical studies.  
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Figure 2-4. Structures of TAK analogs 
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Maraviroc (MVC, UK-427,857, Pfizer) (19) (Figure 2-5) is another selective 
CCR5 antagonist with potent antiviral activity against all CCR5-tropic HIV-1 viruses 
at low nanomolar concentrations (mean 90% inhibitory concentration of 2.0 nM)90 It 
was obtained by medicinal chemistry optimization of a high throughput screening 
lead, the imidazopyridine derivative UK-107,543 (20)90 (Figure 2-5). The initial 
modification of 20 by introducing an amide bond into the structure (21) (Figure 2-5) 
solved the high lipophilicity problem of the lead.91 Later study revealed that only the 
S enantiomer of 21 showed good potency. However, this type of piperidine-based 
CCR5 antagonist is also a potent CYP 2D6 inhibitor, which may create problems with 
drug-drug interactions in drug combinational use. Further development led to the 
discovery of tropane-based compound 22 (Figure 2-5), which does not inhibit CYP 
2D6 liabilities, but retains high potency towards CCR5 92. Unfortunately, 22 is also a 
potent inhibitor of the hERG ion channel. This undesired side effect was successfully 
conquered by replacing the benzimidazole group with a triazole moiety and replacing 
the cyclobutyl group with a difluorocyclohexane moity, which resulted in the 
identification of Maraviroc (19).93 Mechanism of action study revealed that 19 binds 
to the cavity formed by the transmembrane helices 2, 3, 6, and 7 of CCR5 receptor, 
which is different with the binding site of TAK-799 94. Thus, 19 does not compete 
with chemokine binding and does not affect associated intracellular signaling.90 In 
clinical trials, it was administered orally with twice-daily dosing. In August 2007, 19 
was approved by the US FDA as a CCR5 antagonist HIV entry inhibitor under the 
brand name Selzentry. 
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Vicriviroc (SCH-D, SCH-417,690, Schering-Plough) (23) (Figure 2-6), a 
piperzine-based CCR5 antagonist, is also currently in Phase III clinical study. It is a 
second-generation compound with improved anti-HIV activity and pharmacokinetic 
profile compared with the first-generation Ancriviroc (SCH-C, SCH-351,125, 
Schering-Plough) (24) (Figure 2-6), a piperidino-piperidine derivative.95,96 Both 
compounds are orally bioavailable and interact within the cavity formed by CCR5 
transmembrane regions, resulting in inhibition of HIV gp120 binding.97 Compound 24 
was discovered first by modification of a high throughput screening lead. However, 
later study revealed that high doses of 24 led to CNS side effects and acute CV 
[prolongations in the QT cardiac interval (time between depolarization and 
repolarization of the heart muscle adjusted for heart rate)].96 The clinical studies of 24 
were then discontinued. Within the piperazino-piperidine series, replacing the N-oxide 
of 25 by 4,6-dimethylpyrimidine carboxamide as in 26 (Figure 2-6) resulted in better 
CV profiles.95 Further optimization of 26 led to the discovery of Vicriviroc (23), 
 27
which has potent, broad-spectrum antiviral activity against diverse HIV-1 subtypes 
and synergistic anti-HIV activity in combinational use with drugs from other classes. 
Another promising candidate in the piperazino-piperidine family is AD101 
(SCH-350,581) (27) (Figure 2-6), which also shows potent anti-HIV-1 activity by 
blocking gp120/CD4 complex and CCR5 interaction. AD101 is currently in 
preclinical study.98 
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Figure 2-6. Structures of Vicriviroc and Ancriviroc analogs 
 
INCB9471 (Incyte Corporation) (28) (Figure 2-7) is another promising 
candidate in Phase II clinical trials. It also belongs to the piperazino-piperidine family. 
The similar structures of INCB9471 and Vicriviroc suggest that they might share the 
same mechanism of action. INCB9471 is an orally bioavailable CCR5 antagonist with 
very potent antiviral activity against a wide range of HIV-1 strains, including drug 
resistant isolates.99  
Aplaviroc (GW873140, formerly ONO4128, AK602, GlaxoSmithKline) (29) 
(Figure 2-7) failed in Phase II clinical trials in October 2005, due to unexpected 
serious hepatotoxicity. It belongs to the spirodiketopiperazine family and exhibits 
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potent antiviral activity with EC50 values around 0.1-0.6 nM.100 Aplaviroc exerts its 
antiviral function by interacting with CCR5 ECL2 rather than binding to the CCR5 
transmembrane cavity, which is distinct from other CCR5 antagonists.100,101  
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Figure 2-7. Structures of INCB9471 and Aplaviroc 
 
Other classes of compounds have also been reported to be CCR5 antagonists. 
GlaxoSmithKline filed a patent (WO2004054974) describing some newly discovered 
anti-HIV-1 CCR5 antagonists. Among these compounds, GSK 163929 (30) (Figure 
2-8) showed nanomolar level inhibition activity towards HIV replication and 
successfully completed preclinical studies.102 NSC651016 (31) (Figure 2-8) inhibits 
chemokine binding of CCR5, CXCR4, CCR1 and CCR3, but does not interact with 
CXCR2 or CCR2b. It inhibits a wide range of HIV-1 variants and HIV-2 isolates, and 
could be developed as a topical microbicide.103 Shikonin (32) (Figure 2-8), a major 
component of purple gromwell (zicao, dried root of Lithospermum erythrorhizon) is a 
CCR5 chemokine antagonist with sub-micromolar level antiviral activity.104 Merck 
reported the discovery of several compounds (33-37) (Figure 2-9) with potent CCR5 
binding affinity. However, the anti-HIV activities of these compounds are only 
moderate.105-108 
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Figure 2-8. Selected promising CCR5 antagonists as anti-HIV agents 
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3-2. CXCR4 Inhibitors 
Although the deletion of CCR5 has little impact on an individual's health, 
CXCR4 is involved in a number of physiological processes. In a mice knockout study, 
knocking out either CXCR4 or its only known natural ligand SDF-1 (stromal 
cell-derived factor) resulted in abnormal cerebral development and was embryonically 
lethal.109,110 Whether CXCR4/SDF-1 is vital only in embryonic development needs to 
be further determined. Deletion of SDF-1 also caused defects in B-cell lymphopoiesis 
and bone marrow myelopoiesis in mice.111 These findings make CXCR4 antagonists 
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less feasible. However, although R5 variants are dominant in initial HIV transmission, 
a switch in co-receptor use occurs after transmission, and the virus gains ability to use 
both R5 and X4 during AIDS progression.78 Therefore, CXCR4 antagonists are still 
necessary. The ideal CXCR4 antagonist should block HIV entry without affecting 
CXCR4 down-stream signaling pathways or causing CXCR4 internalization.  
The initial strategy for developing CXCR4 antagonists also focused on mimics 
of the CXCR4 natural ligand SDF-1. In addition to large molecule polypeptides, 
several small molecule CXCR4 antagonists are also under development. AMD3100 
(AnorMED Inc., now Genzyme Corporation) (38) (Figure 2-10) is a low molecular 
weight bicyclam analog with potent anti-X4 HIV variant activity (EC50 ~1.4 nM).112 
Its development was terminated when abnormal cardiac activity was observed in 
Phase II clinical studies. The second generation cyclam analog AMD3465 (39) 
(Figure 2-10) has only one cyclam unit; the other is replaced by 
N-pyridinylmethylene.113 However, although the antiviral activity of 39 is slightly 
better than that of 38, it still lacks oral bioavailability. The mechanism of action of 
cyclam analogs is related to the multiple positive charges associated with the basic 
nitrogen atoms,114 which interact with negatively charged acidic residues in CXCR4. 
Studies showed that residues D171, D262, and E288 are important in CXCR4 binding 
by 38.114 The third generation AMD070 (AMD11070) (40) (Figure 2-10) is 
structurally different from the prior analogs and is also orally bioavailable.115 It is 
highly specific for the CXCR4 receptor. Compounds 38 and 40 have similar binding 
sites114 and exhibits similar antiviral activity against a broad range of X4 and R5X4 
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isolates, but are not active against R5 strains. Compound 40 is currently in Phase II 
clinical trials. 
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Figure 2-10. Structures of AMD analogs 
 
KRH-1636 (Kureha Chemical Industries) (41) is an arginine-based CXCR4 
antagonist with good anti-HIV-1 activity (EC50 ~42nM).116 It was obtained from 
optimization of a high throughput screening lead. It can be absorbed after 
intraduodenal administration to rats, suggesting that it may be orally bioavailable.116 
Further modification led to the discovery of KRH-2731·5HCl (structure has not been 
released), which is a 41-analog with improved antiviral potency (EC50 = 1.0nM) 
against X4 and R5X4 HIV isolates.117 KRH-2731·5HCl is orally bioavailable. 
Mechanism of action study revealed that it binds to ECL2 and ECL3 (second and 
third extracellular loops) of the CXCR4 receptor.80 
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4. Fusion Inhibitors 
As previously mentioned, the binding of CD4/gp120 complex with a 
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chemokine co-receptor leads to a conformational rearrangement in gp120 that enables 
gp41 to reorient parallel to viral and cellular membranes and expose a highly 
hydrophobic fusion-peptide (FP) region of trimeric gp41, which will later insert into 
the cell membrane. FP is located at the N-terminus of gp41, adjacent to two heptad 
repeats (HRs). During the fusion process, HR1 and HR2 form a thermostable, 
six-helix bundle structure.51 The change in free energy associated with this critical 
step provides the force needed for formation of the fusion pore, through which the 
viral capsid is released into the target cell.51  
 
4-1. Large Molecule Fusion Inhibitors 
As early as the 1990s, researchers realized that synthetic peptides based on the 
HR1 and HR2 sequences of gp41 have anti-HIV properties.118,119 The mechanism of 
action of this oligopeptide class is believed to be competitive binding of the synthetic 
peptides with the corresponding HR regions, which is also called the 
“dominant-negative inhibition model”.120  
Until now, fusion inhibitors have been the most successful class of HIV entry 
inhibitors. Enfuvirtide (T20, Fuzeon, Trimeris/Roche) (42) was approved for use in 
combination with other ARTs in treatment-experienced patients in March 2003 by the 
US FDA.121,122 It is a 36-amino acid synthetic peptide that mimics the HR2 region 
(residues 127 to 162 in C-terminal) of gp41.122 By competitively binding to the HR1 
region of gp41, 42 prevents the formation of the six-helix bundle structure that is 
critical as the energy source for the fusion process.123 Compound 42 shows good 
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antiviral potency and long-term safety in clinical use. A synergistic effect has also 
been observed in its combinational use with other ARTs . However, it is administered 
by subcutaneous injection of 90 mg twice daily, which is highly inconvenient. 
Moreover, inhibitor-naive primary HIV-1 isolates exhibited wide ranging 
susceptibilities to 42, and the compound has a relatively low genetic barrier for 
resistance.124 Thus, enfuvirtide is considered only a second-line antiretroviral agent.  
 
 
The second-generation fusion inhibitor Tifuvirtide (T-1249) shows tenfold 
more potent antiviral activity compared with 42.125 It preserves antiviral efficacy to 
42-resistant HIV-1 isolates as well as HIV-2 and SIV variants,125 and is a 39-amino 
acid peptide mimicking a different region of HR2.126 However, its clinical 
development was halted due to formulation challenges.127  
 
4-2. Small Molecule Fusion Inhibitors – Recent Progress with Triterpene 
Derivatives as HIV Inhibitors 
Until now, most reported fusion inhibitors have been large polypeptides, 
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which lack oral bioavailability and are relatively costly. The azo dye ADS-J1 (43) was 
originally defined as a fusion inhibitor;128 however, recent study discovered that it acts 
before the gp41-dependent fusion step.129 Small molecules that can be easily purified 
during manufacture and are more likely to be orally administrated hold better 
potential to be developed into clinical drugs.  
N
N
N N
N
HO3S SO3H
OH
Me
MeO
NH
OH
SO3H
SO3H
OMe
ADS-J1 (43)  
 
4-2-1. Discovery of RPR103611 and IC9564 
Certain triterpene derivatives represent promising small molecule fusion 
inhibitors (exact binding site is currently unknown, but it has been demonstrated that 
this compound class functions at a post-binding, envelope-dependent step involved in 
fusion of the virus to the cell membrane, as discussed below). Betulinic acid (BA, 
3β-hydroxy-lup-20(29)-en-28-oic acid, 44) and platanic acid (45), both of which are 
pentacyclic triterpenes extracted from Syzigium claviflorum, were first reported in 
1994 to suppress HIV-1IIIB replication in vitro, with EC50 values of 1.4 µM and 6.5 
µM, respectively.130 Because of its promising anti-HIV activity and ready availability 
from various natural sources, including white birch trees, BA was selected as a lead in 
an anti-HIV drug discovery program.  
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C-28 ω-aminoalkanoic acid derivatives of BA were then synthesized and 
evaluated for antiviral activity by De Clercq et al.131 Initially, the chain length 
between the C-28 amide bond moiety and the terminal carboxylic acid group (46a-l, 
m = 1–12) (Figure 2-11) was explored, and incremental chain lengthening 
significantly influenced the anti-HIV-1 potency of the derivatives. Compounds with 
amide side chains between amino-octanoic acid and amino-dodecanoic acid (46g-k, m 
= 7–11) showed increased antiviral potency, with amino-undecanoic acid (46j, m = 10) 
being optimal. Condensation of these C-28 ω-aminoalkanoic acid derivatives with a 
second aminoalkanoic acid produced compounds with two amide moieties at different 
positions of the C-28 side chain. It was then discovered that small peptide amide 
derivatives of the parent octanoic acid analog 46g were more potent than both the 
parent compound and 46j. The presence of a small lipophilic space between the two 
amide moieties increased the anti-HIV-1 activity of 46g by around tenfold, and 
substituents on this second aminoalkanoic acid moiety also modulated the antiviral 
potency. This effort led to the discovery of RPR103611 (47) (Figure 2-11), a statine 
derivative, which inhibits the infectivity of several HIV-1 strains in a 10 nM 
concentration range.131,132  
Research in the authors' laboratories on BA derivatives as HIV entry inhibitors 
focused on the modifications in the isopropylene and C-28 side chains. The study 
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showed that IC9564 (48) (Figure 2-11), a stereoisomer of RPR103611, exhibits 
equally potent anti-HIV-1 activity.133 This same study also revealed that 
dihydro-IC9564 (49) (Figure 11), with a saturated isopropyl rather than isopropenyl 
group, and 50, a L-leucine derivative of (betulinylamino)-undecyclic acid (Figure 
2-11) also were equipotent against HIV-1 virus compared with RPR103611 and 
IC9564.133 Compound 50 is synthesized more easily than RPR103611 and IC9564.  
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Figure 2-11. C-28 Modified BA as HIV Entry Inhibitors 
 
Other triterpene skeletons, including glycyrrhetinic acid (GLA, 51), moronic 
acid (MA, 52), oleanolic acid (OA, 53), and ursolic acid (UA, 54) as well as their 
derivatives modified at a position corresponding to C-28 of BA, were also synthesized 
and evaluated.134 However, none of these analogs were better than RPR103611 and 
IC9564, indicating that the BA triterpenoid skeleton itself, in addition to the C-28 side 
chain moiety, is also a pharmacophore for antiviral potency.  
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4-2-2. Mechanism of Action Study of RPR103611 and IC9564 
RPR103611 does not inhibit RT, integrase, or protease. A time-of-addition 
assay indicated that postponing the addition time of RPR103611 for 2 h cancelled its 
inhibitory potency on HIV-1 replication, suggesting that this compound functions at 
an early stage of the virus life cycle.132 A virus binding assay using recombinant 
soluble CD4 ruled out the possibilities that attachment of virus to target cells or 
CD4-gp120 binding were inhibited. RPR103611 does blockage syncytium formation, 
which indicates that it functions at a post-binding step necessary for virus-membrane 
fusion. Thus, this compound is the first nonpeptidic small molecule found to act as a 
fusion inhibitor.132 
A sequence analysis of RPR103611-resistant mutants indicated that a single 
amino acid change, I84S, in the HIV-1 gp41 region is sufficient to confer drug 
resistance.135 The I84 residue is highly conserved and is only rarely replaced by 
another hydrophobic residue (e.g., phenylalanine). However, I84 is also found in gp41 
of some naturally RPR103611-resistant HIV-1 strains, such as NDK or ELI.135 Thus, 
although the drug-resistant mutants occur on gp41, it would be imprudent to conclude 
that gp41 is the direct target for RPR103611. It is possible that the mutation of I84 to 
a polar amino acid may alter the gp41 conformation so that the stability of the 
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gp120-gp41 complex is affected.135 The mutation could also modify access of a 
compound to a target on gp120. Indeed, a later study from the same group reported 
that the antiviral efficacy of RPR103611 depends on both the sequence of the gp41 
loop region (I84, L91) and the stability of the gp120-gp41 complex.136 Virus with a 
decreased affinity between gp120 and gp41 is more susceptible to RPR103611.136  
A mechanism of action study on IC9564 by Chen et al. revealed that mutations 
in gp120 are responsible for resistance to the compound.137 No mutations on gp41 
were found to significantly affect the antiviral activity of the compound.137 However, 
this discovery does not rule out the possibility that IC9564 and RPR103611 share the 
same mechanism of action, since IC9564-resistant viral strains carry mutations of 
G237R and R252K, which locate in the inner domain of gp120 core. The inner 
domain of gp120 is believed to interact with gp41, indicating that these mutations on 
gp120 may also affect the affinity between gp120 and gp41.137 In this particular study, 
no mutations were found in the regions of gp120 that are well defined for CD4 
binding or chemokine co-receptor binding. In continuing studies, a conformational 
change in gp120 induced by IC9564 was observed by using conformational 
monoclonal antibody.138,139 It was discovered that IC9564 induces a nonproductive 
gp120 conformation that is not able to trigger a conformational rearrangement in gp41 
for membrane fusion.139 This discovery supports the previous speculation that 
triterpenes in this class function as nonpeptidic small molecule fusion inhibitors. 
In their most recent publication, Dr. Chen’s group reported that IC9564 can 
increase the antiviral activity of TAK-779 by more than 100-fold.140 Mutations near 
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the tip of the V3 loop were found among IC9564 escaping viruses. Moreover, IC9564 
can compete with the binding of V3 loop monoclonal antibodies and with the binding 
of CD4-gp120 complex to chemokine receptors.140 These results suggested that 
IC9564 may also function by targeting the V3 loop of gp120, a domain involved in 
chemokine receptor binding.140,141 The exact binding target of triterpene derivatives is 
still under investigation.  
 
4-2-3. Current Status of Triterpene Derivatives as Potent HIV-1 Inhibitors 
Interestingly, the anti-HIV-1 targets of triterpene analogs can vary depending 
on the side chain modification positions. C-28 modified BA analogs are potent HIV 
entry inhibitors, while C-3 modified BA derivatives function by blocking virus 
maturation.142 As shown in Table 2-1, reacting 44 and 55 with an acid anhydride and 
DMAP in pyridine afforded 3-O-acyl-BA and dihydro-3-O-acyl-BA derivatives. BA 
analogues with 3,3-dimethylsuccinyl (DSB, 58), and 3,3-dimethylglutaryl (61) side 
chains exhibited dramatically enhanced anti-HIV activity with EC50 values in the 
nanomolar range. The corresponding substituted dihydro-BA derivatives [65 (DSD) 
and 68] showed comparable potency. Compounds 69 and 70, which have an isovaleryl 
domain but lack a terminal carboxylic acid, were less potent, and compound 62, 
which lack both features, exhibited no activity. In addition, BA analogues with C-3 
ester groups containing no substitutions on the side chain (56, 59, 63, 66) also showed 
reduced or no activities. These data suggested that, within the C-3 side chain, a 
terminal carboxylic acid and an isovaleryl domain contribute to anti-HIV activity.   
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Table 2-1. Structures of 3-O-acyl-BA and dihydro-3-O-acyl-BA derivatives and 
their anti-HIV-1 activities in acutely infected H9 lymphocytes 
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Compd IC50 (µM) EC50 (µM) TI Compd IC50 (µM) EC50 (µM) TI 
44 13.0 1.4 9.3 55 12.6 0.9 14 
56 16 4.0 4 63 13.4 1.8 7.5 
57 15.9 2.7 6.7 64 7.7 0.56 13.8 
58 (DSB) 7 0.00035 20,000 65 (DSD) 4.9 0.00035 14,000
59 12.8 0.044 292 66 7.9 0.9 9 
60 11.7 0.01 1,170 67 5.8 0.0057 1,000 
61 4.5 0.0023 2,000 68 13.1 0.0056 2,344 
62 48 19 2.5 69 83 1.5 56 
    70  NS  
NS: No suppression.   
 
Compound 58 (DSB, PA-457, bevirimat), which exhibits remarkable 
anti-HIV-1 activity with a mean EC50 value of <10 nM against primary and 
drug-resistant HIV-1 isolates,143,144 was chosen to do further mechanism of action 
study. It was discovered that 58 blocks the cleavage of CA-SP1 in the Gag 
polyprotein precursor, resulting in production of morphologically defective, 
non-infectious HIV-1 virions.145 Thus, bevirimat (DSB, PA-457, Panacos 
Pharmaceuticals) (58) represents the first in a class known as HIV-1 maturation 
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inhibitors. It is orally bioavailable and shows good safety and pharmacokinetic 
profiles in Phase IIa clinical trials.146,147 It is encouraging that triterpene analogs can 
be safely and efficiently used in humans.  
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Recent progress in this research area has included the development of 
bi-functional BA analogs, which contain both the C-3 and C-28 side chains, such as 
A12-2 (71), with EC50 value of 2.6 nM.148 This category of compounds preserves the 
anti-entry and anti-maturation activities of the parent compounds, and shows a 
synergistic effect on antiviral potency. 
 
5. Conclusion 
With increasing knowledge of the HIV entry process, various targets involved 
in different stages of viral entry have emerged. Inhibitors of these novel targets hold 
great potential to supplement current HAART, especially to treat individuals 
harboring multidrug-resistant virus. The success of enfuvirtide and maraviroc 
validates the clinical application of viral entry inhibitors as a new class of 
antiretroviral drugs. Many more HIV entry inhibitors are currently in clinical trials, 
and some have already advanced to Phase III clinical studies.  
Triterpenes represent one of these promising compound classes. Within 
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different triterpenoid skeletons, betulinic acid (BA, 44) is of particular interests due to 
its promising anti-HIV-1 activity and ready availability. Modifications of BA at 
different positions can render the compound with enhanced anti-HIV-1 activity with 
different mechanisms of action. Further modification on this compound should 
provide us more SAR information and may lead us to discover novel promising 
anti-HIV agents. With the emergence of HIV virus resistant to different current ARTs, 
the development of new antiviral drugs is still the focus of much research.  
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Chapter 3. Design, Synthesis and Anti-HIV-1 Activity of 
3-O-Acyl-Betulinic Acid Derivatives as Maturation 
Inhibitors 
 
1. Introduction 
As introduced in Chapter 2, our modification study on betulinic acid (BA, 44) 
resulted in the discovery of 3-O-(3’,3’-dimethylsuccinyl)-betulinic acid (bevirimat, 
DSB, PA-457, 58).143 Bevirimat exhibits extremely potent antiviral activity against 
HIV-1 primary isolates and drug-resistant virus, and represents a unique first in a class 
of anti-HIV compounds termed maturation inhibitors (MIs).144,145 It has recently 
succeeded in Phase IIa clinical trials and is currently in Phase IIb clinical 
trials.146,147,149 
Our prior structure-activity relationship (SAR) study of 58 and other 
3-O-acyl-betulinic acid derivatives suggested that both the BA triterpenoid skeleton 
itself and C-3 ester substitution are critical to enhanced anti-HIV-1 activity.142,143 
Within the C-3 side chain, the proper length, a terminal carboxylic acid, and C-3’ 
dimethyl substitution contribute to antiviral potency. However, the C-3 ester groups of 
prior 44-analogs have mainly contained freely rotatable alkyl chains with a terminal 
carboxylic acid group. Therefore, five C-3 conformationally restricted 44-analogs 
were synthesized in order to explore the conformational space of the C-3 ester 
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substitution. Moreover, four 3-O-monomethylsuccinyl betulinic acid (MSB) 
derivatives as well as two additional C-3 modified 44-analogs were designed and 
synthesized to investigate how the methyl substituents on the C-3 side chain impact 
the antiviral potency and further establish SAR of the C-3 modification. This chapter 
reports their design, syntheses, isolation, structural assignment, and SAR study.  
 
2. Design 
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Figure 3-1. Structures of four MSB analogs and other 3-O-acyl BA analogs  
 
Because the presence of C-3 substitution is critical to the anti-HIV-1 activity 
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of 44-derivatives, five conformationally restricted 3-O-acyl-BA analogs (72-76) 
(Figure 3-1) were synthesized and evaluated in HIV-1 infected MT-2 cell lines, in 
order to further explore the conformational space of this pharmacophore. The C-3’ 
dimethyl group was also moved towards the 4’-position of a C-3 glutaryl-substituted 
compound (81) to study the influence of a different positioning of the methyl groups. 
In addition, although we know that the presence of the C-3’ dimethyl within the C-3 
side chain is vital to anti-HIV-1 activity, it is still unclear which, if either, C-3’ methyl 
group of 58 contributes more toward activity. Therefore, 3-O-monomethylsuccinyl 
betulinic acid (MSB) derivatives (77-80) (Figure 3-1) were designed and synthesized. 
Their antiviral activities were also evaluated in vitro against HIV-1 replication in 
MT-2 cell lines. After reviewing the initial promising bioassay results (data listed in 
Table 3-1), compound 82 (Figure 3-1) was designed to further study the impact of the 
substituents within the C-3 side chain and try to improve the antiviral potency of 58.  
 
3. Chemistry 
Compounds 72 and 73 were synthesized by reaction of the corresponding 
cycloalkanedicarboxylic acid with the C-3 β-hydroxyl group of 44 in the presence of 
EDCI and DMAP, resulting in yields of 26% and 35%, respectively (Scheme 3-1). 
Compounds 74-76 and 81 were synthesized according to Scheme 3-2. Reaction of the 
corresponding acid anhydride with 44 furnished the target compounds in yields of 
35-55%.  
To obtain MSB analogs, 44 was treated with 2-methylsuccinic anhydride and 
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DMAP in pyridine at reflux to furnish the racemic 3’-MSB isomers, as well as the 
undesired 2’-MSB isomers. Separation of the four compounds (77-80) was 
challenging, because they differ only by the presence of a 2’ or 3’ (R or S) methyl 
group, but was successfully achieved by using recycle preparative HPLC (Figure 3-2). 
The purities of 77-80 were ascertained by analytical HPLC (Figure 3-3). By 
comparing the 1H-NMR spectra of the purified isomers with those of 58 and 
3-O-(2’,2’-dimethylsuccinyl)-BA (57), peaks 1 and 2 were assigned as the 3’-MSBs, 
and peaks 3 and 4 as the 2’-MSBs. However, the stereochemistries of the C-3’ and 
C-2’ chiral centers were still not determined. Therefore, the 3’R and 3’S isomers were 
also prepared through total synthesis as described below. 
As shown in Scheme 3-3, the hydroxyl of 3R-bromo-2-methylpropanol (83a) 
was first protected by reaction with TBDPSCl in DMF to yield 84a quantitatively. 
The bromide group was then replaced with a cyano group by reaction with sodium 
cyanide in DMSO to furnish 85a in 93% yield. The cyano group was reduced to an 
aldehyde moiety (86a) by using DIBALH, with a yield of 95%.150 The aldehyde was 
then oxidized to a carboxylic acid quantitatively in the presence of NaClO2 and 
NaH2PO4 in DMSO to yield 87a. Reaction of 44 with 87a in the presence of EDCI 
and DMAP led to esterification of the 3β-hydroxy group of 44 with the carboxylic 
acid of 87a to provide 88a in yields of 25-48%. After cleavage of the TBDPS group 
with TBAF in THF, the primary hydroxy group of 89 was oxidized to a carboxylic 
acid in the presence of TEMPO, PhI(OAc)2 in a solution of H2O-CH2Cl2 to give 
3-O-(3’R-methylsuccinyl)-betulinic acid (3’R-MSB, 77).151 The 3’S-MSB isomer (78) 
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was synthesized using the same method starting with 3S-bromo-2-methylpropanol 
(83b). By comparing the HPLC retention times and 1H-NMR spectra of these 
compounds, we determined that peak 1 is the 3’S diastereoisomer (78) and peak 2 is 
the 3’R diastereoisomer (77). Furthermore, the reaction of 2R-methylsuccinic 
anhydride with 44 in THF yielded the 3’R-MSB (77) and 2’R-MSB (79) isomers 
(Scheme 3-1). The HPLC retention times indicated that peak 4 is the 2’R isomer (79). 
Similarly, peak 3 was confirmed as the 2’S isomer (80) (Scheme 3-1). Thus, the 
stereochemistries of the 3’ or 2’ chiral center in 77–80 were fully determined. 
The synthesis of 82 started from the commercially available 
2-ethyl-2-methylsuccinic acid (91), which was stirred in TFAA to form 
2-ethyl-2-methylsuccinic anhydride (92). The reaction of 92 with 44 furnished 
3-O-(3’-ethyl-3’-methylsuccinyl) betulinic acid (82) in 55% yield (Scheme 3-4). 
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Scheme 3-2. Syntheses of compounds 74-81 
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Figure 3-2. Isolation of the four MSB (77-80) isomers by JAI LC-918 recycling 
preparative HPLC. Mobile phase: 85% ACN in water (0.1% TFA); Flowrate: 5.0 
mL/min; Detector: Refractive Index (RI); Column: Alltima C18 5µ 250mm × 22mm. 
Peak 4 (79) and peak 1 (78) were collected during Round 1. Peak 2 (77) and peak 3 
(80) were collected together during Round 1, and subjected again to recycle 
preparative HPLC (Round 2), which yielded pure compounds at cycle 6. Peak 1: 
3’S-MSB (78); Peak 2: 3’R-MSB (77); Peak 3: 2’S-MSB (80); Peak 4: 2’R-MSB (79) 
 51
 
Figure 3-3. Purity confirmation of the four MSB (77-80) isomers by Shimadzu 
LC-20AT. Column: Alltima C18 5µm 150mm x 2.1mm. 
 
4. Results and Discussion 
The newly synthesized conformationally restricted 3-O-acyl-BA analogs 
(72-76) were first tested in acutely HIV-1 infected MT-2 cell lines and compared to 58 
and AZT. The data are listed in Table 3-1. Only the 2-methylmaleic acid substituted 
BA derivative (76) showed moderate anti-HIV-1 activity with a TI of 1.4×102 and 
EC50 of 0.18 µM. A pendant cyclopentyl or cyclohexyl ring within the C-3 side chain 
reduced the antiviral potency of the derivatives (72-75) significantly. One possible 
reason for the reduced or abolished activity of these compounds is that the pendant 
ring moieties are locked into a conformation that is not the bioactive one. 
Alternatively, steric hindrance at the 2’-position [as was seen with 
3-O-(2’,2’-dimethylsuccinyl) BA (57), which had an EC50 of only 2.7 µM] may be a 
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contributing factor to the loss in potency. This hindrance may impart an unfavorable 
interaction with either the binding site, resulting in reduced affinity, or the triterpene 
template, leading to an unfavorable C-3 side chain conformation.  
 
Table 3-1. Anti-HIV-1 activities for compounds 72-82, 90 and 93 in acutely 
infected MT-2 cell lines a 
Compd EC50 (µM) IC50 (µM) Therapeutic Index 
AZT    0.034 1,870 55,000 
58    0.0013 42.78 32,907 
72 2.2 41.89 19 
73    17.3 40.93 2.4 
74 NS 41.06 – 
75 NS 40.27 – 
76    0.18 42.51 236.2 
77    0.12 43.83 365.3 
78    0.0087 32.78 3,768 
79 NS 43.83 – 
80    0.44 43.83 100 
81 0.048 41.75 869.8 
82    0.0006 36.41 60,683 
90 NS 44.93 – 
93 
(77+78) 
   0.016 44.93 2,808 
a All data presented are averages of at least two separate experiments performed by Panacos 
Pharmaceutical Inc. EC50: concentration that inhibits HIV-1 replication by 50%. IC50: 
concentration that inhibits mock-infected MT-2 cell growth by 50%. TI = IC50/EC50. NS: no 
suppression at the testing concentration. 
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In contrast, 3-O-(4’,4’-dimethylglutaryl)-betulinic acid (81) had an antiviral 
EC50 of 0.048 µM and TI of 8.7×102. This result confirms that the dimethyl moiety is 
essential to the anti-HIV-1 potency of 3-O-acyl-BA analogs. Although moving the 
dimethyl substitution to the 2’-position, as in 57, was highly detrimental, moving the 
dimethyl group to the 4’-position of the C-3 side chain was well tolerated and 
significantly increased the antiviral activity, compared with that of the unesterified 
triterpene (44). However, the anti-HIV-1 activity of 81 was still 20-fold less than that 
of 58, indicating that the 3’-position, rather than 4’-position, of the C-3 side chain 
remains the optimal substitution position. Overall, results of the conformationally 
restricted compounds (72-76) and 81 stimulated our interest in further study of the 
importance of the C-3’ dimethyl moiety and the exact contribution of both groups to 
the anti-HIV-1 potency of 58.  
The MSB analogs (77–80) were then synthesized and evaluated in parallel 
with 58 and AZT against viral replication in HIV-1 infected MT-2 cell lines. The 
synthetic intermediate 90 and a 1:1 mixture (93) of the 3’R- and 3’S-MSB isomers (77 
and 78) were also tested. The anti-HIV-1 activity data of these derivatives are also 
listed in Table 3-1.  
Among the MSB derivatives, the 3’S-MSB isomer (78) showed very potent 
antiviral activity with a TI of 3.8×103 and EC50 of 0.0087 µM, which is comparable to 
that of 58 (EC50: 0.0013 µM) and slightly better than that of AZT (EC50: 0.034 µM) in 
this assay system. The 3’R-MSB isomer (77) exhibited only moderate anti-HIV-1 
activity with a TI of 3.7×102 and EC50 of 0.12 µM. The antiviral activity (EC50: 0.016 
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µM) of the mixture (93) of the two stereoisomers fell in between those of 77 and 78. 
This result indicates that the two C-3’ methyl groups in the C-3 ester side chain 
contribute differently to the extremely potent anti-HIV-1 activity of this compound 
class. We postulate that interaction of the 3’S-methyl group with the viral target might 
be essential to the anti-HIV-1 activity of 58. The interaction of the 3’R-methyl group 
within the target is less significant, but still necessary, since 58, with dimethyl 
substitution at C-3’ position, is slightly more potent than 78, which has 
3’S-monomethyl substitution. In comparison with 77 and 78, both 2’-MSBs (79, 80) 
exhibited no or little activity in the same assay. These results agree with those of our 
previous SAR study, indicating that methyl substitution at C-2’ position is not favored 
and does not improve the antiviral activity significantly. In addition, compound 90, 
which differs structurally from 78 only in the presence of a primary hydroxyl rather 
than carboxylic acid at the terminus of the 3-O-acyl side chain, had no activity. This 
result is also consistent with our findings in prior studies that the terminal carboxylic 
acid is essential for enhanced antiviral activity. 
In order to further elucidate the mechanism of action, the production of virus 
from 3’S-MSB (78)-treated HIV-1NL4-3 or resistant variants infected Hela cells were 
subjected to characterization. Radioimmunoprecipitation analyses revealed that, like 
58, 78 also functions as a maturation inhibitor. In detail, 78 specifically inhibited the 
conversion of p25 (CA-SP1) to p24 (CA) in both cell and virion lysates (Figure 3-4), 
resulting in defective Gag processing and production of morphologically abnormal, 
non-infectious virion particles.  
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Figure 3-4. Effect of 3’S-MSB (78) on virus particle production and Gag 
processing. Note the accumulation of p25 in the presence of 78. A1V is CA-SP1 mutants 
resistant to bevirimat (58). L231M is PI-resistant viral mutants. 
 
As stated above, our investigation of the C-3’ chiral center of the anti-HIV-1 
clinical trials agent 58 showed that the 3’S-methyl group is the major contributor to 
enhanced anti-HIV-1 activity, while the 3’R methyl group is less important but still 
necessary. Accordingly, we postulated that the latter effect may be due to insufficient 
interaction of the 3’R substituent within the binding pocket or a slightly different 
positioning of the 3’S-methyl group when a 3’R-moiety is not present. To confirm our 
hypothesis, one of the methyl groups was further enlarged to an ethyl group to give 
the 3’-ethyl-3’-methyl substitution found in 82, which is a mixture of 3’R and 3’S 
isomers. Compound 82 was evaluated and compared with 58 and AZT in the same 
assay system. It showed extremely potent antiviral activity with a TI of 6.1×104 and 
EC50 of 0.0006 µM, which was more active than AZT and the mixture (93) of 
3’R-MSB and 3’S-MSB (77 and 78). Indeed, its potency was slightly better than that 
of the pure 3’S-MSB isomer (78) and that of 58. This result confirms our hypothesis 
that enlarging the C-3’ moiety will further increase the antiviral potency of this 
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compound class. Because the activity of a racemic mixture usually falls between those 
of the two pure isomers (for example, as was seen with 93 compared to 77 and 78), 
whether the 3’R isomer or the 3’S isomer of 82 is more potent needs to be further 
determined. The separation of the two isomers also used recycling preparative HPLC 
(JAI LC-918). This information may help us to better understand the SAR of this 
critical pharmacophore and further improve the anti-HIV-1 activity of this compound 
class. 
To conclude our SAR investigation of the C-3 modification, we found that no 
conformationally restricted 3-O-acyl BA analog (72-76) showed significant antiviral 
activity, indicating that C-3’ dimethyl substitution of the succinyl side chain is crucial 
to the high potency of 58. Further SAR study of the C-3’ chiral center of the newly 
designed MSB analogs (77-80) revealed that the 3’S-methyl group of 58 is the major 
contributor to the compound’s enhanced anti-HIV-1 activity. This result led us to 
design and synthesize 3-O-acyl-BA derivative 82 with an enlarged C-3’ substituent. 
As we anticipated, 82 showed extremely potent antiviral activity, and was slightly 
better than 58. Because 82 is a mixture of the 3’R and 3’S isomers, separation of these 
two isomers may provide us with better SAR information to further design the next 
generation of potent 44-derived HIV-1 maturation inhibitors. 
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5. Experimental Section 
5-1. Chemistry 
The melting points were measured with a Fisher Johns melting apparatus 
without correction. 1H NMR spectra were measured on a 300MHz Varian Gemini 
2000 spectrometer using Me4Si (TMS) as internal standard. The solvent used was 
CDCl3 unless otherwise indicated. Mass spectra were measured on Shimadzu 
LCMS-2010 (ESI-MS). Optical rotations were measured with a Jasco Dip-2000 
digital polarimeter at 20 °C at the sodium D line. Thin-layer chromatography (TLC) 
and preparative thin-layer chromatography (PTLC) were performed on Merck 
precoated silica gel 60 F-254 plates. Flash+TM and CombiFlash systems were used as 
medium pressure column chromatography. Silica gel (200-400 mesh) from Aldrich, 
Inc., was used for column chromatography. All other chemicals were obtained from 
Aldrich, Inc.  
Synthesis of BA derivatives (72 and 73). A solution of betulinic acid (1 eq), 
N-(3-Dimethylaminopropyl)-N’-ethylcarbodiimide hydrochloride (EDCI, 8 eq), 
4-(dimethylamino)pyridine (DMAP, 2 eq) and the proper cycloalkanedicarboxylic 
acid (5 eq) in anhydrous CH2Cl2 (8 mL) was stirred at room temperature overnight 
until the starting material was not observed by TLC. The solution was diluted with 
CH2Cl2 (20 mL) and washed three times with brine and distilled water. The organic 
layer was dried over anhydrous sodium sulfate (Na2SO4) and concentrated to dryness 
under reduced pressure. The residue was chromatographed using a silica gel column 
to yield the pure target compounds. 
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3β-O-[(2’R, 3’R)-3’-Carboxycyclopentanecarbonyl]-betulinic acid (72): 
26% yield (starting with 150 mg of 44); white amorphous powder. Mp 228-230 °C. 
MS (ESI-) m/z: 595.4 (M- - H) for C37H56O6. 1H NMR (300 MHz, CDCl3): δ 4.70, 
4.57 (1H each, s, H-29), 4.45 (1H, dd, J = 7.8, 5.7 Hz, H-3), 3.20 (1H, m, H-19), 3.01, 
2.88 (1H each, m, H-3’, H-2’), 1.85-2.06 (6H, m, 3 × CH2, H-4’, 5’, 6’), 1.65 (3H, s, 
H-30), 0.94 (6H, s, 2 × CH3), 0.85, 0.81, 0.75 (3H each, s, 3 × CH3). [α]20D -15.29 ° (c 
= 0.17, MeOH). 
3β-O-[(2’R, 3’R)-3’-Carboxycyclohexanecarbonyl]-betulinic acid (73): 
35% yield (starting with 150 mg of 44); white amorphous powder. Mp 233-235 °C. 
MS (ESI-) m/z: 609.4 (M- - H) for C38H58O6. 1H NMR (300 MHz, CDCl3): δ 4.71, 
4.59 (1H each, s, H-29), 4.46 (1H, dd, J = 10.2, 5.1 Hz, H-3), 2.98 (1H, m, H-19), 
2.89, 2.71 (1H each, m, H-3’, H-2’), 1.84-2.16 (8H, m, 4 × CH2, H-4’, 5’, 6’, 7’), 1.66 
(3H, s, H-30), 0.94 (9H, s, 3 × CH3), 0.81, 0.79 (3H each, s, 2 × CH3). [α]20D -27.00 ° 
(c = 0.20, MeOH). 
Synthesis of BA derivatives (74-76, 79, 80 and 81). A solution of betulinic 
acid (1 eq), DMAP (2 eq) and the proper acid anhydride (5 eq) in anhydrous pyridine 
(1.5 mL) was stirred at 160 oC for 2 h using microwave. The reaction mixture was 
diluted with EtOAc (20 mL) and washed three times with 20% HCl solution and 
distilled water. The organic layer was dried over anhydrous Na2SO4 and concentrated 
to dryness under reduced pressure. The residue was chromatographed using a silica 
gel column to yield the pure target compounds. 
3β-O-(3’-Carboxycyclohex-5’-enecarbonyl)-betulinic acid (74): 40% yield 
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(starting with 100 mg of 44); white amorphous powder. Mp 178-180 °C. MS (ESI-) 
m/z: 607.4 (M- - H) for C38H56O6. 1H NMR (300 MHz, CDCl3): δ 5.70 (2H, m, H-5’, 
6’), 4.72, 4.60 (1H each, s, H-29), 4.48 (1H, m, H-3), 3.02 (1H, m, H-19), 2.83, 2.72 
(1H each, m, H-3’, H-2’), 2.32-2.27 (4H, m, 2 × CH2, H-4’, 7’), 1.68 (3H, s, H-30), 
1.01, 0.97 (3H each, s, 2 × CH3), 0.89, 0.83, 0.81 (3H each, s, 3 × CH3). [α]20D  
+14.17 ° (c = 0.18, MeOH). 
3β-O-[3’-Carboxybicyclo[2.2.1]hept-5’-enecarbonyl]-betulinic acid (75): 
35% yield (starting with 100 mg of 44); white amorphous powder. Mp 165-167 °C. 
MS (ESI-) m/z: 619.4 (M- - H) for C39H56O6. 1H NMR (300 MHz, CDCl3): δ 5.73 (2H, 
m, H-5’, 6’) 4.71, 4.59 (1H each, s, H-29), 4.45 (1H, m, H-3), 3.01 (1H, m, H-19), 
2.95, 2.76 (1H each, m, H-3’, H-2’), 2.52-2.39 (4H, m, 2 × CH2, H-4’, 7’), 1.67 (3H, s, 
H-30), 0.96 (6H, s, 2 × CH3), 0.91, 0.85, 0.82 (3H each, s, 3 × CH3). [α]20D +24.00 ° 
(c = 0.10, MeOH). 
3β-O-[(Z)-3’-Carboxybut-2-enoyl]-betulinic acid (76): 55% yield (starting 
with 150 mg of 44); red amorphous powder. Mp 169-171 °C. MS (ESI-) m/z: 567.4 
(M- - H) for C35H52O6. 1H NMR (300 MHz, CDCl3): δ 5.89 (1H, s, H-2’), 4.70, 4.58 
(1H each, s, H-29), 4.46 (1H, m, H-3), 2.96 (1H, m, H-19), 1.93 (3H, s, CH3-3’), 1.66 
(3H, s, H-30), 0.94, 0.93, 0.90 (3H each, s, 3 × CH3), 0.80, 0.79 (3H each, s, 2 × CH3). 
[α]20D +9.41 ° (c = 0.17, MeOH). 
3β-O-(2’R-Methylsuccinyl)-betulinic acid (79): 8% (after HPLC separation); 
white amorphous powder. Mp 250–252 °C. MS (ESI-) m/z: 569.38 (M- - H) for 
C35H54O6. 1H NMR (300 MHz, CDCl3): δ 4.73, 4.60 (1H each, s, H-29), 4.52 (1H, t, J 
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= 7.8 Hz, H-3), 2.90-3.10 (2H, m, H-19, H-2’), 2.67, 2.42 (1H each, dd, J = 16.8, 9.6, 
4.2, H-3’), 2.13-2.20 (1H, m, H-13), 1.68 (3H, s, H-30), 1.26, 1.23 (3H, d, J = 7.2 Hz, 
CH3-2’), 0.97 (6H, s, 2 × CH3), 0.86, 0.83, 0.81 (3H each, s, 3 × CH3). [α]20D +12.94 ° 
(c = 0.17, MeOH). 
3β-O-(2’S-Methylsuccinyl)-betulinic acid (80): 15% (after HPLC separation); 
white amorphous powder. Mp 256–259 °C. MS (ESI-) m/z: 569.38 (M- - H) for 
C35H54O6. 1H NMR (300 MHz, CDCl3): δ 4.74, 4.61 (1H each, s, H-29), 4.48 (1H, dd, 
J = 10.8, 4.8 Hz, H-3), 2.80-3.01 (2H, m, H19, H-2’), 2.76, 2.46 (1H each, dd, J = 
16.9, 9.5, 4.7, H-3’), 2.10-2.18 (1H, m, H-13), 1.69 (3H, s, H-30), 1.25, 1.23 (3H, d, J 
= 6 Hz, CH3-2’), 0.97, 0.92 (3H each, s, 2 × CH3), 0.84-0.86 (9H, m, 3 × CH3). [α]20D 
-11.00 ° (c = 0.10, MeOH). 
3β-O-(4’,4’-Dimethylglutaryl)-betulinic acid (81): 53% yield (starting with 
100 mg of 44); white amorphous powder. Mp 228-230 °C. MS (ESI-) m/z: 597.4 (M- - 
H) for C37H58O6. 1H NMR (300 MHz, CDCl3): δ 4.73, 4.61 (1H each, s, H-29), 4.45 
(1H, dd, J = 9.0, 5.2 Hz, H-3), 3.00 (1H, m, H-19), 2.32 (2H, dd, J = 6.6, 5.4 Hz, 
H-2’), 2.16 (1H, m, H-13), 1.69 (3H, s, H-30), 1.22, 1.21 (3H each, d, J = 6 Hz, 2 × 
CH3-4’), 0.97, 0.91 (3H each, s, CH3-23, 24), 0.86, 0.85, 0.83 (3H each, s, CH3-25, 26, 
27). [α]20D -0.77 ° (c = 0.13, MeOH). 
Synthesis of 84a and 84b. A solution of 83a or 83b (1 eq), imidazole (1.1 eq) 
and TBDPSCl (1.1 eq) in dry DMF was stirred at room temperature, until the starting 
material was not observed by TLC. The reaction mixture was diluted with EtOAc and 
washed with 20% HCl solution and distilled water. The organic layer was dried over 
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anhydrous Na2SO4 and concentrated to dryness under reduced pressure. The residue 
was chromatographed using a silica gel column to yield the pure target compounds. 
(3R-Bromo-2-methylpropoxy)(tert-butyl)diphenylsilane (84a): 2.03 g 
(100%) yielded from 83a; colorless oil. MS (ESI+) m/z: 391.2 (M+ + H), 413.2 (M+ + 
Na) for C20H27BrOSi.  
(3S-Bromo-2-methylpropoxy)(tert-butyl)diphenylsilane (84b): 1.44 g 
(100%) yielded from 83b; colorless oil. MS (ESI+) m/z: 391.1 (M+ + H), 413.1 (M+ + 
Na) for C20H27BrOSi.  
Synthesis of 85a and 85b. To a solution of 84a or 84b (1 eq) in dry DMSO 
(10 mL) was added sodium cyanide (3 eq). The mixture was stirred at 120 oC for 2 h 
until the starting material was not observed. After cooling to room temperature, the 
reaction was diluted with ether (30 mL) and washed with distilled water. The organic 
layer was dried over anhydrous Na2SO4 and concentrated to dryness under reduced 
pressure. The residue was chromatographed using a silica gel column to yield the pure 
target compounds. 
4-(tert-Butyldiphenylsilyloxy)-3R-methylbutanenitrile (85a): 1.70g (93%) 
yield starting with 84a; colorless oil. MS (ESI+) m/z: 338.2 (M+ + H) for 
C21H27NOSi.  
4-(tert-Butyldiphenylsilyloxy)-3S-methylbutanenitrile (85b): 1.163 g (93%) 
yield starting with 84b; colorless oil. MS (ESI+) m/z: 338.2 (M+ + H) for 
C21H27NOSi. 
Synthesis of 86a and 86b. To a solution of 85a or 85b (1 eq) in anhydrous 
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toluene (10 mL) was added diisobutylaluminium hydride (DIBALH, 1.1 eq) dropwise 
at 0 oC under argon. After stirring for 30 min, ice water was added slowly followed by 
10% HCl and aqueous saturated potassium tartrate. Stirring was continued for 15 min 
at 0 oC and then the aqueous layer was extracted three times with CH2Cl2. The organic 
layer was dried over anhydrous Na2SO4 and concentrated to dryness under reduced 
pressure. The residue was chromatographed using a silica gel column to yield the pure 
target compounds. 
4-(tert-Butyldiphenylsilyloxy)-3R-methylbutanal (86a): 1.02 g (95%) yield 
starting with 85a; colorless oil. MS (ESI+) m/z: 341.2 (M+ + H) for C21H28O2Si. 
4-(tert-Butyldiphenylsilyloxy)-3S-methylbutanal (86b): 1.047 g (90%) 
yield starting with 85a; colorless oil. MS (ESI+) m/z: 341.2 (M+ + H) for C21H28O2Si. 
Synthesis of 87a and 87b. To a solution of 86a or 86b (1 eq) in dry DMSO 
(1.0 mL) was added NaH2PO4·H2O (0.8 eq in 2.0 mL H2O) and 80% NaClO2 (1.5 eq 
in 2.0 mL H2O) dropwise over 5min. The mixture was stirred overnight. The reaction 
was quenched with saturated NH4Cl solution and extracted with EtOAc. The organic 
layer was washed with brine, dried over anhydrous Na2SO4 and concentrated to 
dryness under reduced pressure. The residue was chromatographed using a silica gel 
column to yield the pure target compounds. 
4-(tert-Butyldiphenylsilyloxy)-3R-methylbutanoic acid (87a): 700 mg 
(100%) yield starting with 86a; colorless oil. MS (ESI-) m/z: 355.2 (M- - H) for 
C21H28O3Si. 1H NMR (300 MHz, CDCl3): δ 7.68-7.62 (4H, m, H ar-2’), 7.45-7.33 
(6H, m, H ar-3’, 4’), 3.59, 3.43 (2H, dd, J = 7.6, 1.5 Hz, H-4), 2.61-2.30 (3H, m, H-2, 
 63
H-3), 1.05 (9H, s, SiC(CH3)3), 0.95 (3H, d, J = 10 Hz, H-5).  
4-(tert-Butyldiphenylsilyloxy)-3S-methylbutanoic acid (87b): 830 mg (76%) 
yield starting with 86b; colorless oil. MS (ESI-) m/z: 355.2 (M- - H) for C21H28O3Si. 
1H NMR (300 MHz, CDCl3): δ 7.68-7.62 (4H, m, H ar-2’), 7.45-7.33 (6H, m, H ar-3’, 
4’), 3.58, 3.42 (2H, dd, J = 7.6, 1.5 Hz, H-4), 2.60-2.30 (3H, m, H-2, H-3), 1.05 (9H, s, 
SiC(CH3)3), 0.95 (3H, d, J = 10 Hz, H-5).   
Synthesis of 88a and 88b. A solution of betulinic acid (1 eq), EDCI (8 eq), 
DMAP (2 eq) and 87a or 87b (5 eq) in anhydrous CH2Cl2 (5 mL) was stirred at room 
temperature overnight, until the starting material was not observed by TLC. The 
solution was diluted with CH2Cl2 (15 mL) and washed three times with brine and 
distilled water. The organic layer was dried over anhydrous Na2SO4 and concentrated 
to dryness under reduced pressure. The residue was chromatographed using a silica 
gel column to yield the pure target compounds. 
3β-O-[4’-(tert-Butyldiphenylsilyloxy)-3’R-methylbutanoyl]-betulinic acid 
(88a): 32% yield starting with 340 mg BA, white powder. Mp 179-181 °C. MS (ESI-) 
m/z: 793.5 (M- - H) for C51H74O5Si. 1H NMR (300 MHz, CDCl3): δ 7.68-7.62 (4H, m, 
H ar-2’), 7.45-7.33 (6H, m, H ar-3’, 4’), 4.72, 4.60 (1H each, s, H-29), 4.45 (1H, m, 
H-3), 3.58, 3.42 (2H, m, H-4’), 2.87-2.95 (2H, m, H-19, H-3’), 2.64-2.42 (2H, m, 
H-2’), 1.69 (3H, s, H-30), 1.28, 1.26 (3H, d, J = 6 Hz, CH3-3’), 1.01 (9H, s, 
SiC(CH3)3), 0.96 (6H, s, 2 × CH3), 0.89, 0.85, 0.82 (3H each, s, 3 × CH3).  
3β-O-[4’-(tert-Butyldiphenylsilyloxy)-3’S-methylbutanoyl]-betulinic acid 
(88b): 48% yield starting with 170 mg BA, white powder. Mp 186-187 °C. MS (ESI-) 
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m/z: 793.5 (M- - H) for C51H74O5Si. 1H NMR (300 MHz, CDCl3): δ 7.68-7.62 (4H, m, 
H ar-2’), 7.45-7.33 (6H, m, H ar-3’, 4’), 4.73, 4.60 (1H each, s, H-29), 4.51 (1H, dd, J 
= 11.1, 4.8 Hz, H-3), 3.60-3.42 (2H, m, H-4’), 2.96-3.03 (1H, m, H-19), 2.86-2.93 
(1H, m, H-3’), 2.73, 2.69 (1H each, dd, J = 11.2, 5.7, 4.8 Hz, H-2’), 1.69 (3H, s, 
H-30), 1.27, 1.25 (3H, d, J = 6 Hz, CH3-3’), 1.02 (9H, s, SiC(CH3)3), 0.97, 0.94, 0.86, 
0.85, 0.81 (3H each, s, CH3-23, 24, 25, 26, 27).  
Synthesis of 89 and 90. A solution of 88a or 88b (1 eq) and TBAF (1.0 M in 
THF, 3 eq) in anhydrous THF was stirred at 0 oC for 1.5 h. The mixture was then 
allowed to warm to room temperature and stirred until there was no starting material 
detected by TLC. The reaction was diluted with 15 mL of CH2Cl2 and washed with 
saturated NH4Cl solution and brine. The organic layer was dried over anhydrous 
(Na2SO4 and concentrated to dryness under reduced pressure. The residue was 
chromatographed using a silica gel column to yield the pure target compounds. 
3β-O-(4’-Hydroxy-3’R-methylbutanoyl)-betulinic acid (89): 100% yield 
from 88a, white powder. Mp 201-203 °C. MS (ESI-) m/z: 555.4 (M- - H) for C35H56O5. 
1H NMR (300 MHz, CDCl3): δ 4.73, 4.60 (1H each, s, H-29), 4.54 (1H, dd, J = 9.9, 
5.7 Hz, H-3), 3.55, 3.42 (2H, m, H-4’), 3.01 (1H, m, H-19), 2.87-2.95 (1H, m, H-3’), 
2.70-2.42 (2H, m, H-2’), 1.68 (3H, s, H-30), 1.27, 1.25 (3H, d, J = 6 Hz, CH3-3’), 
0.93 (6H, s, 2 × CH3), 0.85, 0.84, 0.81 (3H each, s, 3 × CH3). [α]20D +15.50 ° (c = 
0.12, MeOH). 
3β-O-(4’-Hydroxy-3’S-methylbutanoyl)-betulinic acid (90): 100% yield 
from 88b, white powder. Mp 229-231 °C. MS (ESI-) m/z: 555.4 (M- - H) for C35H56O5. 
 65
1H NMR (300 MHz, CDCl3): δ 4.73, 4.60 (1H each, s, H-29), 4.51 (1H, dd, J = 12.5, 
5.6 Hz, H-3), 3.58, 3.43 (2H, m, H-4’), 2.97-3.01 (1H, m, H-19), 2.83-2.92 (1H, m, 
H-3’), 2.70, 2.62 (1H each, dd, J = 16.2, 6.3, 4.8 Hz, H-2’), 1.69 (3H, s, H-30), 1.27, 
1.25 (3H, d, J = 6 Hz, CH3-3’), 1.01, 0.96, 0.86, 0.85, 0.81 (3H each, s, CH3-23, 24, 
25, 26, 27). [α]20D -16.10 ° (c = 0.11, MeOH). 
Synthesis of 77 and 78. To a solution of 89 or 90 (1 eq) in CH2Cl2 (5 mL) was 
added TEMPO (0.1 eq), and PhI(OAc)2 (1.5 eq). The mixture was stirred at room 
temperature until the starting material was not observed by TLC. The reaction was 
filtered through thin silica gel pad and eluted with CH2Cl2 and washed with saturated 
NH4Cl solution and brine. The organic layer was dried over anhydrous Na2SO4 and 
concentrated to dryness under reduced pressure. The residue was chromatographed 
using a silica gel column to yield the pure target compounds. 
3β-O-(3’R-Methylsuccinyl)-betulinic acid (77): 75% yield from 89, white 
amorphous powder. Mp 268–271 °C. MS (ESI-) m/z: 569.38 (M- - H) for C35H54O6. 
1H NMR (300 MHz, CDCl3): δ 4.73, 4.60 (1H each, s, H-29), 4.54 (1H, dd, J = 9.9, 
5.7 Hz, H-3), 3.01 (1H, m, H-19), 2.87-2.95 (1H, m, H-3’), 2.84, 2.42 (1H each, dd, J 
= 15.9, 8.3, 5.6, H-2’), 2.10-2.20 (1H, m, H-13), 1.69 (3H, s, H-30), 1.28, 1.26 (3H, d, 
J = 6 Hz, CH3-3’), 0.97 (6H, s, 2 × CH3), 0.86, 0.83, 0.80 (3H each, s, 3 × CH3). 
[α]20D +13.00 ° (c = 0.05, MeOH). 
3β-O-(3’S-Methylsuccinyl)-betulinic acid (78): 88% yield from 90, white 
amorphous powder. Mp 279–281 °C. MS (ESI-) m/z: 569.38 (M- - H) for C35H54O6. 
1H NMR (300 MHz, CDCl3): δ 4.73, 4.60 (1H each, s, H-29), 4.51 (1H, dd, J = 11.1, 
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4.8 Hz, H-3), 2.96-3.03 (1H, m, H-19), 2.86-2.93 (1H, m, H-3’), 2.70, 2.61 (1H each, 
dd, J = 16.2, 6.3, 4.8 Hz, H-2’), 2.06-2.16 (1H, m, H-13), 1.69 (3H, s, H-30), 1.27, 
1.25 (3H, d, J = 6 Hz, CH3-3’), 0.97, 0.94, 0.86, 0.85, 0.81 (3H each, s, CH3-23, 24, 
25, 26, 27). [α]20D -16.88 ° (c = 0.08, MeOH). 
3β-O-(3’-Ethyl-3’-methylsuccinyl)-betulinic acid (82): 
2-Ethyl-2-methylsuccinic acid (50 mg, 4 eq) was stirred in trifluoroacetic anhydride 
(TFAA) at room temperature for 3 h until the reaction mixture become homogenous. 
The solution was then concentrated to dryness under reduced pressure to yield 
2-ethyl-2-methylsuccinic anhydride (92). Compound 92 was reacted without further 
purification with betulinic acid (36 mg, 1 eq) and DMAP (19 mg, 2 eq) in anhydrous 
pyridine (1.5 mL), stirring at 160 oC for 2 h in microwave. The reaction mixture was 
diluted with EtOAc (10 mL) and washed three times with 20% HCl solution and 
distilled water. The organic layer was dried over anhydrous Na2SO4 and concentrated to 
dryness under reduced pressure. The residue was chromatographed using a silica gel 
column to yield 30 mg (55%) of 82; white amorphous powder. Mp 179-181 °C. MS 
(ESI-) m/z: 597.4 (M- - H) for C37H58O6. 1H NMR (300 MHz, CDCl3): δ 4.70, 4.58 (1H 
each, s, H-29), 4.475 (1H, dd, J = 10.2, 5.6 Hz, H-3), 2.99 (1H, m, H-19), 2.73, 2.55 
(1H each, dd, J = 11.9, 5.6, H-2’), 1.66 (3H, s, H-30), 1.34-1.32 (2H, m, CH2-3’), 1.23 
(3H, s, CH3-3’), 1.18 (2H, m, CH3-3’’), 0.94 (6H, s, 2 × CH3), 0.85, 0.84, 0.78 (3H each, 
s, 3 × CH3). [α]20D -3.00 ° (c = 0.10, MeOH). 
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5-2. HIV-1 Replication Inhibition Assay in MT-2 Cell Lines 134,152,153 
The evaluation of HIV-1 inhibition was carried out as follows using MT-2 
lymphocytes. The human T-cell line, MT-2, was maintained in continuous culture with 
complete medium (RPMI 1640 with 10% fetal calf serum supplemented with 
L-glutamine at 5% CO2 and 37°C. Test samples were first dissolved in dimethyl 
sulfoxide (DMSO) at a concentration of 10 mg/mL to generate master stocks with 
dilutions made into tissue culture media to generate working stocks. The following 
drug concentrations were routinely used for screening: 100, 20, 4 and 0.8 µg/mL. For 
agents found to be active, additional dilutions were prepared for subsequent testing so 
that an accurate EC50 value could be determined. Test samples were prepared, and to 
each sample well, was added 90 µl of media containing MT-2 cells at 3×105 cells/mL 
and 45 µL of virus inoculum (HIV-1 IIIB isolate) containing 125 TCID50. Control wells 
containing virus and cells only (no drug) and cells only (no virus or drug) were also 
prepared. A second identical set of samples were added to cells under the same 
conditions without virus (mock infection) for toxicity determinations (IC50 defined 
below). In addition, AZT and bevirimat (DSB, PA-457) were also assayed during each 
experiment as a positive drug control. On day 4 PI, the assay was terminated and 
culture supernatants were harvested for p24 antigen ELISA analysis. The p24 antigen 
is the core protein of HIV and, therefore, it was an indirect measure of virus present in 
the supernantants. The p24 antigen assay used a HIV-1 anti-p24 specific monoclonal 
antibody as the capture antibody coated on 96-well plates. Following a sample 
incubation period, rabbit serum containing antibodies for HIV-1 p24 was used to tag 
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any p24 ‘captured’ onto the microtiter well surface. Peroxidase conjugated goat 
anti-rabbit serum was then used to tag HIV-1 p24 specific rabbit antibodies that have 
complexed with captured p24. The presence of p24 in test samples was revealed by 
addition of substrate to peroxidase. P24 in the culture medium was quantitated against 
a standard curve containing known amounts of p24. The compound toxicity was 
determined by XTT using the mock-infected sample wells. If a test sample inhibited 
virus replication and was not toxic, its effects were reported in the following terms: 
EC50, the concentration of the test sample that was able to suppress HIV replication 
by 50%; IC50, the concentration of test sample that was toxic to 50% of the 
mock-infected cells; and therapeutic index (TI), the ratio of the IC50 to EC50.  
 
5-3. HIV-1 Maturation Inhibition Assay 145 
Hela cells were transfected with pNL4-3 or mutated HIV-1 virus (A1V or 
L231M) and cultured in the absence or presence of 78. Two days post-transfection, 
cells were metabolically labeled for 2h with 35S-Met/Cys. Cell lysates were prepared, 
and virions were pelleted by ultracentrifugation. Cell and viral lysates were 
immunoprecipitated with HIV-Ig. Western blotting was then performed154,155 and p25 
and p24 are indicated. 
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Chapter 4. Synthesis of 28,30-Disubstituted Betulinic Acid 
Derivatives as Novel HIV-1 Entry Inhibitors 
 
1. Introduction 
The betulinic acid (BA, 44) triterpenoid skeleton contains three functional 
groups – C-3 hydroxyl group, C-28 carboxylic acid group and C-19 isopropenyl 
moiety (Figure 4-1). Structural modification of the first two groups resulted in 
identification of different anti-HIV-1 targets. C-3 esterification of BA led to the 
discovery of bevirimat (DSB, 58), which is a maturation inhibitor (MI) that blocks 
cleavage of p25 (CA-sp1) to functional p24 (CA).142,143,145 On the other hand, the 
C-28 side chain was proven to be a necessary pharmacophore for anti-HIV-1 entry 
activity, as seen with RPR103611 (47), IC9564 (48) and A43-D (94) (Figure 4-1), 
which showed potent antiviral activity (EC50 0.05-2 µM) in different assay 
systems.131,133,136,148 Mechanism of action study revealed that C-28 modified BA 
derivatives function at a post-binding, envelope-dependent step involved in fusion of 
the virus to the cell membrane.132 Because most reported fusion inhibitors are large 
molecules that lack orally bioavailability and are relatively costly, analogs 47, 48, and 
94 represent a promising class of small molecule fusion inhibitors. However, the 
clinical development of 47 by Rhone-Poulenc (now Sanofi-Aventis) was stopped due 
to poor “pharmacodynamic properties”,141 suggesting that further modification of this 
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compound class is still necessary. Because the C-19 isopropenyl group has been less 
investigated, modification was carried out on this moiety, as well as the C-28 side 
chain, in order to explore SAR and generate potent BA-derived HIV-1 entry inhibitors. 
This chapter reports their design, syntheses and bioassay data. 
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Figure 4-1. Structures of BA and selected C-28 modified BA derivatives 
 
2. Design 
The C-28 side chain of 44 and its contribution to HIV-1 entry inhibition 
activity has been extensively investigated, and these studies led to the identification of 
lead compounds 47, 48 and 94 (Figure 4-1). However, less effort has been focused on 
the C-19 isopropenyl moiety and its effect on HIV replication. Limited SAR on C-19 
modification suggested that 20(29) double bond saturated dihydro-BA (55) and its 
derivatives showed similar antiviral activity, but slightly increased cytotoxicity, 
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compared with 44 and its corresponding derivatives. Insertion of thioether-linked 
substitution on the C-30 allyl position slightly decreased anti-HIV-1 potency in the 
resulting BA analogs, while substitution through an amine bond abolished antiviral 
activity.  
Because the available SAR is very limited, we carried out additional 
modification on the C-30 side chain in order to better explore its contribution towards 
anti-HIV-1 activity. In this study, diverse substituents were introduced into the C-30 
allyl position (Figure 4-2), including a bromide group (96), methylene chains (97-99) 
and aromatic rings (100-104), which may facilitate hydrophobic interactions, as well 
as morpholine moieties (105-106) and a hydroxyl group (107), which may form 
hydrogen bonds with the binding target. Because analogs with a thioether moiety 
showed only slightly decreased anti-HIV-1 activity, we selected a bioisosteric oxygen 
ether bond as the primary linkage between the added C-30 substituents and the BA 
backbone. Moreover, leucine was incorporated into the C-28 side chain, because 
28-leucine-BA (15bh, 95) (Figure 4-1) showed moderate in vitro anti-HIV-1 entry 
activity (EC50: ~1µM) in a luciferase-based envelope-induced fusion assay. The 
anti-HIV-1 replication activity of these newly synthesized 28,30-disubstituted BA 
analogs (Series I, 96-107) were evaluated in both HIV-1IIIB infected MT-2 and 
HIV-1NL4-3 infected MT-4 cell lines.  
After reviewing bioassay data and attempting to explain the poor 
“pharmacodynamic properties” of 47, the partition coefficient (Log P) value of several 
lead compounds including 47/48 (diastereoisomers), 94 and 95 were calculated by 
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ACD/LogP DB software. The calculated Log P values of 47/48, 94 and 95 are 9.38 (± 
0.63), 9.03 (± 0.54) and 9.57 (± 0.55), respectively. The hydrophobic effect may be 
related to poor tissue distribution profile, increased toxicity and low solubility, which 
may result in poor pharmacodynamic properties in the body. Therefore, several novel 
28, 30-disubstituted BA derivatives (Series II, 108-112) (Figure 4-2) were designed 
and synthesized to address these issues. In this new series, 8-aminooctanoic acid was 
attached at the BA C-28 side chain via an amide bond. Thus, this group replaced the 
shorter leucine moiety in 95 or the mono-acetate protected 1,7-heptanediamine in 94. 
In addition, polar groups such as a hydroxyl group (110) and morpholine moiety (111) 
were incorporated into the C-30 substitution in order to increase the hydrophilicity 
and water solubility of the derivatives. Analog 111, with a morpholine group in the 
C-30 side chain, proved to be a good antiviral hit. Accordingly, its terminal carboxylic 
acid was reacted with methylamine to form a second amide bond in the C-28 side 
chain (112) and modulate the Log P value.  
In addition, the C-3 β-hydroxyl group of 96 was esterified with 
2’,2’-dimethylsuccinic anhydride to furnish 113 (Figure 4-2). This analog was 
designed to study how the presence of both C-28 and C-30 substitutions affected the 
activity of the C-3 modified BA derivative bevirimat (DSB, 58).  
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3. Chemistry 
Scheme 4-1 depicts the syntheses of 28,30-disubstituted BA derivatives 97-16 
and 111-112. The C-3 β-hydroxyl group of BA was protected as the acetate ester by 
reaction with acetic anhydride to yield 3-OAc-BA (114). Compound 114 was treated 
with oxalyl chloride in dichloromethane to yield an intermediate acid chloride, which 
was then reacted with readily prepared leucine methyl ester and 8-aminooctanoic acid 
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methyl ester to furnish 115 and 116 in yields of 81% and 98%, respectively. Allylic 
bromination of 115 and 116 was carried out using N-bromosuccinimide (NBS) in 
dilute acetonitrile at room temperature to provide 30-bromo BA derivatives 117 and 
118 in 66% and 72.5% yield, respectively. More concentrated solvent conditions or 
heating led to the formation of byproducts, which had close Rf values, resulting in 
difficult separation. We first attempted to use the Trost-Tsuji π-allylpalladium 
procedure156 to replace the bromide group in 117 and 118 with different nucleophiles. 
In detail, palladium acetate and triphenylphosphine were stirred with triethylamine in 
THF at room temperature for 30 min. After a yellow-orange suspension was formed, 
the appropriate nucleophilic compound and 30-bromo BA derivative 117 were added, 
and the reaction was carried out at reflux for more than 144 h.156 The whole process 
was conducted under dry nitrogen atmosphere. However, no product was detected. An 
alternative synthetic method was then applied. In this method, the desired 
nucleophilic compound was first treated with 10 equivalents of NaH under dry 
nitrogen gas in THF for 30 min. The 30-bromo BA derivative (117 or 118) was then 
added into the system. The reactions were carried out using a microwave apparatus at 
120 °C for 30 min. After the reaction mixture was cooled to room temperature, 1 mL 
MeOH-H2O was added to convert the intermediate esters to carboxylic acids by 
saponification, which furnished the target compounds 97-106 and 111 in 59-77% 
yields. Reaction of 111 with methylamine in the presence of HOBt/EDCI in 
dichloromethane led to 112 in a 69% yield. 
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Scheme 4-1. General synthetic route to 97-106, 111-112 
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Saponification of intermediate esters 116-118 with 2N sodium hydroxide in 
MeOH/THF yielded the corresponding carboxylic acids 108, 96 and 109 
quantitatively (Scheme 4-2). Reaction of silver acetate with the 30-bromo BA 
derivatives 117 and 118, in the presence of a catalytic amount of the phase transfer 
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catalyst tetrabutylammonium bromide (Bu4NBr) in acetonitrile, gave diacetoxy esters 
119 and 120 in yields of 68% and 69.5%, respectively.157 Saponification of these 
diacetoxy esters were then carried out with 2N sodium hydroxide in MeOH/THF to 
yield 30-hydroxyl BA derivatives 107 and 110 (Scheme 4-2).  
The 3,28,30-trisubstituted BA analog 113 was synthesized according to 
Scheme 4-3. Compound 96 was reacted with 2’,2’-dimethylsuccinic anhydride in the 
presence of DMAP in pyridine at 160 °C using microwave technology for 3h to 
furnish 113 in 32% yield. A longer reaction time was needed compared to 
corresponding esterification of BA. 
 
4. Results and Discussion 
The anti-HIV-1 replication activities of Series I (96-107), Series II (108-112), 
113 and some intermediates (115-120) were assessed in HIV-1IIIB infected MT-2 cells 
in parallel with AZT, bevirimat (DSB, 58) and 95. The results are summarized in 
Table 4-1. Selected compounds were further evaluated in HIV-1NL4-3 infected MT-4 
cells using the prior best entry inhibitor hit 94 as the control, and the data are listed in 
Table 4-2. 
Among Series I compounds, 104 and 106 showed very weak antiviral activity 
against HIV-1IIIB, while the remaining 28,30-disubstituted BA derivatives from this 
series did not inhibit replication of either the HIV-1IIIB or HIV-1NL4-3 variant. 
Surprisingly, 95, which showed moderate anti-HIV-1 entry activity in an in vitro 
fusion assay, also did not exhibit antiviral replication activity in these general 
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screenings. This result indicates that the C-30 modification of 95 did not cause the 
resulting derivatives from Series I to lose antiviral potency. However, because neither 
the presence of different C-30 substitutions nor reduction of the 20(29) double bond 
increased anti-HIV-1 activity of BA derivatives, the C-19 isopropenyl moiety is 
unlikely to be an activity pharmacophore. Thus, C-30 modification may still be useful 
to influence pharmacological properties, such as hydrophilicity and solubility.  
The conflicting results with 95 in the HIV replication and fusion assays and 
the poor “pharmacodynamic properties” of 47 led us to postulate that introduction of 
the critical C-28 lipophilic side chain may result in derivatives with poor 
physicochemical properties or stability problems. The calculated partition coefficient 
(Log P) values of 47/48, 94 and 95 (average 9.33) support our postulate. Therefore, 
our next step in developing potent anti-HIV-1 entry inhibitors was to increase the 
derivatives’ antiviral potency as well as improve their physicochemical properties.  
Accordingly, in analog 108 of Series II analogs, the C-28 amide side chain is 
8-aminooctanoic acid rather than leucine as in 95. Other groups, including bromide, 
hydroxyl and 2-morpholinoethoxy, were also introduced at C-30 to provide 
corresponding analogs 109–111, respectively. While 95 showed no suppression of 
HIV-1IIIB replication, 108, 109 and 111 had EC50 values ranging from 1.8 to 3.3 µM 
(Table 4-1). However, the introduction of a free hydroxyl group at C-30 reduced the 
antiviral activity of 110 by several folds. Because prior studies showed that a primary 
amine substituent at C-30 is also unfavorable, it seems that a hydrogen bond donor is 
not tolerated near the C-19 isopropenyl moiety. Nevertheless, our results still confirm 
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that, except for hydroxyl and amine moieties, the C-30 position of BA can 
accommodate some diverse substituents without influencing the antiviral activity of 
C-28 modified BA derivatives (compare 108 and 111). The introduction of the 
morpholinoethoxy moiety in 111 reduced the Log P value to 8.26 (± 0.69), resulting in 
a notable increase in the derivative’s solubility. In addition, because prior studies have 
shown that a second amide bond near the end of the C-28 side chain is necessary for 
enhanced antiviral potency, the terminal carboxylic acid of 111 was reacted with 
methylamine to produce 112. Interestingly, 112 differs from the prior best hit A43-D 
(94) only in the direction of the terminal amide linkage (-CONHCH3 in 112 and 
-NHCOCH3 in 94). Analog 112 exhibited potent anti-HIV-1 activity with an EC50 
value of 0.09 µM and TI of 250 against both HIV-1IIIB and HIV-1NL4-3 variants, which 
were similar to those of 94 (EC50: 0.10 µM, TI > 150) and comparable to those of 58 
(EC50: 0.011 µM, TI > 3.6×103). Moreover, 112 shows a significantly reduced Log P 
value of 7.50 (± 0.72) compared to those of 94 and 47/48, resulting in greater water 
solubility. Since Compound 112 is also a C-28 modified BA derivative, we postulate 
that it also functions as a HIV-1 entry inhibitor.  
Intermediates 115-118 as well as diacetoxy esters 119 and 120 did not inhibit 
HIV-1IIIB replication at the tested concentrations. This result is consistent with our 
previous finding that a C-28 terminal carboxylic acid or amide moiety is necessary for 
antiviral potency. An ester group at the C-28 side chain terminus and acetyl protection 
of the C-3 β-hydroxyl group reduced anti-HIV-1 activity significantly. 
Finally, the C-3 β-hydroxyl group of 96 was esterified with 
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2’,2’-dimethylsuccinic anhydride to give 113. This analog showed extremely potent 
antiviral activity with an EC50 value of 0.009 µM and TI of 3.5×103, which are similar 
to those of bevirimat (DSB, 58) and slightly better than those of AZT (Table 4-1). 
This result suggests that the presence of small substitutions on C-28 and C-30 of BA 
does not harm the high anti-HIV-1 potency of 58. Thus, incorporation of polar groups 
into the C-30 position may also help to improve the hydropholicity of bi-functional 
BA derivatives. 
In conclusion, diverse 28,30-disubstituted BA analogs were synthesized in our 
study. We found that hydrogen bond donors such as a hydroxyl group and primary 
amine moieties are not tolerated near the C-19 isopropenyl moiety. Otherwise, C-30 
substitution did not significantly influence the anti-HIV-1 activity of the C-28 
modified BA derivative. Therefore, the C-30 position serves as a good place to 
incorporate water-solubilizing moieties to increase the hydrophilicity of C-28 
modified BA derivatives. Accordingly, combination of a morpholinoethoxy group at 
C-30 together with aminooctanoic acid N-methylamide at C-28 led to the discovery of 
112, which showed potent anti-HIV-1 activity similar to that of 47, 48 and 94. 
Compared to 47/48 and 94, 112 had a smaller calculated Log P value and significantly 
increased water solubility, suggesting that it may have a better tissue distribution 
profile. Moreover, a 3,28,30-trisubstituted BA analog 113 was synthesized in this 
study. The high potency of 113 suggests that combination of C-3 and C-28 
modifications (for activity) and C-30 modification (for physicochemical properties) 
into one BA molecule is feasible. 
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Table 4-1. Anti-HIV-1 replication activities of 96-113, 115-120 in HIV-1IIIB 
infected MT-2 cell lines a 
 EC50 (µM) IC50 (µM) TI  EC50 (µM) IC50 (µM) TI 
AZT 0.056 1,870 33,392 107 NS 30.72 – 
58 0.011 40 3,636 108 3.3 > 33.44 > 10.1 
95 NS 29.75 – 109 2.3 > 36.94 > 16.1 
96 NS 26.77 – 110 14.8 > 40.72 > 2.8 
97 NS 40.72 – 111 1.8 > 24.76 > 13.8 
98 NS 25.32 – 112 0.09 22.31 249.9 
99 NS 24.92 – 115 NS 39.94 – 
100 NS 21.74 – 116 NS 38.23 – 
101 NS 16.67 – 117 NS 35.47 – 
102 NS 24.44 – 118 NS 34.11 – 
103 NS 20.81 – 119 NS 36.55 – 
104 27.8 > 34.55 > 1.2 120 28.5 > 35.11 > 1.2 
105 NS 27.48 – 113 0.009 > 32.18 > 3,576
106 26.6 > 35.76 > 1.4     
a All data presented are averages of at least two separate experiments performed by Panacos 
Pharmaceutical Inc., Gaithersburg, MD. EC50: concentration that inhibits HIV-1IIIB replication 
by 50%. IC50: concentration that inhibits mock-infected MT-2 cell growth by 50%. TI = 
IC50/EC50. NS: no suppression at the testing concentration (10µg/mL).  
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Table 4-2. Anti-HIV-1 replication activities of 95-107 and 112 in HIV-1NL4-3 
infected MT-4 cell lines b 
 EC50 (µM) IC50 (µM) c TI  EC50 (µM) IC50 (µM) TI 
94 0.10 > 10 > 150 102 NS NT – 
95 NS NT – 103 NS NT – 
96 NS NT – 104 NS NT – 
97 NS NT – 105 NS NT – 
98 NS NT – 106 NS NT – 
99 NS NT – 107 NS NT – 
100 NS NT – 112 0.09 > 10 > 138 
101 NS NT –     
b All data presented are averages of at least two separate experiments performed by Dr. 
Chin-Ho Chen, Duke University, NC. c IC50 was not tested for inactive compounds. EC50: 
concentration that inhibits HIV-1NL4-3 replication by 50%. IC50: concentration that inhibits 
mock-infected MT-4 cell growth by 50%. TI = IC50/EC50. NS: no suppression at the testing 
concentration (10µg/mL).  
 
5. Experimental Section 
5-1. Chemistry 
The melting points were measured with a Fisher Johns melting apparatus 
without correction. 1H NMR spectra were measured on a 300MHz Varian Gemini 
2000 spectrometer using Me4Si (TMS) as internal standard. The solvent used was 
CDCl3 unless otherwise indicated. Mass spectra were measured on Shimadzu 
LCMS-2010 (ESI-MS). Optical rotations were measured with a Jasco Dip-2000 
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digital polarimeter at 20 °C at the sodium D line. Thin-layer chromatography (TLC) 
and preparative thin-layer chromatography (PTLC) were performed on Merck 
precoated silica gel 60 F-254 plates. Flash+TM and CombiFlash systems were used as 
medium pressure column chromatography. Silica gel (200-400 mesh) from Aldrich, 
Inc., was used for column chromatography. All other chemicals were obtained from 
Aldrich, Inc.  
3-O-Acetyl-betulinic acid (114): A mixture of betulinic acid (2.1 g), pyridine 
(1.5 mL) and acetic anhydride (Ac2O, 20mL) was stirred at room temperature 
overnight until it became homogenous. The reaction was then poured into ice-cold 
water (30 mL) and stirred for 20 min. The crude product was filtered off and purified 
on a silica-gel column to yield 1.98 g (87% yield) of pure 114; white amorphous 
powder. Mp 289-291 °C. MS (ESI-) m/z: 497.38 (M- - H) for C32H50O4. 1H NMR (300 
MHz, CDCl3): δ 4.74, 4.61 (1H each, s, H-29), 4.47 (1H, dd, J = 9.9, 5.9 Hz, H-3), 
3.01 (1H, m, H-19), 2.05 (3H, s, OCOCH3), 1.69 (3H, s, H-30), 0.97, 0.93, 0.86, 0.84, 
0.83 (3H each, s, 5 × CH3). 
Syntheses of BA derivatives 115 and 116. Oxalyl chloride solution (2M in 
CH2Cl2, 10 mL) was added to 114 (1 eq) in CH2Cl2 (10 mL) and stirred for 2 h. After 
concentration under vacuum, the residual mixture was treated with leucine methyl 
ester (1.6 eq), or 8-aminooctanoic acid methyl ester (1.6 eq) and triethylamine (Et3N, 
1.2 eq) in CH2Cl2. The mixture was stirred at room temperature overnight until no 
starting material was observed by TLC. The solution was then diluted with CH2Cl2 
(20 mL) and washed three times with brine and distilled water. The organic layer was 
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dried over anhydrous Na2SO4 and concentrated to dryness under reduced pressure. 
The residue was chromatographed using a silica gel column to yield the pure target 
compounds. 
Methyl N-[3β-Acetoxy-lup-20(29)-en-28-oyl]-leucinate (115): 1.15 g (80.5% 
yield) starting from 1 g of 114; white amorphous powder. Mp 230-232 °C. MS (ESI+) 
m/z: 626.48 (M+ + H), 648.47 (M+ + Na) for C39H63NO5. 1H NMR (300 MHz, CDCl3): 
δ 5.87 (1H, d, J = 8 Hz, -CONH-), 4.72, 4.59 (1H each, s, H-29), 4.64 (1H, m, 
-NHCH-), 4.49 (1H, t, J = 8 Hz, H-3), 3.73 (3H, s, -COOCH3), 3.05 (1H, m, H-19), 
2.10-2.20 (1H, m, H-13), 2.04 (3H, s, OCOCH3), 1.68 (3H, s, H-30), 1.01 (6H, s, 
leucine moiety -(CH3)2), 0.97 (6H, s, 2 × CH3), 0.89, 0.84, 0.83 (3H each, s, 3 × CH3).  
Methyl N-[3β-Acetoxy-lup-20(29)-en-28-oyl]-8-aminooctanoate (116): 643 
mg (98% yield) starting from 500 mg of 114; light yellow amorphous powder. Mp 
104-105 °C. MS (ESI+) m/z: 654.5 (M+ + H) for C41H67NO5. 1H NMR (300 MHz, 
CDCl3): δ 5.57 (1H, t, J = 6 Hz, -CONH-), 4.73, 4.60 (1H each, s, H-29), 4.45 (1H, m, 
H-3), 3.67 (3H, s, -COOCH3), 3.30-3.08 (3H, m, H-19, -CONHCH2-), 2.50 (1H, m, 
H-13), 2.31 (2H, t, J =7 Hz, -CH2COOCH3), 2.05 (3H, s, OCOCH3), 1.68 (3H, s, 
H-30), 0.97, 0.94 (3H each, s, 2 × CH3), 0.85, 0.84, 0.81 (3H each, s, 3 × CH3).  
Syntheses of BA derivatives 117 and 118. A mixture of N-bromosuccinimide 
(1.1 eq) and 115 or 116 (1 eq) in acetonitrile (ACN, 30 mL) was stirred at room 
temperature until the starting material was not observed by TLC. The reaction was 
concentrated to dryness under reduced pressure and chromatographed over silica gel 
to yield pure target compounds. 
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Methyl N-[3β-Acetoxy-30-bromo-lup-20(29)-en-28-oyl]-leucinate (117): 
297 mg (66% yield) starting from 400 mg of 115; light yellow amorphous powder. 
Mp 127-129 °C. MS (ESI+) m/z: 704.4 (M+ + H), 706.4 (M+ + H) for C39H62BrNO5. 
1H NMR (300 MHz, CDCl3): δ 5.81 (1H, d, J = 8 Hz, -CONH-), 5.11, 5.05 (1H each, 
s, H-29), 4.65 (1H, m, -NHCH-), 4.45 (1H, t, J = 8 Hz, H-3), 4.00 (2H, s, H2-30), 3.72 
(3H, s, -COOCH3), 3.10 (1H, m, H-19), 2.50-2.32 (1H, m, H-13), 2.05 (3H, s, 
OCOCH3), 1.02 (6H, s, leucine moiety -(CH3)2), 0.99 (6H, s, 2 × CH3), 0.89, 0.86, 
0.85 (3H each, s, 3 × CH3).  
Methyl N-[3β-Acetoxy-30-bromo-lup-20(29)-en-28-oyl]-8-aminooctanoate 
(118): 402 mg (72.5% yield) starting from 360 mg of 116; light yellow amorphous 
powder. Mp 99-101 °C. MS (ESI+) m/z: 732.4 (M+ + H), 734.4 (M+ + H) for 
C41H66BrNO5. 1H NMR (300 MHz, CDCl3): δ 5.59 (1H, t, J = 6 Hz, -CONH-), 5.13, 
5.04 (1H each, s, H-29), 4.47 (1H, t, J = 8.1 Hz, H-3), 4.00 (2H, s, H2-30), 3.67 (3H, s, 
-COOCH3), 3.41-3.09 (3H, m, H-19, -CONHCH2-), 2.46 (1H, m, H-13), 2.31 (2H, t, 
J=7.5 Hz, -CH2COOCH3), 2.04 (3H, s, OCOCH3), 0.97, 0.93 (3H each, s, 2 × CH3), 
0.89, 0.84, 0.83 (3H each, s, 3 × CH3).  
Syntheses of BA derivatives 97-106 and 111. NaH (60% in mineral oil) was 
washed three times with hexane. A solution of appropriate nucleophilic compound (8 
eq) and NaH (10 eq) in anhydrous THF (1.5 mL) was stirred under dry nitrogen at 
room temperature for 30 min. The 30-bromo BA derivative 117 or 118 (1 eq) was then 
added into the system. The reaction was heated using microwave at 120 oC for 30 min. 
After cooling to room temperature, 1 mL MeOH-H2O was added into the mixtures 
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and stirred to transform the intermediate esters to carboxylic acids by saponification. 
The reaction was neutralized with 10% HCl and dried under vacuum and reconstituted 
with EtOAc. The organic layer was washed with brine and dried over anhydrous 
Na2SO4 and concentrated to dryness under reduced pressure. The residue was 
chromatographed using a silica gel column to yield the pure target compounds. 
N-[3β-Hydroxy-30-ethoxy-lup-20(29)-en-28-oyl]-leucine (97): 22 mg (59% 
yield) starting from 40 mg of 117; white amorphous powder. Mp 128-130 °C. MS 
(ESI-) m/z: 612.4 (M- - H) for C38H63NO5. 1H NMR (300 MHz, CDCl3): δ 5.88 (1H, d, 
J = 8 Hz, -CONH-), 4.93, 4.92 (2H, br s, H-29), 4.63-4.58 (1H, m, -NHCH-), 3.90 
(2H, s, H2-30), 3.47 (2H, m, 30-OCH2CH3), 3.18 (1H, dd, J = 11.1, 5.4 Hz, H-3), 2.99 
(1H, m, H-19), 2.50-2.32 (1H, m, H-13), 1.00 (9H, br s, 30-OCH2CH3, leucine moiety 
-(CH3)2), 0.96 (6H, s, 2 × CH3), 0.89, 0.86, 0.85 (3H each, s, 3 × CH3).  
N-[3β-Hydroxy-30-propoxy-lup-20(29)-en-28-oyl]-leucine (98): 23 mg 
(60% yield) starting from 40 mg of 117; white amorphous powder. Mp 116-117 °C. 
MS (ESI-) m/z: 626.5 (M- - H) for C39H65NO5. 1H NMR (300 MHz, CDCl3): δ 6.13 
(1H, br s, -CONH-), 4.91, 4.90 (2H, br s, H-29), 4.52 (1H, m, -NHCH-), 3.90 (2H, s, 
H2-30), 3.36 (2H, t, J = 6.9 Hz, 30-OCH2CH2CH3), 3.18 (1H, dd, J = 11.1, 5.4 Hz, 
H-3), 2.99 (1H, m, H-19), 0.96, 0.94, 0.92, 0.89 (15H, m, 30-O(CH2)2CH3, leucine 
moiety -(CH3)2, CH3-23, 24), 0.82, 0.81, 0.79 (3H each, s, 3 × CH3). 
N-[3β-Hydroxy-30-butoxy-lup-20(29)-en-28-oyl]-leucine (99): 10 mg (37% 
yield) starting from 30 mg of 117; yellow amorphous powder. Mp 104-105 °C. MS 
(ESI-) m/z: 640.2 (M- - H) for C40H67NO5. 1H NMR (300 MHz, CDCl3): δ 6.01 (1H, 
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br s, -CONH-), 4.90, 4.88 (2H, br s, H-29), 4.58 (1H, m, -NHCH-), 3.89 (2H, s, 
H2-30), 3.37 (2H, m, 30-OCH2(CH2)2CH3), 3.17 (1H, m, H-3), 3.01 (1H, m, H-19), 
0.99 (9H, br s, 30-O(CH2)3CH3, leucine moiety -(CH3)2), 0.96 (6H, s, 2 × CH3), 0.86, 
0.84, 0.81 (3H each, s, 3 × CH3).  
N-[3β-Hydroxy-30-phenethoxy-lup-20(29)-en-28-oyl]-leucine (100): 37 mg 
(77% yield) starting from 50 mg of 117; light yellow amorphous powder. Mp 155-157 
°C. MS (ESI-) m/z: 688.4 (M- - H) for C44H67NO5. 1H NMR (300 MHz, CDCl3): δ 
7.68-7.62 (2H, m, H ar-3’), 7.28-7.20 (3H, m, H ar-2’, 4’), 5.97 (1H, br s, -CONH-), 
4.91, 4.90 (2H, br s, H-29), 4.44 (1H, m, -NHCH-), 3.93 (2H, s, H2-30), 3.64 (2H, t, J 
= 7.2 Hz, 30-OCH2CH2ph), 3.17 (1H, dd, J = 11.1, 5.4 Hz, H-3), 2.91 (1H, m, H-19), 
2.57 (2H, m, 30-OCH2CH2ph), 0.95 (12H, s, leucine moiety -(CH3)2, CH3-23, 24), 
0.89, 0.78, 0.74 (3H each, s, 3 × CH3).  
N-[3β-Hydroxy-30-(4’-methoxyphenethoxy)-lup-20(29)-en-28-oyl]-leucine 
(101): 46 mg (64% yield) starting from 70 mg of 117; light yellow amorphous powder. 
Mp 128-129 °C. MS (ESI-) m/z: 718.5 (M- - H) for C45H69NO6. 1H NMR (300 MHz, 
CDCl3): δ 7.27, 7.16-7.13, 6.85-6.82 (5H, m, H ar-2’, 3’, 4’), 5.97 (1H, br s, -CONH-), 
4.91, 4.89 (H each, br s, H-29), 4.48 (1H, m, -NHCH-), 3.93 (2H, s, H2-30), 3.79 (3H, 
s, ar-OCH3), 3.60 (2H, t, J = 7.2 Hz, 30-OCH2CH2ph(p-OCH3)), 3.17 (1H, dd, J = 
11.1, 5.4 Hz, H-3), 2.85 (1H, t, J = 7.5 Hz, H-19), 2.39 (3H, m, 
30-OCH2CH2ph(p-OCH3), H-13), 0.95, 0.93, 0.90 (15H, s, leucine moiety -(CH3)2, 3 
× CH3), 0.79, 0.75 (3H each, s, 2 × CH3).  
N-[3β-Hydroxy-30-(4’-fluorophenethoxy)-lup-20(29)-en-28-oyl]-leucine 
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(102): 24 mg (40% yield) starting from 60 mg of 117; light yellow amorphous powder. 
Mp 102–104 °C. MS (ESI-) m/z: 706.4 (M- - H) for C44H66FNO6. 1H NMR (300 MHz, 
CDCl3): δ 7.16-6.80 (5H, m, H ar-2’, 3’, 4’), 5.96 (1H, br s, -CONH-), 4.90, 4.89 (2H, 
br s, H-29), 4.48 (1H, m, -NHCH-), 3.92 (2H, s, H2-30), 3.61 (2H, t, J = 7.2 Hz, 
30-OCH2CH2ph(p-F)), 3.17 (1H, m, H-3), 2.87 (1H, t, J = 7.5 Hz, H-19), 2.36-2.10 
(3H, m, 30-OCH2CH2ph(p-F), H-13), 0.95, 0.88 (15H, s, leucine moiety -(CH3)2, 3 × 
CH3), 0.75, 0.73 (3H each, s, 2 × CH3).  
N-[3β-Hydroxy-30-(4’-bromophenethoxy)-lup-20(29)-en-28-oyl]-leucine 
(103): 18 mg (41% yield) starting from 40 mg of 117; light yellow amorphous powder. 
Mp 127-129 °C. MS (ESI-) m/z: 706.4 (M- - H) for C44H66BrNO6. 1H NMR (300 MHz, 
CDCl3): δ 7.56-7.28 (5H, m, H ar-2’, 3’, 4’), 5.96 (1H, br s, -CONH-), 4.91, 4.90 (2H, 
br s, H-29), 4.48 (1H, m, -NHCH-), 3.91 (2H, s, H2-30), 3.60 (2H, t, J = 7.0 Hz, 
30-OCH2CH2ph(p-Br)), 3.17 (1H, dd, J = 11.0, 5.6 Hz, H-3), 2.89 (1H, t, J = 7.5 Hz, 
H-19), 2.39 (1H, m, 30-OCH2CH2ph(p-Br)), 0.96 (12H, s, leucine moiety -(CH3)2, 2 × 
CH3), 0.82, 0.79, 0.75 (3H each, s, 3 × CH3).  
N-[3β-Hydroxy-30-(4’-chlorophenethoxy)-lup-20(29)-en-28-oyl]-leucine 
(104): 16 mg (38% yield) starting from 40 mg of 117; light yellow amorphous powder. 
Mp 119-121 °C. MS (ESI-) m/z: 706.4 (M- - H) for C44H66ClNO6. 1H NMR (300 MHz, 
CDCl3): δ 7.18-6.87 (5H, m, H ar-2’, 3’, 4’), 5.96 (1H, br s, -CONH-), 4.91, 4.90 (2H, 
br s, H-29), 4.48 (1H, m, -NHCH-), 3.91 (2H, s, H2-30), 3.62 (2H, t, J = 6.8 Hz, 
30-OCH2CH2ph(p-Cl)), 3.17 (1H, dd, J = 11.0, 5.6 Hz, H-3), 2.87 (1H, t, J = 7.5 Hz, 
H-19), 2.36-2.06 (3H, m, 30-OCH2CH2ph(p-Cl), H-13), 0.96 (15H, s, leucine moiety 
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-(CH3)2, 3 × CH3), 0.81, 0.76 (3H each, s, 2 × CH3).  
N-[3β-Hydroxy-30-morpholino-lup-20(29)-en-28-oyl]-leucine (105): 22 mg 
(41% yield) starting from 60 mg of 117; white amorphous powder. Mp 98-100 °C. MS 
(ESI-) m/z: 653.5 (M- - H) for C40H66N2O5. 1H NMR (300 MHz, CDCl3): δ 5.61 (1H, 
d, J = 6 Hz, -CONH-), 4.92, 4.90 (H each, s, H-29), 4.63-4.58 (1H, m, -NHCH-),  
3.72 (4H, m, 30-N(CH2CH2)2O), 3.17 (1H, dd, J = 11.1, 5.4 Hz, H-3), 3.00 (3H, m, 
H-19, H2-30), 2.53 (4H, m, 30-N(CH2CH2)2O), 2.42 (1H, m, H-13), 0.96 (6H, s, 
leucine moiety -(CH3)2), 0.92 (6H, s, 2 × CH3), 0.86, 0.81, 0.75 (3H each, s, 3 × CH3).  
N-[3β-Hydroxy-30-(2'-morpholinoethoxy)-lup-20(29)-en-28-oyl]-leucine 
(106): 26 mg (56% yield) starting from 50 mg of 117; white amorphous powder. Mp 
89-91 °C. MS (ESI-) m/z: 697.4 (M- - H) for C42H70N2O6. 1H NMR (300 MHz, 
CDCl3): δ 5.61 (1H, d, J = 8 Hz, -CONH-), 4.92, 4.90 (H each, s, H-29), 4.59 (1H, m, 
-NHCH-), 3.94 (2H, s, H2-30), 3.72 (4H, m, -N(CH2CH2)2O), 3.58 (2H, t, J = 5.7 Hz, 
30-OCH2CH2-morpholine), 3.18 (1H, dd, J = 11.4, 4.6 Hz, H-3), 3.01 (1H, m, H-19), 
2.60 (2H, t, J = 5.4 Hz, 30-OCH2CH2-morpholine), 2.53 (4H, m, -N(CH2CH2)2O), 
1.00 (6H, s, leucine moiety -(CH3)2), 0.96 (6H, s, 2 × CH3), 0.89, 0.85, 0.80 (3H each, 
s, 3 × CH3).  
N-[3β-Hydroxy-30-(2'-morpholinoethoxy)-lup-20(29)-en-28-oyl]-8-aminoo
ctanoic acid (111): 51 mg (64% yield) starting from 80 mg 118; white amorphous 
powder. Mp 111-112 °C. MS (ESI-) m/z: 725.5 (M- - H) for C44H74N2O6. 1H NMR 
(300 MHz, CDCl3): δ 5.61 (1H, d, J = 8 Hz, -CONH-), 4.91, 4.90 (H each, s, H-29), 
3.94 (2H, s, H2-30), 3.72 (4H, m, -N(CH2CH2)2O), 3.58 (2H, t, J = 5.7 Hz, 
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30-OCH2CH2-morpholine), 3.18 (3H, m, -CONHCH2-, H-3), 3.01 (1H, m, H-19), 
2.60 (2H, t, J = 5.4 Hz, 30-OCH2CH2-morpholine), 2.53 (4H, m, -N(CH2CH2)2O), 
2.28 (2H, t, J =7.5 Hz, -CH2COOH), 0.96 (6H, s, 2 × CH3), 0.92, 0.81, 0.75 (3H each, 
s, 3 × CH3).  
N’-[N-[3β-Hydroxy-30-(2'-morpholinoethoxy)-lup-20(29)-en-28-oyl]-8-am
inooctanoyl]-aminomethane (112): A solution of 111 (30 mg, 1 eq), EDCI (2 eq), 
N-Hydroxybenzotriazole (HOBt, 1 eq), Et3N (0.05 mL) and methylamine 
hydrochloride (2 eq) in anhydrous CH2Cl2 (8 mL) was stirred at room temperature 
overnight until the starting material was not observed by TLC. The solution was 
diluted with CH2Cl2 (20 mL) and washed three times with brine and distilled water. 
The organic layer was dried over anhydrous Na2SO4 and concentrated to dryness 
under reduced pressure. The residue was chromatographed using a silica gel column 
to yield 21 mg (69% yield) of pure 112; white amorphous powder. Mp 106-107 °C. 
MS (ESI+) m/z: 740.5 (M+ + H) for C45H77 N3O5. 1H NMR (300 MHz, CDCl3): δ 5.61 
(2H, m, 2 × -CONH-), 4.92, 4.90 (H each, s, H-29), 3.94 (2H, s, H2-30), 3.72 (4H, m, 
-N(CH2CH2)2O), 3.58 (2H, t, J = 5.7 Hz, 30-OCH2CH2-morpholine), 3.28-3.14 (3H, 
m, -CONHCH2-, H-3), 3.01 (1H, m, H-19), 2.81 (3H, d, J = 4.8 Hz, -CONHCH3), 
2.60 (2H, t, J = 5.4 Hz, 30-OCH2CH2-morpholine), 2.53 (4H, m, -N(CH2CH2)2O), 
2.16 (2H, t, J =7.5 Hz, -CH2CONHCH3), 0.96 (6H, s, 2 × CH3), 0.92, 0.81, 0.75 (3H 
each, s, 3 × CH3).  
Syntheses of BA derivatives 119 and 120. A solution of 30-bromo BA 
derivative 117 or 118 (1 eq), silver acetate (AgOAc, 2 eq) and tetrabutylammonium 
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bromide (Bu4NBr, 0.2 eq) in acetonitrile (1.5 mL) was heated using microwave at 100 
oC for 25 min. The precipitant was filtered and the solution was concentrated to 
dryness under vacuum. The residue was chromatographed over a silica-gel column to 
yield the pure diacetoxy intermediates 119 and 120. 
Methyl N-[3β,30-diacetoxy-lup-20(29)-en-28-oyl]-leucinate (119): 80 mg 
(68% yield) starting from 120 mg of 117; off-white amorphous powder. Mp 201-203 
°C. MS (ESI+) m/z: 684.5 (M+ + H) for C41H65NO7. 1H NMR (300 MHz, CDCl3): δ 
5.69 (1H, br s, -CONH-), 4.97, 4.94 (2H, d, J = 9, H-29), 4.58-4.52 (3H, m, -NHCH-, 
H2-30), 4.45 (1H, t, J = 8 Hz, H-3), 3.72 (3H, s, -COOCH3), 3.10 (1H, m, H-19), 
2.50-2.32 (1H, m, H-13), 2.08 (6H, s, 2 × OCOCH3), 1.05 (6H, s, leucine moiety 
-(CH3)2), 0.96 (6H, s, 2 × CH3), 0.89, 0.82, 0.81(3H each, s, 3 × CH3).  
Methyl N-[3β,30-diacetoxy-lup-20(29)-en-28-oyl]-8-aminooctanoate (120):  
77.8 mg (69.5% yield) starting from 80 mg of 118; white amorphous powder. Mp 
167-169 °C. MS (ESI+) m/z: 712.5 (M+ + H) for C43H69NO7. 1H NMR (300 MHz, 
CDCl3): δ 5.60 (1H, t, J = 4.6 Hz, -CONH-), 4.94, 4.90 (1H each, s, H-29), 4.56 (2H, 
s, H2-30), 4.45 (1H, t, J = 7 Hz, H-3), 3.66 (3H, s, -COOCH3), 3.41-3.09 (3H, m, 
H-19, -CONHCH2-), 2.46 (1H, m, H-13), 2.31 (2H, t, J=7.5 Hz, -CH2COOCH3), 2.05 
(6H, s, 2 × OCOCH3), 0.97, 0.96, 0.85, 0.81, 0.80 (3H each, s, 5 × CH3).  
Syntheses of BA derivatives 96, 107-110. To a solution of the appropriate 
ester intermediates 116-120 (1 eq) in MeOH (8 mL) and THF (4 mL) was added 2N 
NaOH (4 mL). The mixture was stirred overnight, then neutralized with 20% HCl. 
The solution was dried under vacuum and reconstituted with EtOAc. The organic 
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layer was washed with brine and dried over anhydrous Na2SO4 and concentrated to 
dryness under reduced pressure. The residue was chromatographed using a silica gel 
column to yield the pure target compounds.  
N-[3β-Hydroxy-30-bromo-lup-20(29)-en-28-oyl]-leucine (96): 102 mg 
(100% yield) starting from 110 mg of 117; white amorphous powder. Mp 102-104 °C. 
MS (ESI-) m/z: 646.41, 648.39 (M- - H) for C36H58BrNO4. 1H NMR (300 MHz, 
CDCl3): δ 5.86 (1H, d, J = 8 Hz, -CONH-), 5.11, 5.02 (1H each, s, H-29), 4.65 (1H, m, 
-NHCH-), 3.90 (2H, s, H2-30), 3.17 (1H, dd, J = 9.7, 5.4 Hz, H-3), 3.10-3.03 (1H, m, 
H-19), 1.00 (6H, s, leucine moiety -(CH3)2), 0.96 (6H, s, 2 × CH3), 0.83, 0.80, 0.79 
(3H each, s, 3 × CH3). [α]25D -10.5 ° (c = 0.15, MeOH). 
N-[3β,30-Dihydroxy-lup-20(29)-en-28-oyl]-leucine (107): 24 mg (98% yield) 
starting from 30 mg of 119; white amorphous powder. Mp 145-148 °C. MS (ESI-) m/z: 
584.5 (M- - H) for C36H59NO5. 1H NMR (300 MHz, CDCl3): δ 5.89 (1H, br s, 
-CONH-), 4.91, 4.90 (1H each, s, H-29), 4.68 (1H, m, -NHCH-), 4.12 (2H, s, H2-30), 
3.17 (1H, dd, J = 11.2, 5.6 Hz, H-3), 3.01 (1H, m, H-19), 2.34 (1H, m, H-13), 1.10 
(6H, s, leucine moiety -(CH3)2), 0.99 (6H, s, 2 × CH3), 0.86, 0.83, 0.80 (3H each, s, 3 
× CH3). [α]25D -39.3 ° (c = 0.35, MeOH). 
N-[3β-Hydroxy-lup-20(29)-en-28-oyl]-8-aminooctanoic acid (108): 37 mg 
(100% yield) starting from 40 mg of 116; white amorphous powder. Mp 110-112 °C. 
MS (ESI-) m/z: 596.5 (M- - H) for C38H63NO4. 1H NMR (300 MHz, CDCl3): δ5.60 
(1H, br s, -CONH-), 4.73, 4.60 (1H each, s, H-29), 3.21-3.09 (4H, m, H-3, H-19, 
-CONHCH2-), 2.31 (2H, t, J = 6.9 Hz, -CH2COOH), 2.10-2.20 (1H, m, H-13), 1.68 
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(3H, s, H-30), 0.97 (6H, s, 2 × CH3), 0.85, 0.79, 0.75 (3H each, s, 3 × CH3). [α]25D 
-3.6 ° (c = 0.19, CHCl3). [α]25D -8.48 ° (c = 0.20, MeOH). 
N-[3β-Hydroxy-30-bromo-lup-20(29)-en-28-oyl]-8-aminooctanoic acid 
(109): 44 mg (95% yield) starting from 50 mg of 118; white amorphous powder. Mp 
119-122 °C. MS (ESI-) m/z: 674.4 (M- - H) for C38H62BrNO4. 1H NMR (300 MHz, 
CDCl3): δ5.60 (1H, br s, -CONH-), 5.13, 5.04 (1H each, s, H-29), 4.00 (2H, s, H2-30), 
3.21-3.09 (4H, m, H-3, H-19, -CONHCH2-), 2.34 (2H, m, -CH2COOH), 0.96 (6H, s, 2 
× CH3), 0.92, 0.82, 0.81 (3H each, s, 3 × CH3). [α]25D -16.5 ° (c = 0.22, MeOH). 
N-[3β,30-Dihydroxy-lup-20(29)-en-28-oyl]-8-aminooctanoic acid (110): 50 
mg (80% yield) starting from 58 mg of 120; white amorphous powder. Mp 135-137 
°C. MS (ESI-) m/z: 612.5 (M- - H) for C38H63NO5. 1H NMR (300 MHz, CDCl3): δ5.61 
(1H, br s, -CONH-), 4.94, 4.90 (1H each, s, H-29), 4.12 (2H, s, H2-30), 3.25-3.15 (3H, 
m, H-3, -CONHCH2-), 3.01 (1H, m, H-19), 2.34 (2H, t, J = 7.6 Hz, -CH2COOH), 2.06 
(1H, m, H-13), 0.97, 0.96 (3H each, s, 2 × CH3), 0.92, 0.82, 0.75 (3H each, s, 3 × 
CH3). [α]25D -143.3 ° (c = 0.10, MeOH).  
N-[3β-O-(3’,3’-Dimethylsuccinyl)-30-bromo-lup-20(29)-en-28-oyl]-leucine 
(113): A solution of 96 (50 mg, 1 eq), DMAP (1 eq) and 2’,2’-dimethylsuccinic 
anhydride (5 eq) in anhydrous pyridine (1.5 mL) was stirred at 160 oC for 3 h using 
microwave. The reaction mixture was diluted with EtOAc (15 mL) and washed three 
times with 20% HCl solution and distilled water. The organic layer was dried over 
anhydrous Na2SO4 and concentrated to dryness under reduced pressure. The residue 
was chromatographed using a silica gel column to yield 20 mg (32% yield) of 113; 
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light yellow amorphous powder. Mp 105-107 °C. MS (ESI-) m/z: 774.5 (M- - H) for 
C42H66BrNO7. 1H NMR (300 MHz, CDCl3): δ 5.86 (1H, d, J = 8 Hz, -CONH-), 5.11, 
5.02 (1H each, s, H-29), 4.65 (1H, m, -NHCH-), 4.54 (1H, dd, J = 11.2, 5.7 Hz, H-3), 
3.90 (2H, s, H2-30), 2.99 (1H, m, H-19), 2.64-2.42 (2H, m, H-2’), 1.30, 1.26 (3H each, 
s, 2 × CH3-3’), 1.00 (6H, s, leucine moiety -(CH3)2), 0.96 (6H, s, 2 × CH3), 0.87, 0.86, 
0.81 (3H each, s, 3 × CH3).  
 
5-2. HIV-1IIIB Replication Inhibition Assay in MT-2 Cell Lines 152,153 
This screening was performed by Panacos Pharmaceutical Inc. The general 
procedure was described previously in Chapter 3, 5-2.  
 
5-3. HIV-1NL4-3 Replication Inhibition Assay in MT-4 Cell Lines 134,148 
A 96-well microtiter plate was used to set up the HIV-1NL4-3 replication 
screening assay. NL4-3 variants at a multiplicity of infection (MOI) of 0.01 were used 
to infect MT4 cells. Culture supernatants were collected on day 4 post-infection for 
the p24 antigen capture using an ELISA kit from ZeptoMetrix Corporation (Buffalo, 
New York). 
 
5-4. Cell Fusion Assay 133,148 
TZM cells that expressed luciferase upon fusion with envelop-expressing COS 
cells were used as fusion partners. The fusion assays were performed by transfecting 
monkey kidney cells (COS) with an expression vector pSRHS that contained the 
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HIV-1 NL4-3 envelope genes. Electroporation was performed to express the HIV-1 
envelope on COS cells. Briefly, COS cells (106) in culture medium were incubated 
with 2 µg of the envelop expression vector on ice for 10min. Electroporation was 
performed using a gene pulser (BioRad, Hercules, CA) with capacitance set at 950  
µF and voltage at 150 V. The transfected COS cells were cultured for 1 day before 
mixing with TZM cells. TZM cells (10 × 104) were incubated with COS cells (104) in 
96-well flat-bottomed plates (Costar) in a 100 µL culture medium. Compounds to be 
tested at various concentrations in 10 µL of culture medium were incubated with cell 
mixtures at 37 oC for 24 h. Luciferase activity was quantified using a Biotek 
luminometer. 
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Chapter 5. Novel Designed 3,28-Disubstituted BA Analogs 
with Improved Metabolic Stability as Potent Anti-HIV-1 
Inhibitors  
 
1. Introduction 
Although bevirimat (DSB, 58), a C-3 modified BA derivative functioning as a 
HIV-1 maturation inhibitor, is now efficiently proceeding in clinical trials,146,147 
clinical development of C-28 modified BA analog RPR103611 (47) has been less 
successful due to poor “pharmacodynamic properties”.141 This result led us to 
speculate that the C-28 long lipophilic side chain, which is critical for anti-HIV-1 
entry activity, may cause the problems. In Chapter 4, we reported the synthesis of 112, 
which has a similar C-28 side chain and comparable antiviral potency to those of 47, 
IC9564 (48) and A43-D (94). Compound 112 also has a water solubilizing moiety 
introduced at the C-30 position, and consequently, showed increased hydropholicity 
and better physicochemical properties than 47, 48 and 94.  
Deficiency in ADME (absorption, distribution, metabolism, and excretion) 
properties can be a major cause of failure during drug development. Therefore, to 
optimize our BA-derived drug lead(s) and guide further structural modification, 
metabolic stabilities of current C-28 modified BA analogs were further evaluated in 
vitro. From these studies, we learned that these compounds have a relatively short half 
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life (t1/2). Thus, a novel C-28 side chain was designed to investigate SAR, enhance 
antiviral potency, and increase metabolic stability. This chapter reports new analog 
design, syntheses, anti-HIV-1 activity and metabolic stability assessment. 
In addition, we know that A12-2 (71) (Figure 5-1), which contains both the 
C-3 side chain of 58 and C-28 side chain of 94 in one BA molecule, is currently our 
best bi-functional inhibitor, preserving both anti-entry and anti-maturation 
activities.148 However, like 94, 71 also has metabolic problems, likely due to the C-28 
side chain. Therefore, the newly designed C-28 side chain was also incorporated into 
the disubstituted BA derivatives. Their syntheses and bioassay data will also be 
discussed in this chapter. 
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Figure 5-1. Structure of 71 
 
2. Design 
In vitro metabolic stability assessment of potential drug candidates in an early 
phase of drug discovery is a more cost-effective approach than in vivo studies to 
identify compounds with unfavorable ADME characteristics. Thus, a metabolic 
stability test of C-28 modified BA derivatives was performed. In this study, 108, 
which has the common anti-entry C-28 side chain 8-aminooctanoic acid, was 
incubated with pooled human liver microsomes to assess its in vitro stability, because 
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cytochrome P450 enzymes are often the principal means of metabolism of many 
pharmaceuticals. Results from the study revealed that 108 exhibited a relatively short 
half life, suggesting that it carries some structural feature that is easily metabolized. 
To overcome this shortcoming, a cyclic secondary amine (from 4-piperidine butyric 
acid), rather than a primary amine, was used to form the critical amide bond with the 
C-28 carboxylic acid group, which yielded 121 (Figure 5-2). This design attempted to 
increase steric hindrance at the C-28 position, so that the amide bond would be less 
available to metabolic enzymes, while maintaining the general length and terminal 
carboxylic acid of the C-28 side chain in 108. The metabolic stability of 121 was also 
evaluated in human liver microsomes and compared to that of 108. Dimethylsuccinyl 
and dimethylglutaryl side chains were then introduced at the C-3 position of 121 to 
furnish 122 and 123 (Figure 5-2) and explore the impact of the newly designed C-28 
side chain on anti HIV-1 activity of 3,28-disubstituted BAs. Antiviral activity was 
evaluated in HIV-1IIIB infected MT-2 cell lines. 
Because an amide is generally more stable in vivo than an ester moiety, we 
also synthesized 3,28-disubstituted BA analog 124. Its C-3 side chain is similar to that 
of the potent 58, except for a C-3 amide rather than ester bond (Figure 5-2). Analog 
124 was also assayed against HIV-1IIIB in MT-2 cell lines. 
According to prior SAR conclusions, introduction of a second amide bond 
near the tail of the C-28 side chain is necessary for enhanced anti-HIV-1 entry 
activity.131 Therefore, four different amine moieties were introduced at the terminal 
carboxylic acid of 121 to yield 125-128 (Figure 5-2). Three analogs (126-128) 
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contained a water-solubilizing morpholine moiety in the introduced amide 
substitution to explore its impact on antiviral activities and physicochemical 
properties. A dimethylsuccinyl ester was then incorporated at the C-3 position of these 
four newly synthesized HIV-1 entry inhibitors to furnish a new generation of 
BA-derived bi-functional HIV-1 inhibitors (129-132) (Figure 5-2). 
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Figure 5-2. Structures of 108 and 121-132 
 
3. Chemistry 
Scheme 5-1 depicts the synthesis of 3β-amino BA analog 124. Oxidation of 44 
with 2 equivalents of PDC produced the 3-keto-BA 133 (87% yield). L-leucine methyl 
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ester was reacted with the C-28 carboxylic acid of 133 in the presence of DMAP and 
EDCI to furnish 134 (58% yield). The keto moiety of 134 was then converted to an 
oxime by treatment with hydroxylamine hydrochloride (NH2OH·HCl) in pyridine, 
which yielded 135 (90% yield). The 3β-amine 136 was readily prepared in 82% yield 
from oxime 135 by enantioselective reduction of the Schiff base with TiCl3 and 
NaCNBH3, as reported by Leeds and Kirst.157 Treatment of 136 with 
2,2-dimethylsuccinic anhydride under DMAP in pyridine yielded 137 (62% yield). 
Finally, hydrolysis of 137 with 2N sodium hydroxide furnished the desired 3, 
28-disubstituted, 3β-amino BA analog 124. 
The syntheses of 121-123, 125-132 were carried out according to Scheme 5-2. 
First, the 3β-hydroxyl group of 44 was protected with an acetyl moiety. Then, the 
3-OAc-BA (114) was treated with oxalyl chloride in dichloromethane to yield the acid 
chloride intermediate, followed by reaction with the readily prepared 4-piperidine 
butyric acid methyl ester to provide 138 (94% yield). Saponification of 138 with 2N 
sodium hydroxide in MeOH/THF yielded the desired lead compound 121 
quantitatively. Esterification of 121 with 2,2-dimethylsuccinic anhydride and 
2,2-dimethylglutaric anhydride using DMAP in pyridine led to 122 and 123 in yields 
of 55% and 36%, respectively. The syntheses of 125-128 were carried out by reacting 
121 with different amines in the presence of HOBt and EDCI, which yielded 125-128 
(80-100% yields). Reaction of the 3β-hydroxyl group of 125-128 with 
2,2-dimethylsuccinic anhydride using DMAP in pyridine provided the 
3,28-disubstituted target compounds 129-132 (58-81% yields). 
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4. Results and Discussion 
The newly synthesized BA derivatives 121-132 were evaluated in vitro for 
suppression of HIV-1IIIB replication in MT-2 lymphocytes and compared to AZT and 
bevirimat (DSB, 58). Compounds 129-132, which showed potent antiviral activity in 
this first assay, were further tested against HIV-1NL4-3 in MT-4 cell lines, in parallel 
with the prior best BA-derived HIV-1 entry inhibitor A43-D (94) and IC9564 (48). All 
bioassay data are summarized in Table 5-1. 
We discovered that bioisosteric replacement of the C-3 ester bond with an 
amide bond in 3,28-disubstituted BA analog 124 caused a significant decrease in 
antiviral activity (EC50: 13.2 µM), suggesting that an amide moiety is not tolerated at 
the BA C-3 position. This result is consistent with the previous finding that C-3 
esterification is critical for high antiviral potency of BA-derived maturation inhibitors.  
Changing the C-28 side chain from 8-aminooctanoic acid (108) to 4-piperidine 
butyric acid (121) significantly increased in vitro metabolic stability. Specifically, 
approximately 50% of parent lead compound 108 disappeared after around 35 
minutes of incubation with pooled human liver microsomes, indicating that it was 
degraded quite easily in the assay system. Comparatively, it took about 110 min to 
lose 50% of 121, suggesting a much longer half life (Figure 5-3). Thus, 121 represents 
a better lead for the development of C-28 modified BA-derived HIV-1 entry inhibitors 
and 3,28-disubstituted HIV inhibitors. Indeed, compound 122, which resulted from 
esterifying 121 with the C-3 side chain of 58, showed very potent anti-HIV-1 activity 
with a TI of 1.4 ×103 and an EC50 value of 0.015 µM, which was similar to that of 58 
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(EC50: 0.012 µM). This result proves that the presence of this novel C-28 side chain 
does not harm the antiviral potency of 58. Compound 123, with a 
4’,4’-dimethylglutaryl rather than 3’,3’-dimethylsuccinyl C-3 ester side chain, had a 
higher antiviral EC50 value (0.23 µM), confirming the importance of the positioning 
of the dimethyl substitution as discussed in Chapter 3. 
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Figure 5-3. Metabolic stability of 108 and 121. Y scale: percentage of parent compound 
(concentration); X scale: time. Data presented are averaged from two separate experiments. 
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Because we previously found that introduction of a second amide bond is 
necessary for enhanced anti-HIV-1 entry activity of C-28 modified BA analogs, we 
also synthesized and evaluated 125-128, which have different amide substituents 
linked to the terminal carboxylic acid of 121. Moreover, the C-3 side chain of 58 was 
also incorporated into the C-3 position of the newly synthesized metabolically stable 
BA analogs 125-128, to provide 3,28-disubstituted target compounds 129-132. Their 
antiviral potency was then tested against both HIV-1IIIB and HIV-1NL4-3 isolates.  
From the results, we discovered that 125-128 only showed weak antiviral 
potency. This result is likely due to the slightly reduced length of the new C-28 side 
chain compared with previous 8-aminooctanoic chain (108). Indeed, the BA analog 
with 7-aminoheptanoic acid introduced to the C-28 position showed a 16-fold 
decreased anti-HIV activity compared with 108, confirming the importance of the 
length of C-28 side chain.131  
Compounds 131 and 132, derived from 127 and 128, which contain a 
morpholine ring at the end of C-28 side chain that is separated from the terminal 
amide bond by a short alkyl spacer (two or three methylenes), exhibited extremely 
potent anti-HIV-1 replication activity with EC50 values of 0.007 µM and 0.006 µM, 
respectively, which are around 2-fold better than that of DSB (58). Their activities are 
also 2-3 fold more potent than the previous best entry inhibitors IC9564 (48) and 
A43D (94). Compound 130, derived from 126, with morpholine directly involved in 
the amide bond, had similar anti-HIV-1 potency (EC50: 0.011 µM) to that of 58. 
Compound 129 with methylamine at the end of C-28 showed a slightly decreased 
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antiviral potency compared with 58. From these results, we postulate that a longer 
C-28 chain is important for enhanced antiviral activity in 3, 28-disubstituted BA 
analogs. The better potency of 131 and 132 indicates that the high antiviral activity of 
58 can be further increased with proper C-28 substitution. Moreover, because the 
C-28 side chains in all prior potent HIV inhibitors terminate in a free carboxylic acid 
or amide, the success of 131 and 132 also demonstrates that other polar groups at the 
end of this side chain can also increase antiviral potency.  
To conclude, in this study, different modifications were performed at C-3 and 
C-28 positions of BA in order to improve the antiviral activity and physicochemical 
profiles of the compounds. Bioisosteric replacement of the C-3 ester bond in a 
3,28-disubstituted analog with an amide bond (124) actually decreased antiviral 
potency, confirming again the importance of C-3 esterification to antiviral activity. 
Using a cyclic secondary amine moiety (piperidine) rather than a primary amine to 
form the C-28 amide bond significantly increased the metabolic stability of the 
derivatives in pooled human liver microsome assessment. Subsequent introduction of 
a second amide bond at the carboxylic terminus of this metabolically stable C-28 side 
chain and introduction of the 3’,3’-dimethylsuccinyl side chain at the C-3 position 
resulted in the discovery of 131 and 132, which showed extremely potent antiviral 
activity, slightly better than that of AZT and bevirimat (58). Both compounds have a 
morpholine moiety linked to the second amide bond through a short methylene chain 
and showed good solubility. 131 and 132 also showed good metabolic stability. Thus, 
they should serve as better leads for the development of a next generation of 
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BA-derived 3,28-disubstituted HIV-1 inhibitors. 
 
Table 5-1. Anti-HIV-1 replication activities of 121-132 
HIV-1IIIB a HIV-1NL4-3 b 
Compd 
EC50 (µM) IC50 (µM) TI  EC50 (µM) IC50 (µM) TI 
AZT 0.056 1,870 33,115 - c - - 
58  0.012 42.88 3,573 - c - - 
48 - c - - 0.089 > 10 > 112.4 
94 - c - - 0.085 > 10 > 117.6 
121 21.72 41.05 1.15 - c - - 
122 0.015 20.83 1,389 - c - - 
123 0.23 33.24 144.5 - c - - 
124 13.2 35.87 2.7 - c - - 
125 NT d NT d - - c - - 
126 > 3.6e 23.99 - - c - - 
127 > 0.35 e 14.50 - - c - - 
128 > 0.34 e 23.43 - - c - - 
129 0.067 33.31 497.2 0.24 > 10 > 41.7 
130 0.011 19.23 1,748 0.07 8.8 121.4 
131 0.007 17.31 2,473 0.035 8.5 283.9 
132 0.006 18.52 3,087 0.031 8.6 245.7 
a All data presented are averages of at least two separate experiments performed by Panacos 
Pharmaceutical Inc., Gaithersburg, MD. b All data presented are averages of at least two 
separate experiments performed by Dr. Chin-Ho Chen, Duke University, NC. c not tested in 
the experiment. d not tested due to solubility issue. e endpoint not achieved. EC50: 
concentration that inhibits HIV-1 replication by 50%. IC50: concentration that inhibits 
mock-infected cell growth by 50%. TI = IC50/EC50.  
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5. Experimental Section 
5-1. Chemistry 
Melting points were measured with a Fisher Johns melting apparatus without 
correction. 1H NMR spectra were measured on a 300MHz Varian Gemini 2000 
spectrometer using Me4Si (TMS) as internal standard. The solvent used was CDCl3 
unless otherwise indicated. Mass spectra were measured on Shimadzu LCMS-2010 
(ESI-MS). Optical rotations were measured with a Jasco Dip-2000 digital polarimeter 
at 20 °C at the sodium D line. Thin-layer chromatography (TLC) and preparative 
thin-layer chromatography (PTLC) were performed on Merck precoated silica gel 60 
F-254 plates. Flash+TM and CombiFlash systems were used as medium pressure 
column chromatography. Silica gel (200-400 mesh) from Aldrich, Inc., was used for 
column chromatography. All other chemicals were obtained from Sigma-Aldrich, Inc.  
3-Deoxy-betulinic acid (133): To a solution of betulinic acid (2 g, 1eq) in 
DMF was added pyridium dichromate (PDC, 2 eq). The mixture was stirred at room 
temperature for 2 h. The reaction mixture was diluted with EtOAc (30 mL) and the 
precipitate was filtered through a short pack of Florisil. The solution was washed with 
20% HCl and distilled water. The organic layer was dried over anhydrous Na2SO4 and 
concentrated to dryness under vacuum. The residue was chromatographed using a 
silica gel column to yield 1.68 g (87%) of pure 133, white powder. Mp 246-248 °C. 
MS (ESI-) m/z: 453.3 (M- - H) for C30H46O3. 1H NMR (300 MHz, CDCl3): δ 4.72, 
4.58 (1H each, s, H-29), 3.09 (1H, m, H-19), 2.41-2.26 (2H, m, H-2), 1.69 (3H, s, 
H-30), 0.98, 0.97, 0.96, 0.92, 0.89 (3H each, s, 5 × CH3).  
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Methyl N-[3-Deoxy-lup-20(29)-en-28-oyl]-leucinate (134): A solution of 
133 (500 mg, 1 eq), DMAP (0.6 eq) and EDCI (1.6 eq) in CH2Cl2 was stirred at 0 oC 
for 30 min. Leucine methyl ester (1.6 eq) and Et3N (1 eq) was then added into the 
system and stirred at room temperature overnight. The reaction was diluted with 
CH2Cl2 (20 mL) and washed with brine. The organic layer was then dried over 
anhydrous Na2SO4 and concentrated to dryness under vacuum. The residue was 
chromatographed using a silica gel column to yield 372 mg (58%) of pure 134, white 
amorphous powder. Mp 191-193 °C. MS (ESI+) m/z: 582.5 (M+ + H) for C37H59NO4. 
1H NMR (300 MHz, CDCl3): δ 5.87 (1H, d, J = 8.4 Hz, -CONH-), 4.70, 4.59 (1H 
each, s, H-29), 4.64 (1H, m, -NHCH-), 3.73 (3H, s, -COOCH3), 3.05 (1H, m, H-19), 
2.41-2.26 (2H, m, H-2), 1.68 (3H, s, H-30), 1.06, 1.02 (3H each, s, leucine moiety 
-(CH3)2), 0.98 (3H, s, CH3), 0.96 (6H, s, 2 × CH3), 0.92, 0.89 (3H each, s, 2 × CH3).  
Methyl N-[3-Oxime-lup-20(29)-en-28-oyl]-leucinate (135): A solution of 
134 (230 mg, 1eq), and hydroxylamine hydrochloride (4 eq) in pyridine (10 mL) was 
heated at 50 oC for 2 h. After cooling to room temperature, the reaction mixture was 
diluted with CH2Cl2 and washed three times by 20% HCl and brine. The organic layer 
was then dried over anhydrous Na2SO4 and concentrated to dryness under vacuum. 
The residue was chromatographed using a silica gel column to yield 235 mg (90%) of 
pure 135, white amorphous powder. Mp 213-215 °C. MS (ESI+) m/z: 582.5 (M+ + H) 
for C37H59NO4. 1H NMR (300 MHz, CDCl3): δ 5.87 (1H, d, J = 8.4 Hz, -CONH-), 
4.70, 4.59 (1H each, s, H-29), 4.64 (1H, m, -NHCH-), 3.73 (3H, s, -COOCH3), 3.05 
(1H, m, H-19), 2.20-2.15 (2H, m, H-2), 1.67 (3H, s, H-30), 1.05, 1.02 (3H each, s, 
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leucine moiety -(CH3)2), 0.98 (3H, s, CH3), 0.96 (6H, s, 2 × CH3), 0.94, 0.92 (3H each, 
s, 2 × CH3).  
Methyl N-[3β-Amino-lup-20(29)-en-28-oyl]-leucinate (136): To a solution 
of 135 (100 mg, 1eq) and ammonium acetate (15 eq) in MeOH was added sodium 
cyanoborohydride (NaCNBH3, 20 eq) under nitrogen atmosphere. The reaction was 
cooled to 0 oC, and 15% aqueous titanium trichloride (TiCl3, 3 eq) was added 
dropwise over 45 min. The mixture was stirred at room temperature overnight, and 
then treated with 2N NaOH until pH = 10. The solution was dried under vacuum and 
the resided aqueous solution was extracted with CH2Cl2 and washed with distilled 
water until pH = 7. The organic layer was then dried over anhydrous Na2SO4 and 
concentrated to dryness under vacuum. The residue was chromatographed using a 
silica gel column to yield 80 mg (82%) of pure 136, white amorphous powder. Mp 
135-137 °C. MS (ESI+) m/z: 582.5 (M+ + H) for C37H59NO4. 1H NMR (300 MHz, 
CDCl3): δ 5.86 (1H, d, J = 7 Hz, -CONH-), 4.72, 4.58 (1H each, s, H-29), 4.64 (1H, m, 
-NHCH-), 3.73 (3H, s, -COOCH3), 3.05 (1H, m, H-19), 2.44 (1H, m, H-3), 2.10-1.90 
(1H, m, H-13), 1.68 (3H, s, H-30), 0.97 (9H, s, CH3-23, leucine moiety-(CH3)2), 0.96, 
0.94, 0.93, 0.92 (3H each, s, 4 × CH3).  
Methyl N-[3β-Acetoxy-lup-20(29)-en-28-oyl]-4-piperidine butanoate (138): 
Oxalyl chloride solution (2M in CH2Cl2, 10mL) was added to 114 (800 mg, 1 eq) in 
CH2Cl2 (10 mL) and stirred for 2 h. After concentration under vacuum, the residual 
mixture was treated with 4-piperidine butyric acid methyl ester (1.6 eq) and 
triethylamine (Et3N, 0.1 mL) in CH2Cl2. The mixture was stirred at room temperature 
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overnight until no starting material was observed by TLC. Then, the solution was 
diluted with CH2Cl2 (20 mL) and washed three times with brine and distilled water. 
The organic layer was dried over anhydrous Na2SO4 and concentrated to dryness 
under reduced pressure. The residue was chromatographed using a silica gel column 
to yield 1.02 g (94%) of pure 138, white amorphous powder. Mp 195–197 °C. MS 
(ESI+) m/z: 666.5 (M+ + H) for C42H67NO5. 1H NMR (300 MHz, CDCl3): δ 4.72, 4.57 
(1H each, s, H-29), 4.47 (1H, dd, J = 11.1, 5.7 Hz, H-3), 3.67 (3H, s, -COOCH3), 
3.67-3.47 (4H, m, 28-CON(CH2CH2)2CH-), 2.99 (1H, m, H-19), 2.31 (2H, t, J =7 Hz, 
-CH2COOCH3), 2.05 (3H, s, OCOCH3), 1.68 (3H, s, H-30), 0.96 (6H, s, 2 × CH3), 
0.94, 0.82, 0.75 (3H each, s, 3 × CH3).  
Synthesis of BA derivatives 121 and 124. To a solution of the appropriate 
ester intermediates 138 or 137 (1 eq) in MeOH (8 mL) and THF (4 mL) was added 
2N NaOH (4 mL). The mixture was stirred overnight, and then neutralized with 20% 
HCl. The solution was dried under vacuum and reconstituted with EtOAc. The 
organic layer was washed with brine and dried over anhydrous Na2SO4 and 
concentrated to dryness under reduced pressure. The residue was chromatographed 
using a silica gel column to yield the pure target compounds.  
N-[3β-Hydroxy-lup-20(29)-en-28-oyl]-4-piperidine butyric acid (121): 190 
mg (100%) starting from 200 mg of 138, white amorphous powder. Mp 145-146 °C. 
MS (ESI-) m/z: 608.4 (M- - H) for C39H63NO4. 1H NMR (300 MHz, CDCl3): δ 4.72, 
4.57 (1H each, s, H-29), 3.67-3.47 (4H, m, 28-CON(CH2CH2)2CH-), 3.19 (1H, m, 
H-3), 2.99 (1H, m, H-19), 2.31 (2H, t, J = 8.4 Hz, -CH2COOH), 1.68 (3H, s, H-30), 
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0.96 (6H, s, 2 × CH3), 0.94, 0.82, 0.81 (3H each, s, 3 × CH3). [α]25D -22.7 ° (c = 0.33, 
MeOH). 
N’-[3β-N-(3’,3’-Dimethylsuccinyl)-lup-20(29)-en-28-oyl]-leucine (124): 24 
mg (98%) starting from 25 mg of 137; white amorphous powder. Mp 248-250 °C. MS 
(ESI-) m/z: 695.5 (M- - H) for C42H68N2O6. 1H NMR (300 MHz, CDCl3): δ 5.87 (1H, 
d, J = 7.6 Hz, -CONH-), 4.72, 4.58 (1H each, s, H-29), 4.64 (1H, m, -NHCH-), 3.59 
(1H, m, H-3), 2.99 (1H, m, H-19), 2.64-2.42 (2H, m, H-2’), 1.68 (3H, s, H-30), 1.30, 
1.26 (3H each, s, 2 × CH3-3’), 1.00 (6H, s, leucine moiety -(CH3)2), 0.96 (6H, s, 2 × 
CH3), 0.89, 0.86, 0.85 (3H each, s, 3 × CH3). [α]25D -16.1 ° (c = 0.28, MeOH). 
Synthesis of BA derivatives 125-128. A solution of 121 (1 eq), EDCI (2 eq), 
HOBt (1 eq), Et3N (0.05 mL) and appropriate amine (2 eq) in anhydrous CH2Cl2 (8 
mL) was stirred at room temperature overnight until the starting material was not 
observed by TLC. The solution was diluted with CH2Cl2 (20 mL) and washed three 
times with brine and distilled water. The organic layer was dried over anhydrous 
Na2SO4 and concentrated to dryness under reduced pressure. The residue was 
chromatographed using a silica gel column to yield pure target compounds. 
N’-[N-[3β-Hydroxy-lup-20(29)-en-28-oyl]-4-piperidine-butanoyl]-aminom
ethane (125): 46 mg (100%) starting from 50 mg of 121, off-white amorphous 
powder. Mp 202-204 °C. MS (ESI+) m/z: 623.5 (M+ + H) for C40H66N2O3. 1H NMR 
(300 MHz, CDCl3): δ 5.44 (1H, br s, -CONHCH3), 4.69, 4.54 (1H each, s, H-29), 
3.58-3.54 (4H, m, 28-CON(CH2CH2)2CH-), 3.16 (1H, m, H-3), 2.95 (1H, m, H-19), 
2.78 (3H, d, J = 4.8 Hz, -CONHCH3), 2.16 (2H, t, J = 7.5 Hz, -CH2CONHCH3), 1.66 
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(3H, s, H-30), 0.93 (6H, s, 2 × CH3) ,0.92, 0.90, 0.79 (3H each, s, 3 × CH3). [α]25D 
-10.7 ° (c = 0.19, MeOH). 
N’-[N-[3β-Hydroxy-lup-20(29)-en-28-oyl]-4-piperidine-butanoyl]-morphol
ine (126): 53 mg (87%) starting from 50 mg of 121, white amorphous powder. Mp 
132-133 °C. MS (ESI+) m/z: 679.5 (M+ + H) for C43H70N2O4. 1H NMR (300 MHz, 
CDCl3): δ 4.69, 4.54 (1H each, s, H-29), 3.66-3.60 (8H, m, 28-CON(CH2CH2)2CH-, 
-CON(CH2CH2)2O), 3.42 (4H, m, -CON(CH2CH2)2O), 3.14 (1H, m, H-3), 2.95-2.60 
(1H, m, H-19), 2.27 (2H, t, J = 9.2 Hz, -CH2CON(CH2CH2)2O), 1.65 (3H, s, H-30), 
0.93 (3H each, s, 2 × CH3), 0.91, 0.83, 0.79 (3H each, s, 3 × CH3). [α]25D -20.0 ° (c = 
0.31, MeOH).  
N’-[N-[3β-Hydroxy-lup-20(29)-en-28-oyl]-4-piperidine-butanoyl]-2-amino
ethylmorpholine (127): 54 mg (91%) starting from 55 mg of 121, white amorphous 
powder. Mp 114-116 °C. MS (ESI+) m/z: 722.6 (M+ + H), 744.5 (M+ + Na) for 
C45H75N3O4. 1H NMR (300 MHz, CDCl3): δ 6.79 (1H, br, s, -CONHCH2-), 4.68, 4.53 
(1H each, s, H-29), 3.69-3.67 (8H, m, 28-CON(CH2CH2)2CH-, -CH2N(CH2CH2)2O), 
3.31 (2H, m, -CONHCH2-), 3.17 (1H, m, H-3), 2.95-2.60 (1H, m, H-19), 2.43 (6H, m, 
-CH2N(CH2CH2)2O), 2.17 (2H, t, J = 7.5 Hz, -CH2CONHCH2-), 1.63 (3H, s, H-30), 
0.93 (3H each, s, 2 × CH3), 0.90, 0.79, 0.72 (3H each, s, 3 × CH3). [α]25D -10.6 ° (c = 
0.15, MeOH). 
N’-[N-[3β-Hydroxy-lup-20(29)-en-28-oyl]-4-piperidine-butanoyl]-3-amino
propylmorpholine (128): 54 mg (90%) starting from 50 mg of 121, white amorphous 
powder. Mp 122-124 °C. MS (ESI+) m/z: 736.6 (M+ + H) for C46H77N3O4. 1H NMR 
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(300 MHz, CDCl3): δ 5.93 (1H, br, s, -CONHCH2-), 4.69, 4.54 (1H each, s, H-29), 
3.70-3.67 (8H, m, 28-CON(CH2CH2)2CH-, -CH2N(CH2CH2)2O), 3.33 (2H, dd, J = 12, 
6, -CONHCH2-), 3.15 (1H, m, H-3), 2.95-2.60 (1H, m, H-19), 2.47-2.41 (6H, m, 
-CH2N(CH2CH2)2O), 2.16 (2H, t, J = 7.5 Hz, -CH2CONHCH2-), 1.65 (3H, s, H-30), 
0.93 (3H each, s, 2 × CH3), 0.91, 0.79, 0.72 (3H each, s, 3 × CH3). [α]25D -7.5 ° (c = 
0.18, MeOH). 
Synthesis of 122-123, 137, 129-132. A solution of the appropriate BA analogs 
(1 eq), DMAP (1.5 eq) and the appropriate acid anhydride (5 eq) in anhydrous 
pyridine (1.5 mL) was stirred at 160 oC for 3 h using microwave. The reaction 
mixture was diluted with EtOAc (15 mL) and washed three times with 20% HCl 
solution and distilled water. The organic layer was dried over anhydrous Na2SO4 and 
concentrated to dryness under reduced pressure. The residue was chromatographed 
using a silica gel column to yield pure target compounds. 
N-[3β-O-(3’,3’-Dimethylsuccinyl)-lup-20(29)-en-28-oyl]-4-piperidine 
butyric acid (122): 20 mg (41%) starting from 50 mg of 121, white amorphous 
powder. Mp 116-118 °C. MS (ESI+) m/z: 738.6 (M+ + H), (ESI-) m/z: 736.5 (M- - H) 
for C45H71NO7. 1H NMR (300 MHz, CDCl3): δ 4.72, 4.57 (1H each, s, H-29), 4.47 
(1H, t, J = 7.5, H-3), 3.65-3.50 (4H, m, 28-CON(CH2CH2)2CH-), 2.98 (1H, m, H-19), 
2.64-2.42 (2H, m, H-2’), 2.30 (2H, t, J = 7.2 Hz, -CH2COOH), 1.68 (3H, s, H-30), 
1.27, 1.25 (3H each, s, 2 × CH3-3’), 0.95, 0.93, 0.84, 0.83, 0.82 (3H each, s, 5 × CH3). 
[α]25D -27.7 ° (c = 0.30, MeOH).  
N-[3β-O-(4’,4’-Dimethylglutaryl)-lup-20(29)-en-28-oyl]-4-piperidine 
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butyric acid (123): 12 mg (38%) starting from 30 mg of 121, white amorphous 
powder. Mp 143-145 °C. MS (ESI+) m/z: 752.4 (M+ + H), (ESI-) m/z: 750.4 (M- - H) 
for C46H73NO7. 1H NMR (300 MHz, CDCl3): δ 4.72, 4.57 (1H each, s, H-29), 4.47 
(1H, t, J = 7.5, H-3), 3.65-3.50 (4H, m, 28-CON(CH2CH2)2CH-), 3.00 (1H, m, H-19), 
2.35-2.30 (4H, m, H-2’, -CH2COOH), 1.68 (3H, s, H-30), 1.27, 1.25 (3H each, s, 2 × 
CH3-3’), 0.96 (6H, s, 2 × CH3), 0.89, 0.86, 0.82 (3H each, s, 3 × CH3). [α]25D -23.1 ° 
(c = 0.20, MeOH).  
Methyl N’-[3β-N-(3’,3’-Dimethylsuccinyl)-lup-20(29)-en-28-oyl]-leucinate 
(137): 37 mg (38%) starting from 80 mg of 136; white amorphous powder. Mp 
187-189 °C. MS (ESI+) m/z: 711.5 (M+ + H), 733.4 (M+ + Na) for C43H70N2O6. 1H 
NMR (300 MHz, CDCl3): δ 5.69 (1H, br s, -CONH-), 4.70, 4.58 (1H each, s, H-29), 
4.62 (1H, m, -NHCH-), 3.73 (3H, s, -COOCH3), 3.59 (1H, m, H-3), 2.99 (1H, m, 
H-19), 2.64-2.42 (2H, m, H-2’), 1.68 (3H, s, H-30), 1.30, 1.26 (3H each, s, 2 × 
CH3-3’), 1.09 (6H, s, leucine moiety -(CH3)2), 0.97 (6H, s, 2 × CH3), 0.92, 0.82, 0.80 
(3H each, s, 3 × CH3).  
N’-[N-[3β-O-(3’,3’-Dimethylsuccinyl)-lup-20(29)-en-28-oyl]-4-piperidine- 
butanoyl]-aminomethane (129): 17 mg (48%) starting from 30 mg of 125, white 
amorphous powder. Mp 166-169 °C. MS (ESI+) m/z: 751.6 (M+ + H) for C46H74N2O6. 
1H NMR (300 MHz, CDCl3): δ 5.43 (1H, br s, -CONHCH3), 4.69, 4.54 (1H each, s, 
H-29), 4.47 (1H, t, J = 7.5, H-3), 3.68-3.60 (4H, m, 28-CON(CH2CH2)2CH-), 2.98 
(1H, m, H-19), 2.79 (3H, d, J = 3.4 Hz, -CONHCH3), 2.67-2.62 (2H, m, H-2’), 2.14 
(2H, t, J = 6.8 Hz, -CH2CONHCH3), 1.65 (3H, s, H-30), 1.30, 1.25 (3H each, s, 2 × 
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CH3-3’), 0.93, 0.91 (3H each, s, 2 × CH3), 0.90, 0.80, 0.79 (3H each, s, 3 × CH3). 
[α]25D -25.0 ° (c = 0.12, MeOH). 
N’-[N-[3β-O-(3’,3’-Dimethylsuccinyl)-lup-20(29)-en-28-oyl]-4-piperidine- 
butanoyl]-morpholine (130): 23 mg (55%) starting from 35mg of 126, off-white 
amorphous powder. Mp 122-124 °C. MS (ESI+) m/z: 807.6 (M+ + H) for C49H78N2O7. 
1H NMR (300 MHz, CDCl3): δ 4.69, 4.54 (1H each, s, H-29), 4.45 (1H, t, J = 6.9, 
H-3), 3.66-3.61 (8H, m, 28-CON(CH2CH2)2CH-, -CON(CH2CH2)2O), 3.45-3.42 (4H, 
m, -CON(CH2CH2)2O), 2.99-2.82 (1H, m, H-19), 2.67-2.52 (2H, m, H-2’), 2.28 (2H, t, 
J = 7.8 Hz, -CH2CON(CH2CH2)2O), 1.65 (3H, s, H-30), 1.26 (6H, s, 2 × CH3-3’), 
0.92, 0.90 (3H each, s, 2 × CH3), 0.79 (6H, s, 2 × CH3), 0.77 (3H, s, CH3). [α]25D 
-19.1 ° (c = 0.41, MeOH).  
N’-[N-[3β-O-(3’,3’-Dimethylsuccinyl)-lup-20(29)-en-28-oyl]-4-piperidine- 
butanoyl]-2-aminoethylmorpholine (131): 14 mg (41%) starting from 30 mg of 127, 
white amorphous powder. Mp 121-123 °C. MS (ESI+) m/z: 850.4 (M+ + H) for 
C51H83N3O7. 1H NMR (300 MHz, CDCl3): δ 7.01 (1H, br, s, -CONHCH2-), 4.70, 4.54 
(1H each, s, H-29), 4.45 (1H, t, J = 10.2, H-3), 3.81-3.78 (8H, m, 
28-CON(CH2CH2)2CH-, -CH2N(CH2CH2)2O), 3.48 (2H, m, -CONHCH2-), 2.85-2.70 
(7H, m, -CH2N(CH2CH2)2O, H-19), 2.60-2.52 (2H, m, H-2’), 2.14 (2H, t, J = 7.5 Hz, 
-CH2CONHCH2-), 1.25 (6H, s, 2 × CH3-3’), 1.63 (3H, s, H-30), 0.93 (3H each, s, 2 × 
CH3), 0.90, 0.79, 0.72 (3H each, s, 3 × CH3). [α]25D -18.0 ° (c = 0.16, MeOH). 
N’-[N-[3β-O-(3’,3’-Dimethylsuccinyl)-lup-20(29)-en-28-oyl]-4-piperidine- 
butanoyl]-3-aminopropylmorpholine (132): 17 mg (47%) starting from 30 mg of 
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128, white amorphous powder. Mp 1125-127 °C. MS (ESI+) m/z: 864.6 (M+ + H) for 
C52H85N3O7. 1H NMR (300 MHz, CDCl3): δ 6.76 (1H, br, s, -CONHCH2-), 4.69, 4.54 
(1H each, s, H-29), 4.30 (1H, m, H-3), 3.81-3.67 (8H, m, 28-CON(CH2CH2)2CH-, 
-CH2N(CH2CH2)2O), 3.28 (2H, m, -CONHCH2-), 2.96 (1H, m, H-19), 2.80-2.73 (6H, 
m, -CH2N(CH2CH2)2O), 2.60-2.52 (2H, m, H-2’), 2.16 (2H, t, J = 7.5 Hz, 
-CH2CONHCH2-), 1.65 (3H, s, H-30), 1.25, 1.24 (6H, s, 2 × CH3-3’), 0.92, 0.90 (3H 
each, s, 2 × CH3), 0.80, 0.79, 0.78 (3H each, s, 3 × CH3). [α]25D -14.1 ° (c = 0.24, 
MeOH). 
 
5-2. In Vitro Metabolic Stability Assessment in Human Liver Microsomes  
5-2-1. Materials 
BA derivatives 108, 121 and 122 were synthesized and characterized in our 
study. NADPH, MgCl2, KH2PO4, formic acid and ammonium acetate were purchased 
from Sigma-Aldrich. HPLC-grade acetonitrile and water was purchased from VWR. 
Pooled human liver microsomes were purchased from BD biosciences (Woburn, MA).  
5-2-2. Sample Preparation 
Stock solutions of 108 and 121 (1 mg/ml) were prepared by dissolving the 
pure compound in methanol and stored at 4oC. For measurement of metabolic stability, 
108 and 121 were brought to a final concentration of 3 µM with 0.1 M potassium 
phosphate buffer at pH 7.4, which contained 0.2 mg/ml human liver microsome and 5 
mM MgCl2. The incubation volumes were 800 µl. Reactions were started by adding 
80 µl of NADPH (final concentration of 1.0 mM) and stopped by taking the aliquots 
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over time, then adding to 1.5 volumes of ice-cold acetonitrile. Incubations of all 
samples were conducted in duplicate. For each sample, 100 µl aliquots were taken out 
at 0, 5, 15, 30, 60, 120 min time points. After addition of 150 µl ice-cold acetonitrile, 
the mixture was centrifuged at 12,000 rpm for 5 min at 0 oC. The Supernatant was 
collected and 20 µl of the supernatant was directly injected to LCMS. The following 
controls were also conducted: 1) positive control incubations that contain liver 
microsomes, NADPH and the substrate propranolol; 2) negative control incubations 
that omit NADPH and 3) baseline control that only contain liver microsomes and 
NADPH. 
5-2-3. HPLC-MS Conditions 
Analysis was carried out on Shimadzu LCMS-20 with an electrospray 
ionization source. An Alltima C18 5µm 150mm x 2.1mm column was used with a 
gradient elution at a flow rate of 1.5 ml/min. The initial elution condition was 
acetonitrile (B) in water (A, with 0.1% formic acid and 5mM ammonium acetate) at 
55%. After staying at initial condition for 3 min, the concentration of B increased 
linearly to 90% at 15 min, and stayed at 90% for 2 min. The mobile phase was then 
returned to the initial condition and re-equilibrated for 3 min. The MS conditions were 
optimized to detector voltage: +1.35 kV, acquisition mode: SIM of the appropriate 
molecular weights of the testing compounds. The CDL temperature is 200 oC, heat 
block is 230 oC and neutralizing gas flow is 1.5 L/min. Samples were injected by 
auto-sampler. Electrospray ionization was operated in the positive ion mode.  
Full-scan spectra were also monitored over the range of 180 - 1000 m/z.  
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5-3. HIV-1IIIB Replication Inhibition Assay in MT-2 Cell Lines 145,152 
This screening was performed by Panacos Pharmaceutical Inc. The general 
procedure was described previously in Chapter 3, 5-2. 
 
5-4. HIV-1NL4-3 Replication Inhibition Assay in MT-4 Cell Lines 133,148 
This screening was performed by Dr. Chin-Ho Chen, Duke University. The 
general procedure was described previously in Chapter 4, 5-3. 
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Chapter 6. Concluding Remarks and Perspectives for Future 
Directions of Research on BA Derivatives 
 
1. BA Derivatives as Potent HIV-1 Inhibitors 
1-1. SAR Conclusions of BA Derivatives as Potent HIV-1 Inhibitors 
Targeting Maturation and Entry Processes 
In this study, three series of compounds were designed, synthesized and 
bio-evaluated as a continuing study of BA derivatives as potent HIV-1 inhibitors. 
Based on the screening results assessed in HIV-1IIIB infected MT-2 lymphocytes and 
HIV-1NL4-3 infected MT-4 lymphocytes, we determined the following SAR 
conclusions. 
A C-3 dimethylsuccinyl side chain is a key pharmacophore for HIV-1 
maturation inhibition activity of BA analogs. Dimethyl substitution at the C-3’ 
position within the C-3 side chain, especially the 3’S-methyl group (as in 78), is 
critical for the extremely high antiviral potency of DSB (58). Enlarging one of the 
C-3’ methyls to an ethyl group further enhanced anti-HIV-1 activity, as was seen with 
82. In contrast, C-3 side chains containing pendant rings (conformationally restricted) 
dramatically decreased antiviral activity. C-28 and C-30 substitutions did not harm the 
high antiviral potency of C-3 modified BA analogs. Actually, the existence of 
appropriate C-28 side chains can further increase the derivatives’ anti-HIV-1 potency. 
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At C-28, a long methylene side chain and a second amide bond near its end are 
critical for HIV-1 entry inhibition activity of BA analogs. The metabolic stability of 
the C-28 amide bond was increased significantly by replacing the primary amine 
moiety with a secondary cyclic amine (specifically piperidine). Introduction of a 
morpholine-containing moiety at the end of the C-28 side chain increased the antiviral 
activity of 3, 28-disubstituted BA analogs 131 and 132 by several-fold. The success of 
these two compounds suggests that larger substitutents can be tolerated near the C-28 
amide bond and that a third nitrogen at the end of the C-28 side chain can further 
increase activity. The high antiviral potency of 3, 28-disubstituted BA analogs may be 
due to synergistic effects. These findings give us a new direction for the development 
of BA-derived potent HIV-1 inhibitors. 
Except for amine moieties and a hydroxyl group, the C-30 position can 
accommodate certain substitutions through an ether bond that do not significantly 
affect the antiviral potency of the BA derivatives. This result suggests that the C-30 
position can serve as a good place to incorporate water-solubilizing moieties, which 
can improve the physicochemical properties of BA analogs. Indeed, compound 112, 
which contains a morpholine moiety in its C-30 substituent, showed very potent 
antiviral activity and much increased solubility. 
 
1-2. Future Research Directions 
3,28,30-Trisubstituted BA derivatives can be synthesized starting from 
28,30-disubstituted analogs. These tri-substituted BA analogs are very likely to show 
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significant antiviral maturation and entry activities as well as promising 
physicochemical properties suitable for clinical development, because the C-3 and 
C-28 modifications ensure high potency, while C-30 water-solubilizing substitutions 
can significantly improve hydrophilicity. For example, compound 139 (Figure 6-1) 
can be synthesized starting from 112. Based on our prior SAR conclusions, 139 
incorporates important pharmacophores and is very likely to exhibit potent antiviral 
potency and significantly increased solubility.  
For BA-derived HIV-1 entry inhibitors, improving the pharmacodynamic and 
pharmacokinetic properties of the long lipophilic C-28 side chain should be the main 
focus of future design. Currently, this class of compounds shows high lipophilicity 
and relatively low metabolic stability. In the present study, we demonstrated that the 
C-28 position could tolerate cyclic secondary amine substitutions (piperidine) with 
similar antiviral activity and increased metabolic stability. Accordingly, we feel that 
incorporating heteroatoms in the middle of the C-28 side chain is a good approach to 
increase hydrophilicity of future compounds, while maintaining good antiviral 
potency. Therefore, compound 140 (Figure 6-1) was designed. Replacement of the 
piperidine moiety with a piperazine moiety increases the calculated Log P value of the 
derivative to around 7.6, which is much lower than that of the original piperidine 
analogs. Moreover, analogs with a piperazine moiety are likely to have better 
metabolic stability compared to ones with primary amines. Because 140 contains a 
longer C-28 side chain critical for anti-entry activity, it should exhibit potent antiviral 
activity similar to 108. Thus, development of C-28 piperazine analogs (140 and its 
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analogs) is a good direction for the next generation of BA-derived HIV-1 entry 
inhibitors. The best entry inhibitors can be further developed into 3,28-disubstituted 
bi-functional HIV inhibitors, such as 141 (Figure 6-1). 
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Figure 6-1. Design for future BA derived HIV-1 inhibitors. 
 
2. Modeling of BA Analogs  
2-1. PASS Prediction of BA and DSB Biological Activities 
To date, there are more than 1,000 publications discussing BA (44). In 
addition, nearly 50 patents and patent applications relating to 44 were identified in a 
literature search. Many of these publications and patents pertain to the pharmaceutical 
application of 44 for the treatment of cancer, viral infections, hair loss, and other 
conditions.158 Because 44 shows a good safety profile in vivo, it was further screened 
by using PASS Inet software (Prediction of Activity Spectra for Substances) 
(http://195.178.207.233/PASS/) in an attempt to identify new activities that may 
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provide new therapeutic indications. 
The approach used in PASS is based on the suggestion that 
Activity=f(Structure). Thus, by "comparing" the structure of a new compound with 
structures of well-known biologically active substances, it is possible to estimate if a 
new compound may have a particular effect. The PASS training set contains about 
46,000 biologically active compounds. They include about 16,000 already launched 
drugs and 30,000 drug-candidates now under clinical or advanced preclinical testing. 
The similarity of compounds is characterized by the Euclidean distance (di) between 
compounds in multi-dimensional space of normalized descriptors. The mathematical 
approach is the leave-one-out cross-validated procedure.  
 
Table 6-1. Some of the PASS-predicted biological activities of BA (44) 
Pa a Pi b Predicted Biological Activity 
0.912 0.007 Phosphatase inhibitor  
0.857 0.004 DNA ligase (ATP) inhibitor  
0.781 0.015 Membrane integrity antagonist  
0.759 0.011 GABA A receptor antagonist  
0.733 0.006 Hepatoprotectant  
0.715 0.008 Antinephritic  
0.707 0.007 Hepatic disorders treatment  
0.701 0.005 Retinol dehydrogenase inhibitor  
0.712 0.020 Oxidoreductase inhibitor  
0.660 0.007 Phospholipase C inhibitor  
a: the estimates of probability for the compound to be active. b: the estimates of probability for the 
compound to be inactive. Pa > 0.7 the compound is very likely to reveal this activity in 
experiments; 0.5 < Pa < 0.7 the compound is likely to reveal this activity in experiments. 
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Besides the known antineoplastic and apoptosis agonist activities of 44, PASS 
also predicts that 44 can function as a phosphatase inhibitor, DNA ligase inhibitor, etc. 
These effects may be the mechanisms for its numerous activities. Some interesting 
predicted activities of 44 are listed in Table 6-1. 
Potential biological activities of DSB (58) have also been predicted by PASS. 
One interesting result is that PASS estimates that 58 can also function as apoptosis 
agonist, suggesting that it may be developed as an anticancer agent. Some of the 
interesting predictions are summarized in Table 6-2.  
 
Table 6-2. Some of the PASS-predicted biological activities of DSB (58) 
Pa a Pi b Predicted Biological Activity 
0.879 0.014 Phosphatase inhibitor  
0.842 0.007 Apoptosis agonist  
0.761 0.018 Membrane integrity antagonist  
0.709 0.021 GABA A receptor antagonist  
0.663 0.006 DNA ligase (ATP) inhibitor  
0.597 0.008 Phospholipase C inhibitor 
a: the estimates of probability for the compound to be active. b: the estimates of probability for the 
compound to be inactive. Pa > 0.7 the compound is very likely to reveal this activity in 
experiments; 0.5 < Pa < 0.7 the compound is likely to reveal this activity in experiments. 
 
2-2. Pharmacophore Elucidation Using MOE 2007.09  
Because the exact binding target of BA derivatives is still not clear and the 
X-ray structures of the possible binding targets are not available at this time, 
computational modeling approaches to guide rational drug design of novel 
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BA-derived HIV-1 inhibitors focus mainly on ligand-based drug design. 
Three-dimensional alignment of putative ligands can be used to deduce structural 
requirements for biological activity. For example, CoMFA159 uses a 3D molecular 
alignment as input. Another strategy is pharmacophore elucidation in which several 
ligands are aligned, and a small collection of essential molecular features required for 
biological activity is derived from the alignment.160 Methodologies based upon 3D 
alignment for finding biologically active ligands generally make use of the qualitative 
assumption that if two ligands have similar biological activity and bind in similar 
modes, then the bound conformations of the two ligands align well and inferences can 
be made about the nature of the receptor. 
The purpose of the pharmacophore elucidator is to generate a collection of 
pharmacophore queries from a collection of compounds, some or all of which are 
active against a particular biological target, such that all or most of the active 
compounds satisfy the generated queries. In the absence of receptor information, it is 
hoped that geometric features common to many of the actives will contain 
information related to important interactions between the bound conformations of the 
actives and the receptor. The fundamental approach for pharmacophore elucidation is 
to exhaustively search for all pharmacophore queries that induce a good overlay of 
most of the active molecules and that separate actives from inactives (when inactives 
are present). Thus, the plausibility of the pharmacophore is measured by overlay of 
actives (common binding mode), and the relationship to activity is measured by 
classification accuracy. 
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Because pharmacophore elucidation is a much faster approach to obtain 
information on molecular features and visualized models, it was chosen to align the 
BA-derived HIV-1 inhibitors. MOE (Molecular Operating Environment, Version 
2007.09, Chemical Computing Group, Montreal, Quebec, Canada) was used in this 
preliminary study, and the most active BA-derived HIV-1 inhibitors (122, 129-132) 
(Figure 6-2) were selected to search for the best conformational space.  
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Figure 6-2. Structures of selected active compounds for pharmacophore model 
 
To find common features, MOE can align ligands and maximize overlap over 
a set of pre-determined features. The features are derived from the following 
qualitative notions of a good alignment: 1) the strain energy of each molecule is small, 
2) molecules have similar shapes, 3) molecules have similar LogP (octanol/water) 
values, 4) molecules have comparable molar refractivity,; 5) aromatic atoms overlap, 
6) hydrogen bond donors and acceptors overlap, 7) acidic groups and basic groups 
overlap, 8) atoms of similar partial charge overlap, and 9) hydrophobic areas overlap.  
The resulted pharmacophore model is shown in Figure 6-3. The model 
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indicates that all of the active compounds can attain similar conformations. The BA 
skeleton provides good hydrophobic interactions with the binding pocket, while the 
tails of the C-3 and C-28 side chains form necessary hydrogen bonds with the target. 
In addition, the model indicates that polar moieties could also be accommodated near 
the BA skeleton's C-28 area. This finding supports our intent to incorporate more 
polar moieties into this position to increase the derivatives’ hydrophilicity. The 
synthesis and evaluation of 140 and 141 may validate this design.  
 
 
Figure 6-3. MOE predicted pharmacophore model for compound 122, 129-132. 
White: hydrophobic interaction; Blue: donor-functionality; Red: acceptor-functionality. 
 
To validate this pharmacophore model, it is necessary to screen a database 
including both active BA-derived HIV-1 entry inhibitors and inactive structures. If the 
pharmacophore search can successfully separate the active and inactive groups, this 
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model is considered predictable. Nevertheless, the initial result of this pharmacophore 
elucidation still provides us a straightforward visualized model of the predicted 
interaction between binding targets and active BA derivatives. 
 
2-3. Future Studies on Modeling of BA Analogs Using Variable Selection 
kNN QSAR Method 
Two-dimensional kNN (k-Nearest Neighbor) QSAR method is also a 
ligand-based method of analysis. It is very suitable for building QSAR models of a 
group of small molecules with related structures and varying bioactivities, and using 
these QSAR models to screen different databases to identify new leads. The 2D 
descriptors could accelerate processing time. By generating kNN QSAR models of 
BA-derived anti-HIV-1 agents and running database mining, we may be able to 
identify hits that can serve as good leads for future drug development as anti-HIV-1 
maturation inhibitors and/or entry inhibitors.  
 
2-3-1. Introduction 
In general, the κNN QSAR method uses the kNN classification principle 
combined with the variable selection procedure. A subset of nvar (number of selected 
variables) descriptors between 1 and the total number of the original descriptors is 
selected randomly as a hypothetical descriptor pharmacophore (HDP). The HDP 
selection is optimized by leave-one out cross-validation method where the HDP 
biological activity is predicted by k most similar molecules in the training set (k=1-5) 
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with one compound eliminated from the training set. The similarity of compounds is 
characterized by the Euclidean distance (di) between compounds in multi-dimensional 
space of normalized descriptors (range-scaled). To enhance the kNN QSAR approach, 
distance weighted activity values of the closest neighbors were developed for the 
predictions of activity. The measure of the model performance is the value of the 
leave-one-out cross-validated R2(q2). A flowchart of currently employed kNN 
methodology is displayed in Figure 6-4. 
 
Figure 6-4. Flowchart of kNN Method 
 
2-3-2. Model Validation: Training and Test Set Compound Selection 
The overall modeling process of building the kNN QSAR model of BA- 
derived HIV-1 inhibitors is illustrated in Figure 6-5. The whole data set is divided into 
multiple training and test sets. Several criteria are used to build kNN QSAR models 
Training set in the original descriptor and activity space 
Randomly select a subset of descriptors (a hypothetical descriptor 
pharmacophore) 
Leave out a compound 
Find k nearest neighbors in the training set 
Predict the activity of the eliminated compound by weighted kNN 
using the identified k nearest neighbors. 
N
tim
es
SA (Sim
ulate A
nnealing) 
Select acceptable models (with q2 > 0.6) 
Calculate the predictive ability (R2) of the model 
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for the training data set and select validated models. We will consider a model 
successful if the following values apply. (1) Both the q2 values for the training data set 
and the R2 for the corresponding test data set exceed 0.6. (2) The coefficient of 
determination of Ro (observed) is similar to R2 (predicted), i.e., | R2-Ro2 | / R2 < 0.1. 
(3) The slope of regression of predicted vs observed values is between 0.85 and 1.15. 
 
 
 
Figure 6-5. The workflow of kNN QSAR modeling 
 
2-3-3. Robustness of QSAR Models 
The statistical significance of QSAR models for training sets is tested by the 
standard hypothesis with one tail Z test at the significance level of α=0.05 based on 
the following hypothesis. The null hypothesis states that the q2 of the actual QSAR 
model is not significantly better than other random QSAR models, whereas the 
alternative hypothesis states that the q2 of the actual QSAR model is significantly 
better than other QSAR random models. (i) Ho, h=µ; (ii) H1, h>µ (where µ is the 
Only Accept Models 
that Have a q2 > 0.5, 
R2 > 0.6, etc. 
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Multiple Test 
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Activity 
Prediction
BA derivatives 
Y-Randomization 
Validate Predictive 
Models with Random 
External Set 
Database Mining for 
New Lead 
Identification 
 132
average value of q2 for random QSAR models and h is the value of q2 for the 
experimental QSAR model). 
 
2-3-4. Database Mining 
Validated QSAR models generated by a modified kNN approach will be used 
to mine novel lead anti-HIV-1 agents from different chemical databases, such as 
Chemdiv (over 750,000 compounds). The overall workflow of the data mining 
procedures is shown in Figure 6-6.  
The Euclidean distance (di) in the descriptor pharmacophore space is used to 
evaluate the similarity of all chemical structures in the database and all active probes 
(corresponding descriptors for 10 best QSAR models). All structures are ranked in the 
database by their similarity to a probe, and M structures are selected within a certain 
similarity threshold. The biological activities of these M structures are predicted based 
on the previously generated best kNN QSAR models. Structures with higher 
biological activity predicted by all or a majority of generated QSAR models are 
selected as computational hits.  
To summarize, a ligand-based 2D kNN QSAR method provides us an efficient 
approach to build QSAR models and mine different databases for novel hits. Its 
application into the study of BA-derived HIV-1 inhibitors may help us to expand this 
research into more diverse compound structures. 
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Figure 6-6. Workflow of the data mining procedures. 
 
3. BA Derivatives as Potent Proteasome Inhibitors  
3-1. Introduction 
BA (44) is cytotoxic against several tumor varieties including melanoma, 
neuroectodermal tumor, and malignant brain tumor.161,162 It appears to function by 
inducing apoptosis in cells, irrespective of their p53 status.162,163 While 44 exhibited 
no toxic effects in mice even at a concentration of 500 mg/kg, doses of 44 as low as 5 
mg/kg were determined to significantly impede tumor development.161 Together, these 
encouraging findings have made 44 a very attractive candidate for clinical treatment 
of various forms of cancers. 
Proteasomes are responsible for more than 80% of intracellular protein 
degradation.164 The β subunits of proteasomes have three major proteolytic activities: 
chymotrypsin-like (β5), trypsin-like (β2), and caspase-like (β1). These proteolytic 
activities enable the proteasome to cleave proteins into small peptides. Proteasomes 
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are involved in many essential cellular functions, such as cell cycle regulation, cell 
differentiation, signal transduction pathways, antigen processing for appropriate 
immune responses, stress signaling, inflammatory responses, and apoptosis. 
Interestingly, despite the presence of proteasomes in all eukaryotic cells, malignant 
cells are more sensitive to the loss of proteasome function.165 Possible reasons for this 
difference may be because 1) malignant cells often proliferate rapidly and have 
aberrant cell-cycle checkpoints, which leads to the accumulation of defective proteins 
and increases dependency on proteasomes as a disposal mechanism and 2) inhibition 
of proteasome activity causes a reversal or bypass of some mutational effects in 
cell-cycle and apoptotic checkpoints. In other words, inhibition of the 26S proteasome 
could result in selective inhibition of malignant cell growth. Thus, proteasome 
inhibition has become a strategy for anticancer chemotherapy, and numerous agents 
have been identified to inhibit proteasomes and kill tumor cells, overcome drug 
resistance, and enhance radiation sensitivity. 
Bortezomib (PS341, Velcade, 142) was the first proteasome inhibitor approved 
by the US FDA on May 2003 for treatment of multiple myeloma.166 It shows 
high-affinity specificity and selectivity for the chymotryptic activity of the 
proteasome targeting the active site N-terminal threonine residue.167,168 As a result, 
142 stabilizes IκB and the CDK inhibitors p21 and p27, activates c-Jun-N-terminal 
kinase, and stabilizes the tumor suppressor p53 and pro-apoptotic proteins, which 
results in apoptosis or inhibits cancer cell proliferation.167,169 The successful 
development of 142 into a clinical drug provides us with a valid example of the 
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potential applicability of proteasome inhibitors as anticancer agents. 
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3-2. Proteasome Inhibition Activities of DSB and C-30 Modified BA Analogs 
Our investigation indicated that HIV-1 virions produced in the presence of 
DSB (58) contained much higher amounts of the cellular protein APOBEC3G. 
Because APOBEC3G is subject to proteasome degradation in HIV-1 infected cells, we 
then postulated that the elevated APOBEC3G level in the treated viral particles may 
due to inhibition of proteasomes by 58.  
Further screening of 58 on 20S proteasome activity demonstrated that it 
inhibited chymotrypsin-like activity with an IC50 value of 7.2 µM, did not inhibit 
caspase-like activity, and was a very weak inhibitor (IC50: 20.5 µM) of trypsin-like 
activity. These results are favorable because normal cells may suffer fewer 
consequences from treatment with 58, because two of the main proteolytic activities 
are retained. In our screening, 58 did not inhibit the cellular proteases cathepsin B 
(cysteine protease) and DPPIV (DPP4, CD26, serine protease). Thus, 58 may have 
reduced side effects compared with other proteasome inhibitors such as peptide 
aldehydes and peptide boronates, which also inhibit these cellular proteases. 
Because 58 is a C-3 modified BA derivative, we then synthesized two 
 136
additional compounds (143 and 144) to investigate the impact of the modification on 
proteosome inhibition. These two compounds plus BA (44) and 74 were tested against 
chymotrypsin-like activity of human 20S proteasomes. The results are summarized in 
Table 6-3. From the limited data, we concluded that addition of a C-3 ester group to 
44 can confer activity, and the identity of the ester group can influence potency. 
Within the C-3 side chain, a polar oxygen atom (143) was not tolerated and larger 
lipophilic moieties (58, 74, 144) were favored.  
 
 
Table 6-3. Proteasome inhibition activity of 3-substituted BA analogs a 
H
H
H
H
R1O
OH
O
 
   Compound R1 IC50 (µM)  
44 H NS 
58 
COOH
O
 
7.2 
74 OH
OO
 
< 3 
143 O
O
COOH  
NS 
144 O COOH  
1.6 
a All data presented are averages of at least two separate experiments performed by Dr. Chin-Ho 
Chen, Duke University, NC. IC50: concentration that inhibits the chymotrypsin-like activity of 
human 20S proteasomes by 50%. NS: no inhibition. 
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In our prior results, modification of the C-19 isopropenyl moiety of 44 did not 
affect antiviral potency, but did slightly increase cytotoxicity. Thus, we hypothesized 
that the C-19 position is also related to proteasome inhibition activity. Therefore, 
eleven 28,30-disubstituted compounds (96-98, 100-107) with varying functionalities 
appended to the C-19 isopropenyl group were screened for inhibition of proteasome 
activity. Their structures and anti-proteasome activities are summarized in Table 6-4. 
The preliminary screening data confirmed our hypothesis that substitution at the C-30 
position could increase anti-proteasome activity of 44 analogs. The most active 
derivative 102 had an IC50 value of 1.7 µM, making it five-fold more active than 58. 
From the bioassay data, we concluded that aromatic ring systems at C-30 can 
significantly increase the anti-proteasome chymotrypsin-like activity of 
28,30-disubstituted BA derivatives. Comparatively, polar moieties only slightly 
enhanced anti-proteasome activity.  
Two C-28 monosubstituted BA derivatives were also screened against 
chymotrypsin-like activity of human 20S proteasomes in order to investigate the 
effect of C-28 modification on proteasome inhibition activity. These compounds 
included IC9564 (48) with a long C-28 side chain and 15bh (95) with a short C-28 
side chain (Table 6-4). However, neither of the compounds exhibited anti-proteasome 
activity. Whether introduction of other functional groups at C-28, rather than 
aminoalkanoic acid groups, will increase proteasome inhibition activity needs to be 
further evaluated.  
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Table 6-4. Proteasome inhibition activities of 28,30-disubstituted BA analogs a 
H
H
H
H
HO
R2
H
N
O
O
OH
 
 
Compound R2 IC50 (µM) 
96 Br  5.9 
97 OCH2CH3  13.2 
98 O(CH2)2CH3  3.7 
100 O(CH2)2  
1.8 
101 O(CH2)2 OMe 
2.3 
102 O(CH2)2 F  
1.7 
103 O(CH2)2 Br  
++ (> 90%) 
104 O(CH2)2 Cl  
++ (> 90%) 
105 N O
 
+ (40-60%) 
106 O(CH2)2 N O  
+ (40-60%) 
107 OH  + (40-60%) 
a All data presented are averages of at least two separate experiments performed by Dr. Chin-Ho 
Chen, Duke University, NC. IC50: concentration that inhibits the chymotrypsin-like activity of 
human 20S proteasomes by 50%. ++: strongly inhibits (> 90%) the chymotrypsin-like activity of 
human 20S proteasomes at test concentration (10 µg/ml). +: moderately inhibits (40-60%) the 
chymotrypsin-like activity of human 20S proteasomes at test concentration (10 µg/ml). 
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In conclusion, we discovered that C-3 and C-30 modification with lipophilic 
moities and aromatic rings can significantly increase the anti-proteasome activity of 
BA derivatives. Comparatively, analogs with C-28 amidoalkanoic acids rather than 
leucine side chains had no proteasome inhibition activity. These results suggest that 
3,30-disubstituted BA analogs may possess enhanced anti-proteasome activity and 
have a better potential to be developed into potent proteasome inhibitors and potential 
anticancer drugs. 
 
3-3. Future Planned Studies on Novel BA Analogs as Potent 
Anti-proteasome Agents 
3,30-Disubstituted BA analogs with different functionalities as shown in 
Figure 6-7 can be synthesized and evaluated against human 20S proteasome. This 
design incorporates the favored substitutions in monosubstituted BA analogs into one 
BA molecule. The C-28 carboxylic acid will be kept free in order to increase the 
compound’s solubility. The synthetic methods for these novel compounds are 
summarized in Scheme 6-1. 
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Figure 6-7. 3,30-disubstituted BA analogs to increase anti-proteasome activity 
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